Recherche Images Maps Play YouTube Actualités Gmail Drive Plus »
Connexion
Les utilisateurs de lecteurs d'écran peuvent cliquer sur ce lien pour activer le mode d'accessibilité. Celui-ci propose les mêmes fonctionnalités principales, mais il est optimisé pour votre lecteur d'écran.

Brevets

  1. Recherche avancée dans les brevets
Numéro de publicationUS3850752 A
Type de publicationOctroi
Date de publication26 nov. 1974
Date de dépôt29 oct. 1971
Date de priorité10 nov. 1970
Autre référence de publicationCA967464A, CA967464A1, DE2155658A1, DE2155658B2, DE2155658C3
Numéro de publicationUS 3850752 A, US 3850752A, US-A-3850752, US3850752 A, US3850752A
InventeursA Schuurs, Weemen B Van
Cessionnaire d'origineAkzona Inc
Exporter la citationBiBTeX, EndNote, RefMan
Liens externes: USPTO, Cession USPTO, Espacenet
Process for the demonstration and determination of low molecular compounds and of proteins capable of binding these compounds specifically
US 3850752 A
Résumé
The invention relates to a process for the demonstration and determination of a low molecular compound, such as a hapten, or a protein or antibody capable of binding this compound specifically, contacting a fluid containing such a compound or protein to be determined with a given quantity of the coupling product of such a low molecular compound and an enzyme, and with a given quantity of the component to be determined, which component is brought in an insoluble form, and determining the enzyme activity of the liquid or solid phase of the resulting reaction mixture.
Images(3)
Previous page
Next page
Revendications  disponible en
Description  (Le texte OCR peut contenir des erreurs.)

United States Patent [191 Schuurs et al.

[4 ]*Nov. 26, 1974 1 PROCESS FOR THE DEMONSTRATION AND DETERMINATION OF LOW MOLECULAR COMPOUNDS AND OF PROTEINS CAPABLE OF BINDING THESE COMPOUNDS SPECIFICALLY [75] Inventors: Antonius Hermanus Wilhelmus Maria Schuurs; Bauke Klass Van Weemen, both of Oss, Netherlands [73] Assignee: Akzona Incorporated, Asheville,

[ Notice: The portion of the term of this patent subsequent to Apr. 4, 1989, has been disclaimed.

[22] Filed: Oct. 29, 1971 21 Appl. No.: 193,702

[30] Foreign Application Priority Data Nov. 10, 1970 Netherlands 7016396 [52] US. Cl 195/1035 R, 195/99, 195/63, 424/12 [51] Int. Cl. G01n 31/14, GOln 33/16 8] Field of Search 195/1035 R; 23/253 TP,

[56] References Cited UNITED STATES PATENTS 3,615,222 10/1971 Mead 23/230 B 3,654,090 4/1972 Schuurs et a1. 195/1015 R OTHER PUBLICATIONS Chemical Abstracts 65: ll 124b, (1966). Spector et 11]., 168: 1348. 8. Science," (June 12, 1970).

Primary Examiner-Alvin E. Tanenholtz Attorney, Agent, or Firm-Hugo E. Weisberger [57] ABSTRACT with a given quantity of the component to be deter-- mined, which component is brought in an insoluble form, and determining the enzyme activity of the liquid or solid phase of the resulting reaction mixture.

13 Claims, 6 Drawing Figures PATENT Tia/261974 SHEET 10F 3 O O mu 5 1 N 0.25 0.06 CONCENTRATION ANN-TESTOSTERONE-CELLULOSE (mg/ml) FIG. 2

ng TESTOSTERONE IN THE SAMPLE I PATE NLNNZ SHEET 2M 3 3,850,752

FIG. 3

/o ENZYME ACTIVITY IN SUPERNATANT LIQUID O l I l l l 64 I6 4 l 0.25 0.06 CONCENTRATION ANTI-OESTRADIOL-CELLULOSE (mg/ml) FIG 4 5 lm OESTRADIOL 2 J M Q TESTOSTERONLPROGESTERONE gzo- ANTIOESTRADIOL-CELLULOSE sm /mfl ON. L l l I N O 4 I6 64 256 I024 4096 PATEIIIEDIIUVZBIQYI 3.850.752

suecrsor'a FIG.5

IOO

/o ENZYME ACTIVITY IN SUPERNATANT LIQUID O 8 l I l l I I I6 4 I 0.25 0.06 CONCENTRATION OF ANTPFOLATE-CELLULOSE (mg/ml) FIG, 6

Q g, FOLIC ACID l E 80- E z 5 I GLUTAMIC ACID 40- q I g GLY, ASP, LA I 2 I 4 8 I6 32 64 I28 CONCENTRATION IN ng/mI PROCESS FOR THE DEMONSTRATION AND DETERMINATION OF LOW MOLECULAR COMPOUNDS AND OF PROTEINS CAPABLE OF BINDING THESE COMPOUNDS SPECIFICALLY For the determination of low molecular substances occurring in low concentrations, such as steroid hormones in body fluids, methods have been developed using proteins capable of binding the substance to be determined specifically. These methods are based on the competition between the substance to be determined in the sample and a known quantity of the same substance which is labelled radioactive, for a limited quantity of specific binding protein. The unknown quantity of bindable substance then determines what portion of the radioactive labelled substance is bound by the specific binding protein.

It is also possible to determine by these methods an unknown quantity of specific binding protein by reacting a sample containing an unknown quantity of specific binding protein with a given quantity of bindable radioactive labelled substance.

in the literature it is common practice to distinguish these determination methods according to the nature of the specific binding protein employed, although the underlying principle of all determinations is identical. Thus, for example, they speak of competitive protein binding assays when they employ receptor or transport proteins occurring in the body, and of radioimmunological determinations when they employ antisubstances.

For both types of determinations radioactive labelled substances are required. The work with these substances requires the presence of precious measuring apparatuses, good laboratory facilities and a highly qualified staff. These high requirements prevent a general application of these determination, especially in smaller laboratories.

A process has now been found for the demonstration and determination of a component of the reaction between a low molecular compound and a protein capable of binding this compound specifically using the binding affinity of such components for each other,

characterized in that the determination is performed with a given quantity of the coupling product of the low molecular compound and an enzyme, and with a given quantity of a component of the said reaction which has been made insoluble, and the enzyme activity of the liquid or the solid phase of the resulting reaction mixture is determined, which activity is a measure for the quantity of the reaction component to be determined.

The method found can often by employed for the determination of haptens, which may be regarded as a special group of low molecular compounds, and their anti-substances. These substances mostly occur in low concentrations. According to the original definition of K. Landsteiner haptens are protein-free substances whose chemical configuration is such that they can react with specific antibodies, but not such that they are capable of causing the formation of anitbodies. In order to be able yet to make antibodies against haptens, the haptens must be coupled to polypeptides before being injected into the test animal. In the determination of a low molecular compound the substance to be determined and its coupling product with an enzyme enter into competition for a given quantity of the insoluble specific binding protein. The more low molecular compound the sample contains, the less opportunity the soluble enzyme conjugate of that compound has to combine with the insoluble specific binding protein and the more of the conjugate will remain in the liquid phase, in which the enzyme activity can be measured in a simple manner.

In the determination of a specific binding protein with the same reagents the soluble protein to be determined and the insoluble protein enter into competition for a given quantity of the conjugate of the corresponding low molecular compound and an enzyme. If the content of specific binding protein of the sample is higher, the insoluble protein will bind less of the enzyme conjugate, and consequently more enzyme remains in the liquid phase.

A specific binding protein having two or more binding possibilities can also be demonstrated and determined according to the invention, i.e. with the enzyme conjugate and. with the low molecular compound in an insoluble form. The liquid phase of the reaction mixture then contains the conjugate bound to the specific binding protein and in the solid phase the complex of enzyme conjugate specific binding protein insoluble low molecular compound. The more of the protein to be determined there is in the sample, the more enzyme activity the liquid phase will possess.

By means of an assay curve for a certain system in which increasing contents of substance to be determined have been set off against the enzyme activity found, preferably in the liquid phase, the quantity of substance to be determined in the sample can be derived from a value of enzyme activity found.

The most important reagents of this detennination method is the coupling product of the low molecular substance and an enzyme, for convenience hereinafter also called enzyme conjugate, which on the one hand can react with the specific binding protein, via the low molecular component and on the other hand possesses enzyme activity. This reagent is prepared by a method described for similar products. The second reagent, the insoluble component in the reaction system, serves to facilitate the separation between various enzymecontaining fractions of the reaction mixture. Addition of this reagent causes the fonnation of a solid phase in addition to a liquid phase. The present determinations can in principle be performed without an insoluble component of the reaction system. In that case the various fractions with enzyme activity will have to be separated by, for example, chromatographic or electrophoretic route or gelfiltration. For practical reasons such a determination is less attractive, however,

The enzyme activity of a fraction of the reaction mixture is demonstrated or measured by incubating that fraction with a substrate and other substances required for processing the relative enzyme: reaction. For preference a reaction is used in which a coloured compound is formed or removed whose absorption can also be measured quantitatively in an easy manner.

Low molecular substances which are eligible for demonstration by the new method and have a molecular weight of up to about 1500 are for example: steroids, vitamin B folinic acid, thyroxine and triiodothyronine, releasing factors, histamine, serotonin and other biogenic amines, digoxine, digitoxin, prostaglandins, adrenalin, nor-adrenalin, vegetable hormones such as auxin, kinetin and gibberellic acid, and antibiotics such as penicillin.

The method of demonstrating specific binding proteins for low molecular substances can be employed for, for example, the determination of antibody against penicillin or for the determination of intrinsic factor.

The preparation of conjugates of enzymes and lowmolecular substances can take place in various manners. Some low molecular substances may already possess groups that can be cross-linked with reactive groups at the surface of the enzyme, while other substances will have to be provided with such groups by organic chemical reactions. It stands to reason that the original binding properties of the low molecular compound and the activity of the enzyme may not change essentially during this process. The groups of the enzyme which are particularly suited for coupling reactions are amino and carboxyl groups. If the modified or unmodified low molecular substance also possesses such groups, the coupling can be performed by, for example, reactions known from the peptide synthesis. Furthermore such substances as glutaraldehyde, difluorodinitrodiphenylsulfon, toluene diisocyanate, diand trichloros-triazine can be employed for the coupling reaction.

Specific examples of the coupling of haptens to proteins are described in, for example, Methods in Immunology and lmmunochemistry, vol. I. The methods described are used for the preparation of conjugates for immunisation but they can also be used for the preparation of conjugates of the low molecular substance and an enzyme which are essential in the invention.

The choice of the enzyme that is to be a component of the conjugate (low molecular substance-enzyme) depends on properties such as the specific activity (a high conversion rate enhances the sensitivity of the test system) and the simplicity of the determination of the enzyme. The determination of an enzyme which catalyses a conversion involving coloured reaction components, is simple. Such colorimetric determinations can be automatized in a simple manner.

According to the invention it is also possible to use enzymes which catalyse conversions involving reaction components that can be determined spectrophotometrically or fluorimetrically. These determinations can also be automatized.

For the preparation of the conjugates enzymes such as catalase, peroxidase, B-glucuronidase, fl-D- glucosidase, B-D-galactosidase, urease, glucoseoxidase and galactose-oxidase are preferred, particularly the group of the oxide reductases.

The insoluble specific binding protein or the insoluble low molecular compound to be used in the present determination can be prepared by a known method, for example, by cross-linking with chloroformic acidethylester, by covalent binding with insoluble carriers such as agarose, cross-linked dextran or filter paper, or by physical coupling to insoluble carriers such as plastic objects.

The form in which the reagents can be used are manifold. The component of the reaction system conjugated with an enzyme can be freeze-dried or dissolved in a buffer. Furthermore a solid carrier, for example, a strip of paper impregnated with the conjugate, can be employed.

The insoluble component can be brought in the form of particles of various sizes, such as grains, platelets and rods, or in the form of a strip of some or other carrier material.

For the performance of the process according to the invention a test pack in preferably employed, chiefly composed of:

a. a given quantity of the coupling product of the low molecular compound and an enzyme;

b. a corresponding quantity of one of the components of the reaction system in an insoluble form;

c. a substrate for the determination of the activity of the enzyme employed.

If required, the test pack can also contain the necessary auxiliaries for making a dilution series of the sample to be examined for a quantitative determination, such as test tubes, pipettes and flasks of diluent. For the determination of a hapten or its antibody the test pack contains at least:

a. a given quantity of the coupling product of this hapten and an enzyme;

b. a corresponding quantity of a component of the reaction system in an insoluble form, haptenantibody;

c. a substrate for the determination of the enzyme activity.

The invention is illustrated further by the following examples, which are not to be construed as limiting.

Example I Determination of testosterone A. Preparation of testosterone-S-HRP One hundred milligrams of testosterone-3-(O-carboxymethyl)-oxim and 0.143 ml of tri-nbutylamine were dissolved in 5 ml of dioxan. The solution was cooled down to 2C and then 0.03 ml of isobutylchlorocarbonate were added. After 30 minutes the solution was added to mg of HRP (horse radish peroxidase) in a mixture of 9 ml of water and 6 ml of dioxan, and adjusted to pH 9 with 0.1 N NaOH. This solution was stirred for 4 hours at 2C and dialysed overnight. The precipitate obtained after the dialysate had been adjusted to pH 4.6 was centrifuged after having been left to stand overnight, suspended in 10 ml of water and dissolved by means of caustic soda solution. The material was precipitated three times with 15 ml of acetone at pH 4.5, dissolved in 15 ml of water which had been adjusted at pH 7.8 with caustic soda solution, dialysed and finally lyophilized.

B. Preparation of testosterone-Zl-BSA This conjugate was prepared in the same manner as the testosterone-B-HRP, but the starting materials were 50 mg of testosterone-3-(O-carboxymethyl)- oxim and mg of BSA (bovine serum albumin).

C. Preparation of antibodies against testosterone-3- BSA Five rabbits were injected intrarnuscularly with increasing dosages of testosterone-3-BSA in complete Freunds adjuvant (0.5, 1 and 2 mg) at intervals of 3 weeks. Two weeks after the last injection the animals were injected intravenously with 2 mg of antigen dissolved in physiological salt. One week after that blood was taken from the animals. The antibodies formed against BSA were removed by treating the serum portionwise with BSA-maminobenzyloxymethyl cellulose, prepared in accordance with Gurvichs method (see D). D. Preparation of anti-testosterone cellulose This substance was prepared in accordance with Gurvichs method as described in Biokhimiya 26, 934 (1961):

1. Preparation of aminocellulose:

Fifty grams of Whatman cellulose, which had been frequently washed and decanted, were suspended in 100 ml of a 0.7 sodium acetate solution containing 2 gm of N(m-nitrobenzoxy methylpyridine. The mixture was dried at 6080C and heated for 40 minutes at 125C. The resulting product was thoroughly washed with distilled water, dried at 80C, washed with benzene and dried again. Fifty grams of the dried product were reduced by suspension in 300 ml of a 15% Na S O solution and stirred for 30 minutes at 5060C. The product was filtered and washed with successively distilled water, 30% acetic acid and again with distilled water.

2. Treatment with ammoniacal copper solution:

Forty millilitres of sulphuric acid, 20 ml of 50% nitric acid and 140 ml of distilled water were heated, while stirring, to 90C, after which 5.9 gm of CuO were added in small portions. The solution was boiled for 2 hours and completed to 500 ml with distilled water. Eighty millilitres of this solution were transferred into an icebath and added to 160 ml of cold 4 N NaOI-I, while stirring. After being stirred for 30 minutes, the precipitate was washed twice with distilled water and dissolved in 80 ml of 25% ammonia. To this solution was gradually added 1 gm of aminocellulose. The mixture was stirred for 1.5 hours, after which 40 ml of boiling water were added, whereupon the solution was quickly cooled down to 0C. The solution was neutralized with 10% sulphuric acid, after whichthe aminocellulose flocculated. It was washed with cold distilled watel.

3. Preparation of 'y-globulin:

To rabbit anti-testosterone serum were added 180 mg of Na SO per ml of serum. The mixture was stirred for 1 hour at room temperature, after which the resulting precipitate was centrifuged, washed twice with an 18% Na SO solution and taken up in so much 0.05 M sodium borate of pH 8.6 that the protein concentration was about 10 mg/ml.

4. Binding 'y-globulin to aminocellulose Aminocellulose (350 mg) was suspended in distilled water (50 ml). The suspension was cooled down to 0C. Ten millilitres of a 36% hydrochloric acid were added and after that dropwise 10 ml of a 10% NaNO solution. The suspension was centrifuged, washed with cold distilled water and then with 0.05 M sodium borate of pH 8.6. The cellulose was suspended in 43 ml of 0.05 M sodium borate of pH 8.6. To this suspension were added 7 ml of the 'y-globulin solution prepared. The mixture was stirred for 26 hours at 4C, centrifuged and washed with 0.02 M phosphate buffer of pH 6.0. From the antiserum of each of the 5 immunized rabbits a cellulose suspension was prepared (A E respectively).

E. Determination of testosterone by means of testosterone-3-HRP and anti-testosterone cellulose The following test system was built up: I Immunoreaction buffer of pH 6.0 and containing 2% sheep serum.

II Enzyme reaction 0.5 ml of the supernatant liquid was incubated at room temperature with 1.5 ml of substrate for 30 minutes. The extinction was measured at 460 nm.

The enzyme substrate contained 10 ,ul of 30% hydrogen peroxide and 20 mg of S-aminosalicylic acid in 150 ml of 0.02 M phosphate buffer of pH 6.2.

FIG. 1 shows the measure in which testosterone3- HRP is bound by the anti-testosteronecellulose preparations made. In this case only buffer was added as a sample in the test system. If cellulose is added instead of anti-testosterone-cellulose, more than of the enzyme activity will remain behind in the supernatant liquid. The preparations B, D and E proved to bind hardly any testosterone-3- HRP, but A and C did.

FIG. 2 shows the results of incubation of a testosterone dilution series with testosterone-3-HRP and four different concentrations of anti-testosteronecellulose C 1 mg/ml (I), 2 mg/ml (II), 4 mg/ml (III) and 16 mg/ml (IV). It is obvious that with this system a quantity of about 10 ngm of testosterone can be demonstrated.

EXAMPLE III Determination of ,oestradiol A. Oestradiol-l7-succinyl-HRP was prepared by the mixed anhydride method described in example I A, using 50 mg of oestradiol-l7-hemisuccinate and 50 mg of HRP as starting materials.

B. Oestradiol-17-succinyl-BSA was prepared by the mixed anhydride method described in example I A, using mg of oestradiol-l7-hemisuccinate and mg of BSA as starting materials.

C. For the preparation of antibodies against oestradiol-l7-succinyl-BSA five rabbits were immunized in accordance with the scheme described in example I C. The sera were absorbed with BSA- m-amino-benzyloxymethyl-cellulose.

D. Anti-oestradiol-cellulose was prepared in the same manner as the anti-testosterone-cellulose described in example I D. From each of the immunized rabbits a cellulose preparation was made, numbered 16 up to 20 inclusive.

E. The test was performed analogous to that for testosterone as described in example I E.

FIG. 3 and 4 show a few results. FIG. 3 shows that the immunization yielded 3 usable antisera, of which As 17 has the highest titre.

FIG. 4 shows the test system in which anti-oestradiolcellulose 17 is used in a concentration of 8 mg/ml. The system does not discriminate between oestron and 17B-oestradiol. 17a-oestradiol and especially oestriol show a smaller cross-reaction. Testosterone and progesterone influence the system only in very high concentrations.

Example Ill Determination of antibodies against penicillin Penicilloyl-catalase Thirty milligrams of benzyl penicillinic acid were dissolved in ml of 96% ethanol and added dropwise to 200 mg of catalase in 45 ml of 0.1 M phosphate buffer of pH 7.5. The reaction process was continued for 2 hours, the pH being maintained between 7.2 and 8.2 with 0.5 N NaOH. The reaction mixture was dialysed against 6 X 3 l of 0.02 M phosphate buffer of pH 7.0.

In the same manner 250 mg of benzyl penicillinic acid were coupled to 5 gm of m-aminobenzyloxymethyl-cellulose prepared by Gurvichs method. Biokhimiya 26, 934 (1961). The coupling product was not dialysed however, but washed on a glass filter.

It proved to be possible to demonstrate over -sensitiveness to penicillin in humans in the following manner.

0.2 ml of a sample of non-haemolysed serum were mixed with 0.5 ml of a solution of penicilloyl-catalase (1 800). After 30 minutes mg of the penicilloyl-maminobenzyloxymethyl-cellulose were added. The mixture was rotated, for 30 minutes after which the enzyme activity in the supernatant liquid was determined by adding 0.02 ml of it to 2.8 ml of 0.05 M phosphate buffer of pH 6.8, which contained 1.2 a] of 30% H 0 and following the decrease in the extinction at 240 nm. In the serum from patients who were hyper-sensitive to penicillin less enzyme activity was found in the liquid than in checking with rabbit serum. The serum from normal human beings in these tests did not deviate considerably from normal rabbit serum.

Example IV Determination of folic acid A. Preparation of folate-glucose-oxidase Two hundred milligrams of glucose-oxidase (140 lU/mg) were dissolved in 10 ml of PBS (phosphate buffered saline, a phosphate-containing physiological salt solution) of pH 7.0. Thirty milligrams of l-cyclohexyl-3-( 2-morpholino-ethyl carbodiimide (MCDI) were added and then 24 mg of folic acid. The reaction process lasted 2 hours, after which a thorough dialysis was performed against PBS of pH 7.0.

B. Preparation of folate-MBSA (methylated bovine serum albumin) Folate-MBSA was prepared by Ricker and Stollars process described in Biochemistry 6, 2001 (1967). Twenty-five milligrams of MCDI were added to 50 mg of MBSA in 5 ml of water and then mg of folic acid. Two hours later a yellow precipitate had formed. Finally the whole reaction mixture was dialysed against physiological salt for a considerable time.

C. Preparation of antiserum against folate-MBSA On the days 0, 21 and 42 four rabbits were each injected intramuscularly with 2 mg of folate-MBSA in complete Freunds adjuvant and on day 35 intravenously with 2 mg of folate-MBSA in physiological salt. On day 49 the animals were exsanguinated.

D. Anti-folate cellulose was prepared by the process described in example I D.

E. Test system for folic acid One hundred ul of sample and 700 p.l of anti-folate cellulose suspension were rotated for 3 hours. Two hundred ul of folate-glucose-oxidase (l 1500) were added. The mixture was rotated again for 3 hours and centrifuged, after which the enzyme activity in the supernatant liquid was determined. This was done by mixing 0.5 ml ofit with a solution of 50 mg of glucose, 10 ,ugm of HRP and 1 mg of 5-aminosalicylic acid in 2.5 ml of 0.05N phosphate buffer of pH 6.0 and measuring the extinction after 30 minutes at 460 nm.

FIG. 5 shows the percentage of enzyme bound against the concentration of an anti-folatecellulose.

FIG. 6 shows the sensitivity of the test system in an anti-folate-cellulose concentration of 2 mg/ml and the effect of glycine, asparagine, alanine and glutamic acid.

Example V Determination of digoxin A. Preparation of digoxin-HRP To 22 mg of digoxin, suspended in 1 ml of absolute ethanol, was added dropwise, while stirring, 1 ml of 0.1 M sodium metaperiodate. After 25 minutes 0.3 ml of 0.1 M ethyleneglycol was added. Five minutes later this mixture was added dropwise, while stirring, to a solution 32 mg of horse radish peroxidase (HRP) in 1 ml of distilled water, which had been adjusted to pH 9.5 with a 5% K CO solution. During the reaction the pH was maintained at 9-9.5 with 5% K CO When the pH had become stable 15 mg of NaBH, in 1 ml of distilled water was added. After 3 hours the pH was adjusted to 6.5 with l M formic acid. One hour later 1 M NH OH was added till a pH of 8.5 had been reached. The mixture was dialysed overnight against cold running water. Finally the pH was adjusted at 4.5 with 0.1 N hydrochloric acid. The mixture was left to stand at room temperature for 1 hour and 4 hours at 4C to obtain a precipitate which was centrifuged for 1 hour at 1000 g. The precipitate was dissolved in 5 ml of 0.1 M Nail-[C0 thoroughly dialysed and freeze-dried.

B. Preparation of digoxin-BSA Digoxin bovine serum albumin (BSA) was prepared in the same manner as the above digoxin-HRP, but the starting materials were 436 mg of digoxin and 560 mg of BSA, the quantities of the other reagents having been raised in the same ratio as the digoxin.

C. Preparation of antibodies against digoxin Five rabbits were each injected with 400, 800 and 1600 ugm of digoxin-BSA respectively, at fortnightly intervals. The immunogen was mixed with complete Freunds adjuvant and administered intramuscularly. A fortnight after the last injection the animals were injected intravenously with 800 ugm of digoxin-BSA in physiological salt. Ten days later the animals were bleeded. The serum was adsorbed with BSA-m-aminobenzyloxymethylcellulose. D. Preparation of anti-digoxin-cellulose Anti-digoxin-cellulose was prepared by Gurvichs method as described in example 1 D. E. Determination of digoxin A dilution series was prepared of digoxin in 0.1 M phosphate buffer of pH 7.5 containing 0.9% NaCl, 0.5% Tween-20 and 1.0% of BSA. The dilution series was of from 0.1-100 ngm/ml. One millilitre of a digoxin solution was mixed with 0.1 ml of digoxin-HRP in a suitable dilution, after which 2 mg of antidigoxin-cellulose suspended in 0.4 ml of buffer were added. The mixture was rotated for 6 hours at room temperature, after which it was centrifuged and the enzyme activity in the supernatant liquid determined.

Addition of 0.8 ngm of digoxin proved to cause a measurable increase of enzyme activity in the supernatant liquid. Digitoxin only showed a slight cross-reaction in the system whereas cholesterol, cortisol, oestradiol, testosterone and progesterone did not show any cross-action in the system.

Example VII Determination of transcortine The reagents used for the determination of cortisol, as described in Example IV, were also employed for the determination of transcortine.

Of a dilution series of transcortine of from O 1280 ngm/ml 0.5 ml was incubated for 15 minutes at 4C with 0.2 ml of cortisol-2l-galactose-oxidase in a suit- 10 able dilution. To this dilution series 0.3 ml of transcortine-Sepharose mg/ml) were added and the mixture was rotated for 15 minutes at 4C. The activity in the supernatant liquid was measured as described in example VI. 15 A sample containing 40 ngm/ml of transcortine proved to cause a measurable increase of enzyme activity in the supernatant liquid, whereas in the presence of 320 ngm/ml all the enzyme activity was found in the supernatant liquid.

What is claimed is:

1. Process for the demonstration and determination of a low molecular weight organic compound by means of an antibody against said low molecular weight compound, comprising the steps of:

a. providing a given quantity of the coupling product of said low molecular weight organic compound with an enzyme;

b. providing a corresponding given quantity of an insolubilized antibody against said low molecular weight organic compound;

Example VI Determination of cortisol A. Preparation of cortisol-2l-galactose-oxidase Fifty mg of cortisol-Zl-hemisuccinate and 100 mg of galactose-oxidase were coupled by the mixed anhydride technique as described in example I A. B. Preparation of insoluble transcortine One hundred milligrams of transcortine, purified by DEAE, cellulose, and hydroxyl apatite chromatography respectively, were coupled to 3 gm Sepharose 4 B by the CNBr method, as follows. Three grams of Sepharose 4 B suspension were activated by mixing it with 4 ml of a 2.5% (w/v) CNBr solu tion in distilled water, after which the pH was adjusted between 10 and 11 with 1 N NaOI-l, at which value it was maintained for 6 minutes. The Sepharose was washed with icewaterand with 0.1 M NaHCO Then 100 mg of transcortine in 20 ml of 0.1 M NaHCO were added and the suspension was shakenfor 24 hours at 4C. After being washed with'successively 0.5 M NaI-ICO 0.05 M citrate buffer of pH 1.1 and 0.05 M phosphate buffer of pH 6.0, the Sepharose was kept in the last buffer,

2. The process of claim 1 in which said low molecular weight organic compound is a hapten.

3. The process of claim 1 in which said enzyme is an oxido-reductase.

4. Process for the demonstration and determination of a low molecular weight organic compound by means of a protein capable of reacting to bind said low molecular weight organic compound specifically, comprising the steps of:

to which 0.1% merthiolate had been added. C. Determination of cortisol Of a cortisol-containing sample (standard, plasma or urine) 0.5 ml were extracted twice with methylene chloride (2 X 3 ml). The combined extraction liquids wereevaporated to dryness. The residue was .a. providing a given quantity of the coupling product taken up in 0.5 ml of physiological salt solution and mixed with 0.2 ml of cortisol-2l-galactose-oxidase s z i :Z ggi wlght orgamc compound m a.smtable concentraum? and 1 b. providing a corresponding given quantity of an incomne'sepharose Suspens lon (5 solubilized specific binding protein having more ture was rotate? for mmutes and cenm' than one valency capable of reacting to bind said fuged, after which the enzyme activity in the superlow molecular weight organic compound specifb natant liquid was determined by adding 0.5 m1 of Cally;

it to m1 of Substrate cotlsistillg 9 mg of c. contacting a sample of a fluid containing the low galactose, zofng S'ammOSahCYhC and 10 molecular weight organic compound to be deterof Permdase 150 ml of 002 M Phosphate mined with said components (a) and (b) to form a buffer of pH 6.0. Thirty minutes later the extinction was measured at 460 nm.

Five ngm/ml of cortisol in the sample caused a measurable increase of the enzyme activity in the supernatant liquid. Corticosterone and progesterone 6 reaction mixture; and

d. determining the enzyme activity of the liquid or the solid phase of the resulting reaction mixture, which activity is a measure of the quantity of low molecular weight organic compound to be deter mined.

5. The process of claim 4 in which said enzyme is an oxido-reductase.

6. Process for the demonstration and determination of a specific binding protein having two or more binding sites by means of a low molecular weight organic compound capable of reacting to bind said protein specifically; comprising the steps of:

a. providing a given quantity of the coupling product of said low molecular weight organic compound and an enzyme;

b. providing a corresponding given quantity of an insolubilized specific binding protein having two or more binding sites capable of binding said low molecular weight organic compound;

c. contacting a sample of a fluid containing the protein to be determined with said components (a) and (b) to form a reaction mixture; and

d. determining the enzyme activity of the liquid phase of the resulting reaction mixture, which activity is a measure of the quantity of the specific binding protein to be determined.

7. The process of claim 6 in which said protein is an antibody.

8. A diagnostic pack for the demonstration and determination of a low molecular weight organic compound by means of an antibody against said low molecular weight organic compound, comprising:

a. a given quantity of the coupling product of said low molecular weight organic compound with an enzyme;

b. a corresponding given quantity of an insolubilized antibody against said low molecular weight organic compound; and

c. a substrate for the determination of the enzyme activity of said enzyme.

9. The diagnostic pack of claim 8 in which said enzyme is an oxido-reductase.

10. A diagnostic pack for the demonstration and determination of a low molecular weight organic compound by means of a protein capable of reacting to bind said low molecular weight organic compound spe cifically, comprising:

a. a given quantity of the coupling product of said low molecular weight organic compound with an enzyme;

b. a corresponding given quantity of an insolubilized specific binding protein capable of reacting to bind said low molecular weight organic compound specifically; and

c. a substrate for the determination of the enzyme activity of said enzyme.

11. The diagnostic pack of claim 10 in which said enzyme is an oxido-reductase.

12. A diagnostic pack for the demonstration and determination of a hapten by means of an antibody against said hapten, comprising:

a. a given quantity of the coupling product of said hapten with an enzyme;

b. a corresponding given quantity of an insolubilized antibody against said hapten; and

c. a substrate for the determination of the enzyme activity of said enzyme.

13. The diagnostic pack of claim 12 in which said enzyme is an oxido-reductase.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION PATENT NO. 3,850,752 A Page: 1 of 2 DATED November 26, 1974 vE 0 (5) Schuurs et a1.

It is certified that error appears in the above-identifiedpatent and that said Letters Patent is hereby corrected as shown below:

On the front page of the patent (disclosing the inventors, assignee, Abstract, References Cited, under [21] Appl No. 193,702" the following heading and contents thereunder:

Related U.S. Application Data p In column 1, beneath the title "PROCESS FOR THE DEMONSTRATION AND DETERMINATION OF LOW MOLECULAR COMPOUNDS AND OF PROTEINS CAPABLE OF BINDING THESE COMPOUNDS SPECIFICALLY" Insert the following paragraph:

This application is a continuation-in-part of Ser. No. 762,120, filed September '24, 1968, issued as U.S. Pat. 3,654,090 on April 4, 1972.

In column 4, line 25, change to In column 5, lines 31 32, place "aminocellulose" in quotation marks. I

In column 5, line 48, place "aminocellulose" in quotation marks.

In column 5, line 49, place "aminocellulose" in quotation marks.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION PATENT NO. 3,850,752 Page 2 of 2 DATED November 26, 1974 INVENTQR(S) Schuurs et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In column 7, line 20, change to "z".

Signed and Scaled this Twelfth Day Of Ju1y1983 [SEAL] A nest:

GERALD J. MOSSINGHOFF Arresting Officer Commissioner of Parents and Trademarks

Citations de brevets
Brevet cité Date de dépôt Date de publication Déposant Titre
US3615222 *4 sept. 196826 oct. 1971New England Nuclear CorpMethod and apparatus for measuring the amount of a component in a biological fluid
US3654090 *24 sept. 196820 juil. 1982 Titre non disponible
Citations hors brevets
Référence
1 *Chemical Abstracts 65: 11124b, (1966).
2 *Spector et al., 168: 1348, 8, Science, (June 12, 1970).
Référencé par
Brevet citant Date de dépôt Date de publication Déposant Titre
US3905871 *10 oct. 197416 sept. 1975Syva CoLactam conjugates to enzymes
US3966556 *20 juin 197429 juin 1976Syva CompanyCompounds for enzyme amplification assay methadone analogs
US3975237 *20 juin 197417 août 1976Syva CompanyCompounds for enzyme amplification assay - - ecgonine analogs
US4039385 *19 janv. 19762 août 1977Syva CompanyCardiac glycoside enzyme conjugates
US4040907 *29 déc. 19759 août 1977Syva CompanyIodothyronine enzyme conjugates
US4043872 *29 déc. 197523 août 1977Syva CompanyPolyiodothyronine immunoassay
US4046636 *24 mai 19766 sept. 1977Syva CompanyDiazepam enzyme conjugates
US4061466 *14 oct. 19756 déc. 1977Ingvar Gosta Holger SjoholmBiologically active composition and the use thereof
US4096138 *8 déc. 197520 juin 1978Scherr George HImmunological test procedure
US4098876 *26 oct. 19764 juil. 1978Corning Glass WorksReverse sandwich immunoassay
US4134792 *6 déc. 197616 janv. 1979Miles Laboratories, Inc.Specific binding assay with an enzyme modulator as a labeling substance
US4166767 *16 mars 19774 sept. 1979Dainippon Pharmaceutical Co., Ltd.Insolubilized antibody
US4191613 *19 janv. 19774 mars 1980Syva CompanyMalate dehydrogenase conjugates for enzyme immunoassays
US4203802 *5 déc. 197720 mai 1980Syva CompanyInhibitable enzyme amplification assay
US4248965 *3 oct. 19773 févr. 1981Mochida Seiyaku Kabushiki KaishaImmunochemical process of measuring physiologically active substances
US4250253 *9 mars 197810 févr. 1981Snamprogetti S.P.A.Composition adapted for the determination of tri-iodo thyronine and diagnosis method employing same
US4269938 *8 mars 197926 mai 1981Eastman Kodak CompanyAssay of peroxidatively active materials
US4282325 *7 mai 19794 août 1981Syva CompanyEnzyme bound corticosteroids
US4289748 *31 mai 197915 sept. 1981United States Of AmericaUltrasensitive enzymatic radioimmunoassay method
US4299916 *26 déc. 197910 nov. 1981Syva CompanyPreferential signal production on a surface in immunoassays
US4323647 *15 oct. 19806 avr. 1982University Of MiamiSteric hindrance enzyme immunoassay
US4343896 *1 mai 198010 août 1982Akzona IncorporatedMethod and test pack for the demonstration and determination of an antigen or antibody
US4347312 *20 mars 198031 août 1982Research Triangle InstituteDetection of antibiotics in milk
US4350761 *15 mai 198021 sept. 1982Yamasu Shoyu Kabushiki KaishaMethod of and reagents for quantitative analysis of cyclic nucleotides
US4376825 *30 déc. 198015 mars 1983Syva CompanyEnzyme amplification compounds for assays for androgens
US4391904 *17 avr. 19815 juil. 1983Syva CompanyTest strip kits in immunoassays and compositions therein
US4419453 *30 sept. 19826 déc. 1983The Dow Chemical CompanyImmunological agglutination assays with dyed or colored latex and kits
US4443365 *24 juin 198117 avr. 1984Dainippon Pharmaceutical Company LimitedMethod for determination of the valproic acid and reagents therein
US4467030 *15 mai 198121 août 1984Boehringer Mannheim GmbhDetermination of the thyroxine-binding index in serum
US4506009 *30 mars 198219 mars 1985University Of CaliforniaHeterogeneous immunoassay method
US4530900 *13 sept. 198223 juil. 1985Seragen Diagnostics Inc.Soluble insoluble polymers in enzymeimmunoassay
US4535057 *26 juil. 198213 août 1985Amf IncorporatedImmunoassay employing monoclonal herpes simplex antibody and biotin-avidin detection system
US4604365 *28 mai 19825 août 1986Electro-Nucleonics, Inc.Immunoprecipitation assay
US4713347 *14 janv. 198515 déc. 1987Sensor Diagnostics, Inc.Measurement of ligand/anti-ligand interactions using bulk conductance
US4786594 *14 mai 198622 nov. 1988Syntex (U.S.A.) Inc.Enzyme immunoassay
US5047330 *6 janv. 198810 sept. 1991Commissariat A L'energie AtomiqueCompound labelled by the acetyl cholinesterase of Electrophorus electricus, its preparation process and its use as a tracer or marker in enzymoimmunological determinations
US5268298 *26 avr. 19917 déc. 1993Life Technologies, Inc.System for delivering oxygen to a cell culture medium
US5354692 *8 sept. 199211 oct. 1994Pacific Biotech, Inc.Analyte detection device including a hydrophobic barrier for improved fluid flow
US5391483 *1 juil. 199221 févr. 1995Eastman Kodak CompanyLigand analogs for immunoassays derived from dicarboxylic acid oxidation products
US5516639 *22 juil. 199314 mai 1996Mayo Foundation For Medical Education And ResearchAntibodies specific for human prostate glandular kallkrein
US5587294 *28 oct. 199424 déc. 1996Assay Research, Inc.Method and kit for measuring endogenous cytokines
US5589344 *15 juin 199431 déc. 1996Johnson & Johnson Clinical Diagnostics, Inc.Test kit and method for competitive specific binding assay
US5605800 *6 juin 199525 févr. 1997Institut PasteurMethod of detecting and characterizing a nucleic acid or a sequence of the latter, and enzymatic reactant for the application of this method
US5614504 *21 avr. 199525 mars 1997The University Of South FloridaMethod of making inosine monophosphate derivatives and immunopotentiating uses thereof
US5624804 *1 oct. 199229 avr. 1997The Rockefeller UniversityImmunochemical detection of In vivo advanced glycosylation end products
US5629408 *7 juin 199513 mai 1997The Rockefeller UniversityImmunochemical isolation of in vivo advanced glycosylation endproducts
US5637467 *29 mars 199510 juin 1997Behringwerke AgHeterogeneous assay using a pendulous drop
US5652346 *6 mars 199629 juil. 1997Johnson & Johnson Clinical Diagnostics, Inc.Dicarboxylic acid oxidation products
US5683887 *7 juin 19954 nov. 1997The Rockefeller UniversityImmunochemical detection of in vivo advanced glycosylation endproducts
US5684144 *7 févr. 19944 nov. 1997University Of North TexasEscherichia coli csrA gene, protein encoded thereby, and methods of use thereof
US5702704 *7 juin 199530 déc. 1997The Rockefeller UniversityAntibodies to in vivo advanced glycosylation endproducts
US5703206 *3 août 199430 déc. 1997Univ RockefellerMacrophage inflammatory protein 2 (MIP-2)
US5712101 *7 juin 199527 janv. 1998The Rockefeller UniversityImmunochemical detection of in vivo advanced glycosylation endproducts
US5717074 *7 juin 199510 févr. 1998The Rockefeller UniversityMacrophage-derived inflammatory mediator (MIP-2)
US5726023 *6 juin 199510 mars 1998University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US5728807 *21 juin 199517 mars 1998Ramot-University Authority For Applied Research And Industrial Development, Ltd.Mutated proteins associated with ataxia-telangiectasia
US5733546 *7 juin 199531 mars 1998The Rockefeller UniversityImmunochemical detection of in vivo advanced glycosylation endproducts
US5777093 *28 juil. 19957 juil. 1998Ramot-University Authority For Applied Research & Industrial Development Ltd.cDNAs associated with ataxia-telangiectasia
US5801005 *31 mars 19951 sept. 1998University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5837535 *15 févr. 199617 nov. 1998Henry Ford Health SystemNeuronal-neonatal gene: neuronatin
US5840322 *19 déc. 199624 nov. 1998Ramot-University Authority For Applied Research & Industrial Devel. Ltd.Anti-oral-microbial adhesion fraction derived from vaccinium
US5843673 *7 juin 19951 déc. 1998Curators Of The University Of MissouriMethod of screening for endometriosis
US5846538 *7 juin 19958 déc. 1998University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the her-2/neu oncogene is associated
US5858661 *8 avr. 199612 janv. 1999Ramot-University Authority For Applied Research And Industrial DevelopmentAtaxia-telangiectasia gene and its genomic organization
US5869445 *1 avr. 19969 févr. 1999University Of WashingtonMethods for eliciting or enhancing reactivity to HER-2/neu protein
US5874423 *12 sept. 199623 févr. 1999Yissum Research Development Co. Of The Hebrew University Of JerusalemDigitalis-like compounds
US5876712 *6 juin 19952 mars 1999University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US5876928 *6 juin 19952 mars 1999Institut PasteurMethod of detecting and characterizing a nucleic acid or a sequence of the latter, and enzymatic reactant for the application of this method
US5882644 *22 mars 199616 mars 1999Protein Design Labs, Inc.Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US5939524 *9 déc. 199117 août 1999The Scripps Research InstitutePlatelet GPIII P1A1 and P1A2 epitopes, their preparation and use
US5955262 *8 sept. 199221 sept. 1999Institut PasteurMethod of detecting and characterizing a nucleic acid or reactant for the application of this method
US5965379 *28 oct. 199712 oct. 1999Cytimmune Sciences Inc.Method for measuring endogenous cytokines
US6001968 *17 août 199414 déc. 1999The Rockefeller UniversityOB polypeptides, modified forms and compositions
US6008335 *19 sept. 199728 déc. 1999Cedars-Sinai Medical CenterMethods of screening for ulcerative colitis and Crohn's disease
US6013471 *17 déc. 199611 janv. 2000Hybritech IncorporatedDNA encoding hK2 variant polypeptides
US6048837 *7 juin 199511 avr. 2000The Rockefeller UniversityOB polypeptides as modulators of body weight
US6060260 *27 févr. 19989 mai 2000Dade Behring Inc.Methods for reducing adsorption in an assay
US6075122 *6 juin 199513 juin 2000University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US6093796 *17 déc. 199625 juil. 2000Mayo Foundation For Medical Education And ResearchRecombinant hK2 polypeptide
US6093809 *6 mai 199725 juil. 2000University Technology CorporationTelomerase
US6103234 *7 juin 199515 août 2000The Rockefeller UniversityComposition comprising an antibody to macrophage-derived inflammatory mediator (MIP-2)
US6103237 *26 mars 199615 août 2000Hybritech IncorporatedStable variant hK2 polypeptide
US6124439 *7 juin 199526 sept. 2000The Rockefeller UniversityOB polypeptide antibodies and method of making
US6124448 *7 juin 199526 sept. 2000The Rockfeller UniversityNucleic acid primers and probes for the mammalian OB gene
US6127338 *1 avr. 19983 oct. 2000Calyx Therapeutics, Inc.Orally active fraction of momordica charantia, active peptides thereof, and their use in the treatment of diabetes
US6129917 *21 mars 199710 oct. 2000The University Of Georgia Research Foundation, Inc.Immunogenic compositions comprising porphyromonas gingivalis proteins and/or peptides and methods
US618041130 juil. 199830 janv. 2001The Regents Of The University Of CaliforniaLight-triggered indicators that memorize analyte concentrations
US61875634 août 199913 févr. 2001Yale UniversityβIV-spectrin-polypeptides and nucleic acids encoding same
US62007493 mai 199613 mars 2001Ramot-University Authority For Applied Research And Industrial Development Ltd.Mutated forms of the ataxia-telangiectasia gene and method to screen for a partial A-T phenotype
US620715322 mai 199727 mars 2001Viventia Biotech, Inc.Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US62285757 févr. 19978 mai 2001Affymetrix, Inc.Chip-based species identification and phenotypic characterization of microorganisms
US62286389 juil. 19988 mai 2001University Of North Texas, Health Science Center At Fort WorthEscherichia coli CSRB gene and RNA encoded thereby
US623548619 juin 199822 mai 2001Mayo Foundation For Medical Education & ResearchMethod for detection of breast cancer
US62618369 mai 199717 juil. 2001Geron CorporationTelomerase
US62844962 janv. 19984 sept. 2001University Of South FloridaDNA vector for determining the presence of out-of-reading-frame mutations
US629433428 sept. 199925 sept. 2001Board Of Regents, The University Of Texas SystemGenetic test for equine severe combined immunodeficiency disease
US630334424 juin 199916 oct. 2001Maxygen, Inc.Methods and compositions for polypeptide engineering
US63098537 juin 199530 oct. 2001The Rockfeller UniversityModulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US631290110 sept. 19996 nov. 2001Burstein Technologies, Inc.Spatially addressable, cleavable reflective signal elements, assay device and method
US631971325 juin 199920 nov. 2001Maxygen, Inc.Methods and compositions for polypeptide engineering
US63312753 août 200018 déc. 2001Burstein Technologies, Inc.Spatially addressable, cleavable reflective signal elements, assay device and method
US633516018 déc. 19961 janv. 2002Maxygen, Inc.Methods and compositions for polypeptide engineering
US634234921 juil. 199829 janv. 2002Burstein Technologies, Inc.Optical disk-based assay devices and methods
US63444438 juil. 19995 févr. 2002University Of South FloridaPeptide antagonists of tumor necrosis factor alpha
US63507307 juin 199526 févr. 2002The Rockefeller UniversityOB polypeptides and modified forms as modulators of body weight
US635548424 juin 199912 mars 2002Maxygen, Inc.Methods and compositions for polypeptides engineering
US639185431 juil. 200021 mai 2002Calyx Therapeutics, Inc.Orally active fraction of momordica charantia, active peptides thereof, and their use in the treatment of diabetes
US640685522 nov. 200018 juin 2002Maxygen, Inc.Methods and compositions for polypeptide engineering
US641068713 avr. 199925 juin 2002The Regents Of The University Of CaliforniaPolypeptides for the detection of microtubule depolymerization inhibitors
US642930428 nov. 20006 août 2002The Regents Of The University Of CaliforniaNucleic acids encoding a katanin p60 subunit
US643315524 sept. 199713 août 2002Tanox, Inc.Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US6440682 *24 mai 200027 août 2002Detroit R&D Inc.Detection of hypertension using immunoreactive metabolic products
US645525327 avr. 200024 sept. 2002Maxygen, Inc.Methods and compositions for polypeptide engineering
US645855719 nov. 19981 oct. 2002Genencor International, Inc.Enhancing growth in gram-positive microorganisms using formate supplementation and inactivation of formate-associated transport proteins
US64719567 juin 199529 oct. 2002The Rockefeller UniversityOb polypeptides, modified forms and compositions thereto
US647578914 août 19975 nov. 2002University Technology CorporationHuman telomerase catalytic subunit: diagnostic and therapeutic methods
US647926311 avr. 199712 nov. 2002Baylor College Of MedicineMethod for detection of micrometastatic prostate cancer
US648238916 oct. 199819 nov. 2002University Of South FloridaMethod to diagnose and monitor cellular immune deficiencies
US6482608 *26 mai 200019 nov. 2002The Salk Institute For Biological StudiesCloning and recombinant production of CRF receptor(S)
US649534317 janv. 199517 déc. 2002The Salk Institute For Biological StudiesCloning and recombinant production of CRF receptor(s)
US650655330 mars 199514 janv. 2003Ortho Diagnostics Systems, Inc.Method for diagnosis of Epstein-Barr virus associated disease
US650657914 juil. 199814 janv. 2003Genencor International, Inc.Increasing production of proteins in gram-positive microorganisms using SecG
US652142115 juil. 199818 févr. 2003Genencor International, Inc.Expression vectors encoding Bacillus subtilis disulfide bond isomerase and methods of secreting proteins in gram-positive microorganisms using the same
US65214408 sept. 199818 févr. 2003Genencor International, Inc.Proteases from gram-positive organisms
US653113028 juin 200011 mars 2003The Board Of Trustees Of The Leland Stanford UniversityTreatment of demyelinating autoimmune disease with ordered peptides
US653127719 mars 199811 mars 2003The Curators Of The University Of MissouriEndometriosis-specific secretory protein
US653781513 déc. 200025 mars 2003University Of North Texas, Health Science Center At Fort WorthMethod of altering the expression of csrB to modify the properties of a cell
US654479214 juin 20008 avr. 2003Genencor International, Inc.Production of secreted polypeptides
US657967820 oct. 200017 juin 2003Maxygen, Inc.Methods and compositions for polypeptide engineering
US659650123 févr. 199922 juil. 2003Fred Hutchinson Cancer Research CenterMethod of diagnosing autoimmune disease
US659973117 déc. 199829 juil. 2003Genencor International, Inc.Proteases from gram positive organisms
US66108391 oct. 199726 août 2003Geron CorporationPromoter for telomerase reverse transcriptase
US661351427 avr. 20002 sept. 2003Maxygen, Inc.Methods and compositions for polypeptide engineering
US661711022 nov. 20009 sept. 2003Geron CorporationCells immortalized with telomerase reverse transcriptase for use in drug screening
US66303285 juil. 20017 oct. 2003Genencor International, Inc.Increasing production of proteins in gram-positive microorganisms
US663890512 nov. 199828 oct. 2003The Salk Institute For Biological StudiesCloning and recombinant production of CFR receptor(s)
US664202714 nov. 20014 nov. 2003Genecor International, Inc.Production of secreted polypeptides
US665307224 juin 199925 nov. 2003Maxygen, Inc.Methods and compositions for polypeptide engineering
US666437015 juil. 199916 déc. 2003University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US667362312 sept. 20006 janv. 2004Novocure, Inc.Methods and compositions that control lipid production
US667391421 janv. 19996 janv. 2004John Wayne Cancer InstituteHuman tumor-associated gene
US669996928 nov. 20002 mars 2004The Regents Of The University Of CaliforniaAssays for the detection of microtubule depolymerization inhibitors
US672355014 juil. 199820 avr. 2004Genencor International, Inc.Proteases from gram-positive organisms
US67592436 déc. 20006 juil. 2004Board Of Trustees Of The University Of IllinoisHigh affinity TCR proteins and methods
US677044930 janv. 20013 août 2004Duke UniversityMethods of assaying receptor activity and constructs useful in such methods
US67706228 juin 20013 août 2004Gary A. JarvisN-terminally truncated galectin-3 for use in treating cancer
US67873181 juin 20007 sept. 2004Roskamp Research Institute, LlcAssay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
US67941792 juil. 200221 sept. 2004Genencor International, Inc.Proteases from gram positive organisms
US680888019 janv. 200126 oct. 2004Geron CorporationMethod for detecting polynucleotides encoding telomerase
US683326126 mars 200321 déc. 2004Genencor International, Inc.Proteases from gram-positive organisms
US683326517 août 200121 déc. 2004Genencor International, Inc.Proteases from gram-positive organisms
US68334411 août 200121 déc. 2004Abmaxis, Inc.Compositions and methods for generating chimeric heteromultimers
US68444332 juin 200318 janv. 2005Affymetrix, Inc.Nucleic acid labeling compounds
US684944026 mars 20031 févr. 2005Genencor International, Inc.Proteases from gram-positive organisms
US685269521 mars 20028 févr. 2005Theracos, Inc.Orally active fraction of momordica charantia, active peptides thereof, and their use in the treatment of diabetes
US685871113 juin 200122 févr. 2005Affymetrix, Inc.Labeling reagents
US68640595 déc. 20028 mars 2005Affymetrix, Inc.Biotin containing C-glycoside nucleic acid labeling compounds
US687253713 avr. 199929 mars 2005Regents Of The University Of CaliforniaAssays for the detection of microtubule depolymerization inhibitors
US687280712 juin 200329 mars 2005Genencor International, Inc.Proteases from gram positive organisms
US687558218 août 20005 avr. 2005Omniscience Pharmaceuticals, Inc.Methods and targets of antibiotic resistance
US688156226 mars 200319 avr. 2005Genencor International, Inc.Proteases from gram-positive organisms
US688459015 oct. 199926 avr. 2005Cedars-Sinai Medical CenterMethods of screening for ulcerative colitis and crohn's disease
US690586823 déc. 200214 juin 2005Genencor International, Inc.Proteases from gram-positive organisms
US691133326 mars 200328 juin 2005Genencor International, Inc.Proteases from gram-positive organisms
US692166418 janv. 200226 juil. 2005Regents Of The University Of ColoradoTelomerase
US692409428 nov. 20002 août 2005Affymetrix, Inc.Chip-based species identification and phenotypic characterization of microorganisms
US692728512 nov. 19999 août 2005Geron CorporationGenes for human telomerase reverse transcriptase and telomerase variants
US694629612 sept. 200120 sept. 2005Maxygen, Inc.Methods and compositions for polypeptide engineering
US69535736 oct. 199811 oct. 2005University Of WashingtonCompounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US695821412 avr. 200125 oct. 2005Sequenom, Inc.Polymorphic kinase anchor proteins and nucleic acids encoding the same
US696502011 sept. 200115 nov. 2005Affymetrix, Inc.Nucleic acid labeling compounds
US699217613 févr. 200231 janv. 2006Technion Research & Development Foundation Ltd.Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US69982324 avr. 200114 févr. 2006Quark Biotech, Inc.Methods of diagnosing bladder cancer
US700526218 janv. 200228 févr. 2006Geron CorporationMethods for detecting nucleic acids encoding human telomerase reverse transcriptase
US70188125 nov. 200128 mars 2006Duke UniversityModified G-protein coupled receptors
US703022815 nov. 200018 avr. 2006Miltenyi Biotec GmbhAntigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
US703381721 juin 200225 avr. 2006Genencor International, Inc.Proteases from gram positive organisms
US70377149 janv. 20032 mai 2006Genencor International, Inc.Expression vectors encoding Bacillus subtilis disulfide bond isomerase and methods of secreting proteins in gram-positive microorganisms using the same
US704559614 mai 200216 mai 2006Tanox, Inc.Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US704560420 nov. 200216 mai 2006Tanox, Inc.Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US705318824 févr. 200330 mai 2006Purdue Research FoundationMonoclonal antibodies specific for neoplasia-specific NADH:disulfide reductase
US705326815 juin 200030 mai 2006Danisco A/SPromoter
US705651326 avr. 20016 juin 2006Geron CorporationTelomerase
US706028315 sept. 199313 juin 2006Ortho Diagnostic Systems, Inc.Immunoreactive peptides from Epstein-Barr virus
US707078020 mai 20024 juil. 2006Board Of Trustees Of The Leland Stanford Junior UniversityTreatment of demyelinating autoimmune disease with ordered peptides
US707081924 août 20044 juil. 2006Genencor International, Inc.Proteases from gram positive organisms
US707098624 août 20044 juil. 2006Genencor International, Inc.Proteases from gram positive organisms
US707099024 août 20044 juil. 2006Genencor International, Inc.Proteases from GRAM positive organisms
US707821631 oct. 200218 juil. 2006Genencor International, Inc.Proteases from gram positive organisms
US707837224 août 200418 juil. 2006Genencor International, Inc.Proteases from gram positive organisms
US708739516 janv. 20018 août 2006Quest Diagnostics Investments IncorporatedVitamin D assay
US708741816 déc. 20028 août 2006Bristol-Myers Squibb CompanyPichia pastoris formate dehydrogenase and uses therefor
US709802116 déc. 200429 août 2006Genencor International, Inc.Proteases from gram positive organisms
US710183929 août 20005 sept. 2006Yissum Research Development Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US71089682 avr. 199919 sept. 2006Affymetrix, Inc.Mycobacterial rpoB sequences
US711572222 mai 19973 oct. 2006Viventia Biotech, Inc.Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US71381449 sept. 200221 nov. 2006Nadir AskenasyMethod of inducing immune tolerance via blood/lymph flow-restricted bone marrow transplantation
US71382409 mai 200221 nov. 2006Duke UniversityMethods of assaying receptor activity
US71638001 août 200316 janv. 2007Molecular Devices CorporationMethods of screening compositions for G protein-coupled receptor desensitization inhibitory activity
US716628629 août 200323 janv. 2007Viventia Biotech Inc.Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for prophylaxis and detection of cancers
US71759832 nov. 200113 févr. 2007Abmaxis, Inc.Adapter-directed display systems
US71799052 juin 200320 févr. 2007Affymetrix, Inc.Nucleic acid labeling compounds
US718955525 août 200413 mars 2007Genecor International, Inc.Proteases from gram-positive organisms
US719255511 oct. 200120 mars 2007Orasure Technologies, Inc.Device for collection and assay of oral fluids
US719591111 janv. 200227 mars 2007Geron CorporationMammalian cells that have increased proliferative capacity
US719923420 déc. 20023 avr. 2007Geron CorporationRegulatory segments of the human gene for telomerase reverse transcriptase
US721449630 déc. 20048 mai 2007Duke UniversityModified G-protein coupled receptors
US722071625 août 200422 mai 2007Genencor International, Inc.Proteases from gram-positive organisms
US722390215 nov. 200029 mai 2007Yissum Research Development Company Of The Hebrew University Of JerusalemMethod of producing recombinant Aspergillus niger β-glucosidase and an aroma spreading plant
US724157525 août 200410 juil. 2007Genecor International, Inc.Proteases from gram-positive organisms
US724770321 août 200324 juil. 2007University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US72529484 févr. 20057 août 2007Affymetrix, Inc.Chip-based speciation and phenotypic characterization of microorganisms
US72529503 sept. 19987 août 2007The Regents Of The University Of CaliforniaAssays for detecting modulators of cytoskeletal function
US726228822 nov. 200028 août 2007Geron CorporationNucleic acids encoding human telomerase reverse transcriptase and related homologs
US727081028 déc. 200018 sept. 2007Yeda Research And Development Co. Ltd.Veto cells effective in preventing graft rejection and devoid of graft versus host potential
US728232715 août 200316 oct. 2007Affymetrix, Inc.Nucleic acid labeling compounds
US728563918 janv. 200223 oct. 2007Geron CorporationAntibody to telomerase reverse transcriptase
US729146323 déc. 20036 nov. 2007Affymetrix, Inc.Nucleic acid labeling compounds
US72947012 avr. 200313 nov. 2007Technion Research & Development Foundation Ltd.Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
US731692016 déc. 20048 janv. 2008Genencor International, Inc.Serine proteases from gram-positive microorganisms
US731692417 sept. 20018 janv. 2008Genencor International, Inc.Twin-arginine translocation in Bacillus
US73265318 déc. 20045 févr. 2008Genencor International, Inc.Proteases from gram-positive organisms
US732653521 mai 20035 févr. 2008Ortho Diagnostic Systems Inc.Immunoreactive peptides from Epstein-Barr virus
US732952516 déc. 200412 févr. 2008Genencor International, Inc.Serine proteases from gram-positive microorganisms
US732952616 déc. 200412 févr. 2008Genencor International, Inc.Serine proteases from-gram-positive microorganisms
US732952716 déc. 200412 févr. 2008Genencor International, Inc.Serine proteases from gram-positive microorganisms
US734184416 janv. 200311 mars 2008Regents Of The University Of MinnesotaMethods for diagnosing autism
US73550795 avr. 20058 avr. 2008The Regents Of The University Of CaliforniaThyronamine derivatives and analogs and methods of use thereof
US735822526 août 200315 avr. 2008The Salk Institute For Biological StudiesCloning and recombinant production of CRF receptor(s)
US737824425 avr. 200627 mai 2008Geron CorporationTelomerase promoters sequences for screening telomerase modulators
US738510610 janv. 200110 juin 2008Ramot At Tel Aviv University Ltd.Plants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby
US73904898 oct. 200424 juin 2008Komed Co., Ltd.Monoclonal antibody selectively recognizing listeria monocytogenes, hybridoma producing the antibody, test kit comprising the antibody and detection method of listeria monocytogenes using the antibody
US739369624 sept. 20021 juil. 2008Aspenbio Pharma, Inc.Bovine pregnancy test
US741386424 juin 200419 août 2008Geron CorporationTreating cancer using a telomerase vaccine
US742313920 janv. 20049 sept. 2008Insight Biopharmaceuticals Ltd.High level expression of recombinant human erythropoietin having a modified 5′-UTR
US742314310 mai 20059 sept. 2008Affymetrix. Inc.Nucleic acid labeling compounds
US74296523 août 200430 sept. 2008Abmaxis, Inc.Compositions and methods for generating chimeric heteromultimers
US74323421 mai 20037 oct. 2008Sequenom, Inc.Kinase anchor protein muteins, peptides thereof and related documents
US744277823 sept. 200528 oct. 2008Amgen Inc.Modified Fc molecules
US744278115 août 200228 oct. 2008Urifer Ltd.Diagnosis, prevention and treatment of cancer
US746554411 janv. 200616 déc. 2008Wisconsin Alumni Research FoundationSynthetic cofactor analogs of S-adenosylmethionine as ligatable probes of biological methylation and methods for their use
US746570510 févr. 200516 déc. 2008Yale UniversityNogo receptor antagonists
US746824312 mars 200223 déc. 2008Affymetrix, Inc.2-aminopyrimidin-4-one nucleic acid labeling compounds
US749181818 janv. 200517 févr. 2009Affymetrix, Inc.Nucleic acid labeling compounds
US749842820 juin 20043 mars 2009Evogene Ltd.Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
US751797122 nov. 200014 avr. 2009Geron CorporationMuteins of human telomerase reverse transcriptase lacking telomerase catalytic activity
US753460517 mai 200519 mai 2009Yissum Research Development Company Of The Hebrew University Of JerusalemCD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US753460911 avr. 200519 mai 2009Pluristem Life Systems Inc.Method of expanding undifferentiated hemopoietic stem cells
US75411514 juin 20022 juin 2009Duke UniversitySingle-cell biosensor for the measurement of GPCR ligands in a test sample
US754119417 janv. 20072 juin 2009Orasure Technologies, Inc.Device for collection and assay of oral fluids
US75534845 juin 200230 juin 2009The Regents Of The University Of CaliforniaModulating neuronal outgrowth via the major histocompatibility complex class I (MHC I) molecule
US75539401 févr. 200730 juin 2009Modigene IncLong-acting EPO polypeptides and derivatives thereof and methods thereof
US75539411 févr. 200730 juin 2009Modigene IncLong-acting polypeptides and methods of producing same
US755400722 nov. 200530 juin 2009Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants
US756043711 janv. 200214 juil. 2009Geron CorporationNucleic acid compositions for eliciting an immune response against telomerase reverse transcriptase
US756935720 févr. 20044 août 2009Board Of Trustees Of The University Of IllinoisHigh affinity TCR proteins and methods
US757288824 févr. 200411 août 2009Duke UniversityMethods of assaying receptor activity and constructs useful in such methods
US757618714 juil. 200618 août 2009Genentech, Inc.Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US75856222 nov. 19998 sept. 2009Geron CorporationIncreasing the proliferative capacity of cells using telomerase reverse transcriptase
US76016973 mai 200513 oct. 2009University Of WashingtonCompounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US760514913 juil. 199920 oct. 2009University Of South FloridaModulation of the phospholipase A2 pathway as a therapeutic
US760839515 sept. 200527 oct. 2009Baylor Research InstituteSystemic lupus erythematosus diagnostic assay
US761172320 mars 20033 nov. 2009Nanocyte Inc.Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
US761561026 janv. 200410 nov. 2009Duke UniversityModified trafficking patterns for arrestin and G-protein-coupled receptors via arrestin-ubiquitin chimera
US76187893 avr. 200217 nov. 2009The United States Of America As Represented By The Secretary Of Department Of Health And Human ServicesUse of semenogelin in the diagnosis, prognosis and treatment of cancer
US762254924 juin 200424 nov. 2009Geron CorporationHuman telomerase reverse transcriptase polypeptides
US762570727 sept. 20041 déc. 2009Ramot At Tel Aviv University Ltd.Antibacterial agents and methods of identifying and utilizing same
US763252210 janv. 200615 déc. 2009Nanocyte Inc.Use of stinging cells/capsules for the delivery of active agents to keratinous substances
US76329239 mars 200515 déc. 2009Technion Research & Development Foundation Ltd.Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US763812425 mars 200429 déc. 2009Technion Research & Development Foundation Ltd.Antigen-presenting complex-binding compositions and uses thereof
US764190415 févr. 20085 janv. 2010Konkuk University Industrial Cooperation Corp.IL-32 monoclonal antibodies and uses thereof
US76458611 août 200812 janv. 2010Amgen Inc.Modified Fc molecules
US765522519 févr. 20082 févr. 2010Gamida Cell, Ltd.Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
US765523921 juin 20072 févr. 2010University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US76557641 août 20082 févr. 2010Amgen Inc.Modified Fc molecules
US76557651 août 20082 févr. 2010Amgen Inc.Modified Fc molecules
US76629311 août 200816 févr. 2010Amgen Inc.Modified Fc molecules
US766865815 oct. 200223 févr. 2010Sequenom, Inc.Methods for generating databases and databases for identifying polymorphic genetic markers
US767857311 avr. 200516 mars 2010Pluristem Ltd.Method of preparing a conditioned medium from a confluent stromal cell culture
US768280517 janv. 200823 mars 2010Regents Of The University Of MinnesotaMethods for diagnosing major depression or schizophrenia
US768280617 janv. 200823 mars 2010Regents Of The University Of MinnesotaMethods for diagnosing bipolar disorder
US768705717 déc. 200230 mars 2010Yissum Research Development Company Of The Hebrew University Of JerusalemIn vitro micro-organs, and uses related thereto
US768728113 mars 200730 mars 2010Aspenbio Pharma, Inc.Bovine pregnancy test
US769592717 mars 200613 avr. 2010Detroit R & DDetection of hypertension using glucuronidated metabolic products
US77089844 juin 20074 mai 2010Incyte CorporationMethods of treatment with anitbodies to a chemokine expressed in inflamed adenoid
US771877718 oct. 200618 mai 2010Technion Research & Development Foundation Ltd.MHC-peptide complex binding ligands
US775012117 août 20056 juil. 2010Geron CorporationAntibody to telomerase reverse transcriptive
US77501271 août 20086 juil. 2010Amgen Inc.Modified Fc molecules
US77501281 août 20086 juil. 2010Amgen Inc.Modified Fc molecules
US777687717 juin 200817 août 2010Chemocentryx, Inc.N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
US778139621 juin 200624 août 2010Tel Aviv University Future Technology Development L.P.Peptides directed for diagnosis and treatment of amyloid-associated disease
US778140211 oct. 200524 août 2010Closed Loop Therapies Ltd.Methods and implantable devices for treating supraventricular arrhythmias
US778589830 mai 200331 août 2010Genetic Technologies LimitedMaternal antibodies as fetal cell markers to identify and enrich fetal cells from maternal blood
US779067312 juin 20067 sept. 2010New York UniversityMethods and compositions relating to cystatin C
US781198129 sept. 200412 oct. 2010Yissum Research Development Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US782931324 mai 20069 nov. 2010Eppendorf Array TechnologiesIdentification and quantification of a plurality of biological (micro)organisms or their components
US784282327 oct. 200630 nov. 2010The Regents Of The University Of CaliforniaFluorogenic probes for reactive oxygen species
US784666720 août 20097 déc. 2010Genzyme CorporationMethods for the diagnosis and treatment of lung cancer
US785507519 mai 200821 déc. 2010Gamida Cell Ltd.Methods of controlling proliferation and differentiation of stem and progenitor cells
US787544217 mai 200625 janv. 2011Eppendorf Array TechnologiesIdentification and quantification of a plurality of biological (micro)organisms or their components
US787960926 mars 20071 févr. 2011Geron CorporationRegulatory segments of the human gene for telomerase reverse transcriptase
US788387620 nov. 20078 févr. 2011Stephens David SNeisseria meningitidis serogroup A capsular polysaccharide acetyltransferase, methods and compositions
US788411011 juil. 20088 févr. 2011Chemocentryx, Inc.Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation
US78841911 juin 20078 févr. 2011Danisco Us Inc.Twin-arginine translocation in Bacillus
US78841921 juin 20078 févr. 2011Danisco Us Inc.Twin-arginine translocation in Bacillus
US789324025 juil. 200822 févr. 2011Insight Biopharmaceuticals Ltd.High level expression of recombinant human erythropoietin having a modified 5′-UTR
US78977421 juin 20071 mars 2011Danisco Us Inc.Twin-arginine translocation in Bacillus
US791035019 déc. 200522 mars 2011Abmaxis, Inc.Adaptor-directed helper systems
US791080015 août 200622 mars 2011Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
US792808316 janv. 200819 avr. 2011Yissum Research Development Company Of The Hebrew University Of JerusalemH19 silencing nucleic acid agents for treating rheumatoid arthritis
US794749930 nov. 200324 mai 2011Technion Research & Development Foundation Ltd.Method of dynamically culturing embryonic stem cells
US79558137 juil. 20067 juin 2011Danisco, A/SMethod of using lipid acyltransferase
US79558146 févr. 20077 juin 2011Danisco A/SMethod
US79558529 févr. 20047 juin 2011Gamida Cell Ltd.Expansion of renewable stem cell populations
US796015020 juil. 200914 juin 2011Danisco A/SProduction of a lipid acyltransferase from transformed Bacillus licheniformis cells
US797263814 oct. 20085 juil. 2011Danisco A/SFoodstuff
US79855427 sept. 200626 juil. 2011Institut PasteurGenomic morse code
US798897214 déc. 20072 août 2011Ortho-Clinical Diagnostics, Inc.Immunoreactive peptides from Epstein-Barr virus
US799383012 févr. 20079 août 2011Laboratory Corporation Of America HoldingsProstate-specific gene for diagnosis, prognosis and management of prostate cancer
US799430121 avr. 20099 août 2011The Rockefeller UniversityModulators of body weight, corresponding nucleic acids and proteins
US799850912 nov. 200916 août 2011Nanocyte Inc.Use of stinging cells/capsules for the delivery of active agents to keratinous substances
US80030957 juil. 200623 août 2011Danisco A/SMethod of using lipid acyltransferase
US80078477 août 200630 août 2011Eytan BidermanFeeding formula appliance
US800800818 oct. 200730 août 2011Mitomics Inc.Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers
US800802724 mars 201030 août 2011Incyte CorporationMethods of screening for compounds that modulate the activity of ADEC, a chemokine expressed in inflamed adenoid
US800845310 août 200630 août 2011Amgen Inc.Modified Fc molecules
US80127322 sept. 20096 sept. 2011Danisco A/SFungal lypolytic and amylase enzyme composition and methods using the same
US80129292 juil. 20096 sept. 2011Tel Aviv University Future Technology Development L.P.Peptides directed for diagnosis and treatment of amyloid-associated diseases
US801311818 déc. 20026 sept. 2011The Rockefeller UniversityLynx polypeptides
US80175865 janv. 200913 sept. 2011Ramot At Tel-Aviv University Ltd.Peptide nanostructures encapsulating a foreign material and method of manufacturing same
US801981816 janv. 200713 sept. 2011Zlango Ltd.Communications network system and methods for using same
US802605727 juin 200827 sept. 2011Affymetrix, Inc.Nucleic acid labeling compounds
US803004429 févr. 20084 oct. 2011Danisco A/SLipid acyltransferases
US803045615 déc. 20084 oct. 2011Yale UniversityNogo receptor antagonists
US803455324 juin 200411 oct. 2011Kimberly-Clark Worldwide, Inc.Biomarkers for wound healing
US803491421 sept. 200611 oct. 2011Yissum Research Development Company Of The Hebrew University Of JerusalemNucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer
US803924028 sept. 200518 oct. 2011Yissum Reseach Development Company Of The Hebrew University Of JerusalemRecombinant human T2 RNase and uses thereof
US805051613 sept. 20071 nov. 2011Fluidigm CorporationMethods and systems for determining a baseline during image processing
US805322118 avr. 20078 nov. 2011Danisco A/SEnzymes
US80535542 janv. 20098 nov. 2011Ramot At Tel-Aviv University Ltd.Peptide nanostructures and methods of generating and using the same
US805503413 sept. 20078 nov. 2011Fluidigm CorporationMethods and systems for image processing of microfluidic devices
US806266015 mars 200622 nov. 2011Nanocyte Inc.Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
US80629088 janv. 200922 nov. 2011Orasure Technologies, Inc.Device for collection and assay of oral fluids
US806716412 août 200829 nov. 2011Integrated Dna Technologies, Inc.Microarray system with improved sequence specificity
US806724022 nov. 201029 nov. 2011Esoterix Genetic Laboratories, LlcMethods for the diagnosis and treatment of lung cancer
US80675736 juil. 200629 nov. 2011Yissum Research Development Company Of The Hebrew University Of JerusalemNucleic acid agents for downregulating H19 and methods of using same
US806757416 janv. 200829 nov. 2011Yissum Research Development Company Of The Hebrew University Of JerusalemNucleic acid agents for downregulating H19, and methods of using same
US80713236 avr. 20076 déc. 2011The United States Of America As Represented By The Secretary Of The Department Of Health And Human ServicesHuman monoclonal antibodies that bind human insulin like growth factors and their use
US807607228 sept. 201013 déc. 2011Affymetrix, Inc.Nucleic acid labeling compounds
US808041729 nov. 200620 déc. 2011Gamida-Cell Ltd.Methods of ex vivo hematopoietic stem cell expansion by co-culture with mesenchymal cells
US80881602 juin 20093 janv. 2012Multi-Gene Vascular Systems Ltd. (“MGVS”)Drug-eluting intravascular prostheses and methods of use
US81015638 déc. 200424 janv. 2012Danisco Us Inc.Proteases from gram-positive organisms
US811461919 sept. 200714 févr. 2012The Johns Hopkins UniversityMethods for diagnosis and optimizing treatment of multiple sclerosis
US81295149 févr. 20096 mars 2012Evogene Ltd.Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
US81430453 avr. 200727 mars 2012Danisco A/SMutant Citrobacter freundii phytase polypeptide
US81430466 févr. 200827 mars 2012Danisco Us Inc., Genencor DivisionVariant Buttiauxella sp. phytases having altered properties
US816331513 avr. 201124 avr. 2012Danisco A/SFoodstuff
US816349427 nov. 200324 avr. 2012Technion Research & Development Foundation Ltd.Method for assessing metastatic properties of breast cancer
US816818030 sept. 20091 mai 2012Technion Research & Development Foundation Ltd.Methods and compositions for modulating angiogenesis
US816885720 déc. 20071 mai 2012Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US817338217 août 20108 mai 2012Abbott LaboratoriesAssay for cardiac troponin autoantibodies
US81737936 mai 20098 mai 2012The Rockefeller UniversityNucleic acids encoding modulators of body weight
US81781285 déc. 200215 mai 2012Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Nanoparticles containing polymeric nucleic acid homologs
US81830023 déc. 200922 mai 2012Abbott LaboratoriesAutoantibody enhanced immunoassays and kits
US818303929 mars 200622 mai 2012Miltenyi Biotec GmbhMethod for isolating BDCA-4+ dendritic cells
US819278216 janv. 20075 juin 2012Danisco A/SEnzymatic oil-degumming method
US81933117 févr. 20115 juin 2012Yissum Research Development Company Of The Hebrew University Of JerusalemCD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US81983098 juil. 201012 juin 2012Chemocentryx, Inc.N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl)hetaryl arylsulfonamides
US82027246 oct. 201019 juin 2012Gamida Cell Ltd.Methods of controlling proliferation and differentiation of stem and progenitor cells
US822175724 oct. 201117 juil. 2012G2 Therapies LtdMonoclonal antibodies against extracellular loops of C5aR
US822239220 août 200717 juil. 2012Geron CorporationKit for detection of telomerase reverse transcriptase nucleic acids
US822967721 déc. 200924 juil. 2012Sequenom, Inc.Methods for generating databases and databases for identifying polymorphic genetic markers
US82364937 août 20087 août 2012Affymetrix, Inc.Methods of enzymatic discrimination enhancement and surface-bound double-stranded DNA
US823654327 sept. 20107 août 2012Yissum Research Development Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US823677421 août 20097 août 2012Geron CorporationHuman telomerase catalytic subunit
US82525887 avr. 200428 août 2012Yeda Research And Development Co. Ltd.Stem cells having increased sensitivity to SDF-1 and methods of generating and using same
US826897219 févr. 200918 sept. 2012G2 Inflammation Pty LtdHumanized anti-C5aR antibodies
US82780629 mars 20092 oct. 2012Dupont Nutrition Biosciences ApsMethod of using lipid acyltransferase
US827809828 janv. 20112 oct. 2012Vegenics Pty LimitedMaterials and methods involving hybrid vascular endothelial growth factor DNAs and proteins
US828791223 juin 201116 oct. 2012Nanocyte Inc.Use of stinging cells/capsules for the delivery of active agents to keratinous substances
US828812818 nov. 200416 oct. 2012Eppendorf Array Technologies S.A.Real-time quantification of multiple targets on a micro-array
US829320922 oct. 200923 oct. 2012Segev Laboratories LimitedSystem for delivering therapeutic agents into living cells and cells nuclei
US829368429 nov. 200723 oct. 2012ExiqonLocked nucleic acid reagents for labelling nucleic acids
US830420119 avr. 20126 nov. 2012Abbott LaboratoriesAutoantibody enhanced immunoassays and kits
US831889822 déc. 200627 nov. 2012Universite De LausanneSynthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of cellular relaxation
US832363628 juil. 20114 déc. 2012Prolor Biotech Ltd.Long-acting interferons and derivatives thereof and methods thereof
US833785222 août 200725 déc. 2012G2 Inflammation Pty LtdAnti-C5aR antibodies with improved properties
US833786814 oct. 200925 déc. 2012Nanocyte Inc.Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
US835203124 mai 20078 janv. 2013Impulse Dynamics NvProtein activity modification
US835749524 avr. 200922 janv. 2013Abbott LaboratoriesImmunoassay of analytes in samples containing endogenous anti-analyte antibodies
US836146820 août 201229 janv. 2013G2 Inflammation Pty LtdHumanized anti-C5aR antibodies
US83673928 sept. 20095 févr. 2013Transalgae Ltd.Genetic transformation of algal and cyanobacteria cells by microporation
US837532716 janv. 200612 févr. 2013Zlango Ltd.Iconic communication
US83889548 avr. 20045 mars 2013Laboratoire Francais Du Fractionnement Et Des BiotechnologiesStabilising formulation for immunoglobulin G compositions in liquid form and in lyophilised form
US83945825 mars 200412 mars 2013Genetic Technologies, IncIdentification of fetal DNA and fetal cell markers in maternal plasma or serum
US841531820 juin 20119 avr. 2013Vascular Biogenics Ltd.Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
US842616627 juil. 201123 avr. 2013Prolor Biotech Inc.Long-acting polypeptides and methods of producing same
US842668219 avr. 201223 avr. 2013Evogene Ltd.Isolated polypeptides, polynucleotides useful for modifying water user efficiency, fertilizer use efficiency, biotic/abiotic stress tolerance, yield and biomass in plants
US844043525 juin 200914 mai 2013Dupont Nutrition Biosciences ApsMethod for reducing 1,2-diglyceride content of an edible oil
US844522211 juil. 200721 mai 2013Musc Foundation For Research DevelopmentPredicting heart failure following myocardial infarction by protease and protease inhibitor profiling
US84456377 déc. 200921 mai 2013Abraxis Bioscience, LlcSPARC binding peptides and uses thereof
US84502692 août 201128 mai 2013Prolor Biotech Ltd.Long-acting growth hormone and methods of producing same
US84613031 août 200811 juin 2013Gilead Biologics, Inc.LOX and LOXL2 inhibitors and uses thereof
US846594828 juil. 201118 juin 2013Prolor Biotech Ltd.Long-acting veterinary polypeptides and methods of producing and administering same
US847321630 nov. 200725 juin 2013Fluidigm CorporationMethod and program for performing baseline correction of amplification curves in a PCR experiment
US848169819 mars 20099 juil. 2013The President And Fellows Of Harvard CollegeParallel proximity ligation event analysis
US84818123 juin 20099 juil. 2013Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants generated thereby
US848644130 nov. 201016 juil. 2013Nanocyte Inc.Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
US848664021 mars 200816 juil. 2013Cedars-Sinai Medical CenterIleal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease
US848669319 sept. 201216 juil. 2013Bellicum Pharmaceuticals, Inc.Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
US84970641 nov. 201130 juil. 2013Affymetrix, Inc.Nucleic acid labelling compounds
US849734922 avr. 200730 juil. 2013Centre National De La Recherche Scientifique (Cnrs)Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation
US85064994 janv. 200813 août 2013Musc Foundation For Research DevelopmentPredicting atrial fibrillation recurrence by protease and protease inhibitor profiling
US851299020 août 201020 août 2013Gilead Biologics, Inc.Catalytic domains from lysyl oxidase and LOXL2
US85134889 avr. 200820 août 2013Evogene Ltd.Polynucleotides, polypeptides and methods for increasing oil content, growth rate and biomass of plants
US85244914 sept. 20093 sept. 2013University Of Washington Through Its Center For CommercializationCompounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US85359001 févr. 201017 sept. 2013Dupont Nutrition Biosciences ApsLipolytic enzyme uses thereof in the food industry
US854640822 déc. 20101 oct. 2013Chemocentryx, Inc.Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation
US85632739 avr. 200922 oct. 2013Tel Aviv University Future Technology Development L.P.Method of screening for compounds that disaggregate amyloid aggregates
US856902525 juin 201029 oct. 2013The University Of British ColumbiaTerpene synthases from santalum
US85748323 févr. 20105 nov. 2013Massachusetts Institute Of TechnologyMethods for preparing sequencing libraries
US85748582 oct. 20125 nov. 2013Abbott LaboratoriesAutoantibody enhanced immunoassays and kits
US85867235 sept. 200719 nov. 2013Institut PasteurGenomic morse code
US859215111 nov. 201026 nov. 2013Musc Foundation For Research DevelopmentAssessing left ventricular remodeling via temporal detection and measurement of microRNA in body fluids
US86001685 oct. 20113 déc. 2013Fluidigm CorporationMethods and systems for image processing of microfluidic devices
US86139266 juin 201224 déc. 2013Novo Nordisk A/SAnti-C5a receptor antibodies
US861755110 août 201031 déc. 2013Incyte CorporationMethods of diagnosing pancreatic inflammation by using chemokine PANEC-1 antibodies
US86178671 janv. 201231 déc. 2013Yissum Research Develpment Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US862925030 janv. 200814 janv. 2014Amgen Inc.Hepcidin, hepcidin antagonists and methods of use
US864229510 janv. 20084 févr. 2014Erasmus University Medical CenterCircular chromosome conformation capture (4C)
US86423308 août 20064 févr. 2014Onconon, LlcAntibody compositions, methods for treating neoplastic disease and methods for regulating fertility
US86527883 déc. 200918 févr. 2014Abbott LaboratoriesAssay for diagnosis of cardiac myocyte damage
US865280916 févr. 201018 févr. 2014Dupont Nutrition Biosciences ApsMethod for producing ultra-heat treatment milk
US86581282 févr. 201225 févr. 2014Pop Test Cortisol LlcSystem and method for diagnosis and treatment
US86581676 déc. 201225 févr. 2014Gilead Biologics, Inc.Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
US866910129 déc. 201011 mars 2014Engeneic Molecular Delivery Pty. Ltd.Bacterially derived intact minicells that encompass plasmid free functional nucleic acid for in vivo delivery to mammalian cells
US866934526 janv. 200711 mars 2014Biogen Idec Ma Inc.Nogo receptor antagonists
US867330515 juin 201218 mars 2014G2 Therapies LtdMethods of treatment with antibodies against the extracellular loops of C5aR
US86794851 août 200825 mars 2014Gilead Biologics, Inc.Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
US86800621 juin 200725 mars 2014Deliversir Ltd.System for delivering therapeutic agents into living cells and cells nuclei
US86802464 févr. 201125 mars 2014Gilead Biologics, Inc.Antibodies that bind to lysyl oxidase-like 2 (LOXL2)
US868622724 juil. 20081 avr. 2014Evogene Ltd.Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance and/or biomass and/or yield in plants expressing same
US869196325 août 20058 avr. 2014Engeneic Molecular Delivery Pty. Ltd.Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
US869763422 déc. 200915 avr. 2014Tel Aviv University Future Technology Development L.P.Peptides and methods using same for diagnosis and treatment of amyloid-associated disease
US870999520 août 200729 avr. 2014Geron CorporationMethod for eliciting an immune response to human telomerase reverse transcriptase
US871566511 avr. 20086 mai 2014The General Hospital CorporationMethods for treating cancer resistant to ErbB therapeutics
US871596029 mars 20106 mai 2014Mitomics Inc.Aberrant mitochondrial DNA, associated fusion transcripts and translation products and hybridization probes therefor
US872286618 janv. 200713 mai 2014The United States Of America, As Represented By The Department Of Veterans AffairsIsoform-selective inhibitors and activators of PDE3 cyclic nucleotide phosphodiesterases
US87351279 sept. 201327 mai 2014Yissum Research Development Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US873556621 mars 200827 mai 2014Engeneic Molecular Delivery Pty LtdBacterially derived intact minicells that encompass plasmid free functional nucleic acid for in vivo delivery to mammalian cells
US87478555 avr. 200910 juin 2014Technion Research & Development Foundation LimitedAnti human immunodeficiency antibodies and uses thereof
US875929214 févr. 201224 juin 2014Prolor Biotech, LlcLong-acting coagulation factors and methods of producing same
US877552616 janv. 20078 juil. 2014Zlango Ltd.Iconic communication
US879087124 avr. 200729 juil. 2014Musc Foundation For Research DevelopmentDetecting diastolic heart failure by protease and protease inhibitor plasma profiling
US879123229 oct. 201029 juil. 2014Dupont Nutrition Biosciences ApsProteins
US87912588 juin 200929 juil. 2014The Regents Of The University Of CaliforniaPro-fluorescent probes
US87956822 mai 20085 août 2014Emory UniversityVirus-like particles comprising chimeric human immunodeficiency virus (HIV)/mouse mammary tumor virus (MMTV) envelopes
US879643814 août 20065 août 2014Geron CorporationNucleic acids encoding inactive variants of human telomerase
US880870119 déc. 201219 août 2014G2 Inflammation Pty LtdMethods of inhibiting the interaction of C5aR with C5a with anti-C5aR antibodies
US88095077 déc. 200919 août 2014Vuong TrieuSPARC binding ScFvs
US88158239 mars 201226 août 2014Technion Research & Development Foundation Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
US881873528 juin 201226 août 2014Sequenom, Inc.Methods for generating databases and databases for identifying polymorphic genetic markers
US882183617 mai 20132 sept. 2014Abraxis Bioscience, LlcSPARC binding peptides and uses thereof
US882838613 févr. 20129 sept. 2014Glenveigh Pharmaceuticals, LlcMethod for extending pregnancy by reducing intraventricular hemorrhaging in patients exhibiting at least one symptom of preeclampsia and eclampsia
US883486219 avr. 200516 sept. 2014Nanocyte Inc.Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
US88351202 déc. 200916 sept. 2014Abbott LaboratoriesAssay for cardiac troponin-T (cTnT)
US88354682 mai 201216 sept. 2014Chemocentryx, Inc.N-(2-(hetaryl)aryl)arylsulfonamides and n-(2-(hetaryl)hetaryl) arylsulfonamides
US884604518 juin 201330 sept. 2014Novo Nordisk A/SAnti-C5a receptor antibodies
US884639329 nov. 200630 sept. 2014Gamida-Cell Ltd.Methods of improving stem cell homing and engraftment
US884700821 mai 200930 sept. 2014Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant utility
US88490374 nov. 201330 sept. 2014Fluidigm CorporationMethods and systems for image processing of microfluidic devices
US885946716 juil. 201014 oct. 2014Bioatla, LlcSimultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
US886515822 mai 201221 oct. 2014Ramot At Tel-Aviv University Ltd.Bacteriophages for reducing toxicity of bacteria
US888936413 mai 201018 nov. 2014The Chancellor, Masters And Scholars Of The University Of OxfordClinical diagnosis of hepatic fibrosis using a novel panel of low abundant human plasma protein biomarkers
US88893711 févr. 201018 nov. 2014Dupont Nutrition Biosciences ApsLipolytic enzyme: uses thereof in the food industry
US892165828 oct. 200930 déc. 2014Evogene Ltd.Isolated polynucleotides encoding a MAP65 polypeptide and methods of using same for increasing plant yield
US892770025 févr. 20136 janv. 2015Gilead Biologics, Inc.Catalytic domains from lysyl oxidase and LOXL2
US89372201 mars 201020 janv. 2015Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield, biomass, vigor and/or growth rate of a plant
US894051923 avr. 201027 janv. 2015Dupont Nutrition Biosciences ApsMethod of producing a lipolytic enzyme
US89459286 juin 20133 févr. 2015Kerry B GunningMicroarray system with improved sequence specificity
US894615514 mars 20133 févr. 2015Opko Biologics Ltd.Long-acting polypeptides and methods of producing and administering same
US89568647 juin 201317 févr. 2015Engeneic Molecular Delivery Pty LtdBacterially derived intact minicells that encompass plasmid free functional nucleic acid for in vivo delivery to mammalian cells
US896291524 oct. 200624 févr. 2015Evogene Ltd.Isolated polypeptides, polynucleotides encoding same, transgenic plants expressing same and methods of using same
US897501622 juin 201110 mars 2015Diagnostic Hybrids, Inc.Methods for direct fluorescent antibody virus detection in liquids
US899328424 sept. 201331 mars 2015The University Of British ColumbiaTerpene synthases from Santalum
US899351026 août 201331 mars 2015Tel Aviv University Future Technology Development L.P.Peptides and methods using same for diagnosis and treatment of amyloid-associated disease
US899967022 avr. 20137 avr. 2015Opko Biologics Ltd.Long-acting polypeptides and methods of producing same
US90121627 sept. 200721 avr. 2015The Chancellor, Masters And Scholars Of The University Of OxfordClinical diagnosis of hepatic fibrosis using a novel panel of human serum protein biomarkers
US901272812 juil. 201021 avr. 2015Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US901844518 août 200928 avr. 2015Evogene Ltd.Use of CAD genes to increase nitrogen use efficiency and low nitrogen tolerance to a plant
US902334817 nov. 20095 mai 2015Technion Research & Development Foundation LimitedCompositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US903503921 déc. 201219 mai 2015Protiva Biotherapeutics, Inc.Compositions and methods for silencing SMAD4
US904066727 avr. 201026 mai 2015Dako Denmark A/SAntibody cocktail
US90570929 nov. 201216 juin 2015Zetiq Technologies Ltd.Methods and compositions for identifying a cell phenotype
US90571078 mars 201216 juin 2015King Abdullah University Of Science And TechnologyMolecular biomarker set for early detection of ovarian cancer
US906698212 mars 201430 juin 2015Engeneic Molecular Delivery Pty Ltd.Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells
US909068711 déc. 201328 juil. 2015Incyte CorporationMethods of treating pancreatitis
US909553319 nov. 20094 août 2015Technion Research & Development Foundation LimitedAntigen-presenting complex-binding compositions and uses thereof
US909664515 nov. 20114 août 2015Ramot At Tel-Aviv University Ltd.Dipeptide analogs for treating conditions associated with amyloid fibril formation
US90968658 juin 20104 août 2015Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and/or abiotic stress tolerance
US910275427 juin 200811 août 2015University Of SaskatchewanImmunomodulatory compositions and methods for treating disease with modified host defense peptides
US91079355 janv. 201018 août 2015Gilead Biologics, Inc.Chemotherapeutic methods and compositions
US91141479 déc. 201325 août 2015Pop Test Oncology Limited Liability CompanySystem and method for diagnosis and treatment
US911417528 juin 201125 août 2015Amgen Inc.Modified Fc molecules
US912086226 juil. 20101 sept. 2015Abbott LaboratoriesAntibodies relating to PIVKA-II and uses thereof
US91210228 mars 20111 sept. 2015Monsanto Technology LlcMethod for controlling herbicide-resistant plants
US91259316 avr. 20108 sept. 2015Massachusetts Institute Of TechnologyPost-transcriptional regulation of RNA-related processes using encoded protein-binding RNA aptamers
US913258710 avr. 200815 sept. 2015Stratasys Ltd.System and method for three dimensional model printing
US915064411 avr. 20126 oct. 2015The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesHuman monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
US915686522 oct. 201213 oct. 2015Deliversir LtdSystem for delivering therapeutic agents into living cells and cells nuclei
US917507823 janv. 20093 nov. 2015Amgen Inc.Ferroportin antibodies and methods of use
US917526619 juil. 20133 nov. 2015Gamida Cell Ltd.Enhancement of natural killer (NK) cell proliferation and activity
US91761396 mai 20133 nov. 2015Gilead Biologics, Inc.LOX and LOXL2 inhibitors and uses thereof
US918240317 mai 201010 nov. 2015Zetiq Technologies Ltd.Kits for and methods of differential staining of cervical cancer cells and/or tissues
US921225822 févr. 201215 déc. 2015The Board Of Trustees Of The University Of IllinoisAmphiphilic dendron-coils, micelles thereof and uses
US92280152 janv. 20145 janv. 2016Biogen Idec Ma Inc.Nogo receptor antagonists and methods of increasing neurite outgrowth
US923884321 déc. 201119 janv. 2016Eli Lilly And CompanyCompositions and methods for identifying and differentiating viral components of multivalent shipping fever vaccines
US924200710 janv. 201426 janv. 2016Engeneic Molecular Delivery Pty. Ltd.Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
US924303022 mai 200826 janv. 2016Centre National De La Recherche Scientifique (Cnrs)Optically pure compounds for improved therapeutic efficiency
US92494071 juil. 20132 févr. 2016Opko Biologics Ltd.Long-acting coagulation factors and methods of producing same
US925430926 juin 20139 févr. 2016Centre National De La Recherche Scientifique (Cnrs)Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation
US925528925 oct. 20109 févr. 2016The Trustees Of Columbia University In The City Of New YorkGeometric patterns and lipid bilayers for DNA molecule organization and uses thereof
US926051717 nov. 201016 févr. 2016Musc Foundation For Research DevelopmentHuman monoclonal antibodies to human nucleolin
US926072820 févr. 201516 févr. 2016University Of British ColumbiaTerpene synthases from Santalum
US926146213 déc. 201216 févr. 2016Step Ahead Innovations, Inc.Monitoring of photo-aging of light-based chemical indicators using illumination-brightness differential scheme
US927329514 sept. 20111 mars 2016Dupont Nutrition Biosciences ApsMutant citrobacter freundii phytase polypeptide
US927334914 mars 20131 mars 2016Affymetrix, Inc.Detection of nucleic acids
US928944714 sept. 201222 mars 2016Gilead Biologics, Inc.Chemotherapeutic methods and compositions
US929056424 mai 201222 mars 2016Mountgate Group LimitedCompositions and methods related to the prevention and treatment of rabies infection
US929573331 juil. 201429 mars 2016Abraxis Bioscience, LlcSPARC binding ScFcs
US93032691 mai 20135 avr. 2016Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants
US93082794 août 201412 avr. 2016Abraxis Biosciences, LlcSPARC binding ScFvs
US93145375 août 201419 avr. 2016Abraxis Bioscience, LlcSPARC binding ScFcs
US931664111 janv. 201119 avr. 2016Biogen Ma Inc.Assay for JC virus antibodies
US932835327 avr. 20113 mai 2016Evogene Ltd.Isolated polynucleotides and polypeptides for increasing plant yield and/or agricultural characteristics
US937745811 oct. 201028 juin 2016Biogen Ma Inc.Anti-VLA-4 related assays
US93943071 oct. 201319 juil. 2016Chemocentryx, Inc.Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation
US939536921 oct. 201319 juil. 2016Regents Of The University Of MinnesotaGuinea pig cytomegalovirus (CIDMTR strain)
US940990929 juil. 20149 août 2016Chemocentryx, Inc.N-(2-(hetaryl)aryl)arylsulfonamides and N-(2-(hetaryl)hetaryl)arylsulfonamides
US941193031 janv. 20149 août 2016The Regents Of The University Of CaliforniaMethods for genome assembly and haplotype phasing
US941636313 sept. 201216 août 2016Monsanto Technology LlcMethods and compositions for weed control
US942255713 sept. 201223 août 2016Monsanto Technology LlcMethods and compositions for weed control
US942255813 sept. 201223 août 2016Monsanto Technology LlcMethods and compositions for weed control
US943498522 sept. 20096 sept. 2016University Of MassachusettsMethods of identifying interactions between genomic loci
US944745412 déc. 201320 sept. 2016The Rockefeller UniversityMethod of purifying RNA binding protein-RNA complexes
US944746720 avr. 201020 sept. 2016Genetic Technologies LimitedMethods for obtaining fetal genetic material
US945843811 avr. 20114 oct. 2016Ben Gurion University Of The Negev Research And Development AuthoritySulfotransferase of a red microalga and uses thereof
US94584445 févr. 20134 oct. 2016Opko Biologics Ltd.Long-acting coagulation factors and methods of producing same
US946324128 janv. 201311 oct. 2016Laboratoire Francais Du Fractionnement Et Des BiotechnologiesMethod for stabilising an immunoglobulin G composition in liquid form
US94768843 oct. 201425 oct. 2016University Of MassachusettsHybridization- independent labeling of repetitive DNA sequence in human chromosomes
US94875594 oct. 20118 nov. 2016Elro Pharma SarlCompositions comprising multivalent synthetic ligands of surface nucleolin and glycosaminoglycans
US94877938 juil. 20138 nov. 2016Evogene Ltd.Polynucleotides, polypeptides and methods for increasing oil content, growth rate and biomass of plants
US94877962 févr. 20118 nov. 2016Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
US949353417 avr. 201315 nov. 2016Opko Biologics Ltd.Long-acting oxyntomodulin variants and methods of producing same
US949378522 déc. 201015 nov. 2016Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency
US949452613 déc. 201215 nov. 2016Step Ahead Innovations, Inc.Combined illuminator/light collectors for optical readers
US949452713 déc. 201215 nov. 2016Step Ahead Innovations, Inc.Optical reader optic cleaning systems having motion deployed cleaning elements
US95182675 nov. 201313 déc. 2016Evogene Ltd.Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance and/or biomass and/or yield in plants expressing same
US952294517 avr. 201320 déc. 2016Opko Biologics Ltd.Long-acting oxyntomodulin variants and methods of producing same
US952899814 avr. 201127 déc. 2016Abbott LaboratoriesMethods and reagents for diagnosing rheumatoid arthrtis
US95406424 nov. 201410 janv. 2017The United States Of America, As Represented By The Secretary Of AgricultureCompositions and methods for controlling arthropod parasite and pest infestations
US95499469 nov. 201524 janv. 2017The University Of ChicagoMaterials and methods for preventing and treating microbe-mediated epithelial disorders
US955100621 déc. 201124 janv. 2017Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for improving plant properties
US955621020 avr. 201531 janv. 2017Sabag-Rfa Ltd.System for delivering therapeutic agents into living cells and cells nuclei
US95622356 déc. 20107 févr. 2017A.B. Seeds Ltd.MicroRNA compositions and methods for enhancing plant resistance to abiotic stress
US956756829 sept. 201414 févr. 2017Enlivex Therapeutics Ltd.Method of preparing apoptotic monocytes
US956756919 juil. 201314 févr. 2017Gamida Cell Ltd.Methods of culturing and expanding mesenchymal stem cells
US957421029 juil. 201021 févr. 2017Ramot At Tel-Aviv University Ltd.Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
US958075224 déc. 200928 févr. 2017Cedars-Sinai Medical CenterMethods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
US961131520 juin 20144 avr. 2017Arbor Vita CorporationAntibodies for oncogenic strains of HPV and methods of their use
US961611212 janv. 201511 avr. 2017Technion Research & Development Foundation LimitedCompositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US963098922 juil. 201525 avr. 2017Ramot At Tel-Aviv University Ltd.Dipeptide analogs for treating conditions associated with amyloid fibril formation
US963100013 mars 201225 avr. 2017Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US965043615 oct. 201316 mai 2017Arizona Board Of Regents On Behalf Of Arizona State UniversityAntibody based reagents that specifically recognize toxic oligomeric forms of tau
US96637789 mai 201430 mai 2017OPKO Biologies Ltd.Long-acting coagulation factors and methods of producing same
US967050122 avr. 20136 juin 2017Evogene Ltd.Isolated polypeptides, polynucleotides useful for modifying water user efficiency, fertilizer use efficiency, biotic/abiotic stress tolerance, yield and biomass in plants
US967684621 août 201513 juin 2017The United States Of America As Represented By The Secretary, Department Of Health And Human ServicesHuman monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
US968875925 sept. 201527 juin 2017Amgen, Inc.Ferroportin antibodies and methods of use
US970864825 avr. 201618 juil. 2017University Of MassachusettsHiC: method of identifying interactions between genomic loci
US971557317 févr. 201625 juil. 2017Dovetail Genomics, LlcNucleic acid sequence assembly
US972658110 févr. 20148 août 2017Realbio Technologies Ltd.Sequential lateral flow capillary device for analyte determination
US972667227 mai 20168 août 2017Biogen Ma Inc.Anti-VLA-4 related assays
US973089729 déc. 201515 août 2017Engeneic Molecular Delivery Pty LtdDelivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
US973324214 mars 201415 août 2017Sevident, Inc.Devices for capturing analyte
US973977317 févr. 201522 août 2017David Gordon BermudesCompositions and methods for determining successful immunization by one or more vaccines
US974531228 juin 201629 août 2017Chemocentryx, Inc.Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation
US974563227 août 201429 août 2017Mdna Life Sciences Inc.Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers
US977041314 déc. 201526 sept. 2017The Board Of Trustees Of The University Of IllinoisAmphiphilic dendron-coils, micelles thereof and uses
US977143110 oct. 201226 sept. 2017Ccam Biotherapeutics Ltd.Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM)
US977728818 juil. 20143 oct. 2017Monsanto Technology LlcCompositions and methods for controlling leptinotarsa
US977826222 avr. 20153 oct. 2017Dako Denmark A/SAntibody cocktail
US978468619 juin 201410 oct. 2017Step Ahead Innovations, Inc.Aquatic environment water parameter testing systems and methods
US97902625 avr. 201217 oct. 2017Longevity Biotech, Inc.Compositions comprising glucagon analogs and methods of making and using the same
US979676210 avr. 201424 oct. 20174D Pharma Research LimitedPolypeptide and immune modulation
US97978444 déc. 201524 oct. 2017Step Ahead Innovations, Inc.Chemical indicator element systems for aquatic environment water parameter testing
US980853420 nov. 20137 nov. 2017Opko Biologics Ltd.Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
US20020055617 *12 nov. 19989 mai 2002Marilyn H. PerrinCloning and recombinant production of cfr receptor(s)
US20020061580 *10 sept. 200123 mai 2002Estell David A.Alpha/beta hydrolase-fold enzymes
US20020106661 *23 juil. 20018 août 2002Burstein Laboratories, Inc.Optical disk-based assay devices and methods
US20020110860 *17 sept. 200115 août 2002Sierd BronTwin-arginine translocation in Bacillus
US20020127641 *17 août 200112 sept. 2002Estell David A.Proteases from gram-positive organisms
US20020137681 *20 mai 200226 sept. 2002Lawrence SteinmanTreatment of demyelinating autoimmune disease with ordered peptides
US20020154615 *28 déc. 200024 oct. 2002Martin HansDetection method and device
US20020165149 *10 déc. 20017 nov. 2002Kranz David M.Mutated class II major histocompatibility proteins
US20020172980 *28 févr. 200221 nov. 2002Phan Brigitte ChauMethods for decreasing non-specific binding of beads in dual bead assays including related optical biodiscs and disc drive systems
US20020187467 *2 avr. 199912 déc. 2002Thomas GingerasMycobacterial rpob sequences
US20020187471 *19 janv. 200112 déc. 2002Cech Thomas R.Novel telomerase
US20020192839 *19 févr. 200219 déc. 2002Epitope, Inc.Collection device for single step assay of oral fluids
US20020193310 *21 mars 200219 déc. 2002Bishwajit NagOrally active fraction of momordica charantia, active peptides thereof, and their use in the treatment of diabetes
US20030003464 *27 nov. 20012 janv. 2003Phan Brigitte C.Dual bead assays including optical biodiscs and methods relating thereto
US20030049254 *5 juin 200213 mars 2003Kaufman Daniel L.Modulating neuronal outgrowth via the major histocompatibility complex Class I (MHC I) molecule
US20030054446 *29 nov. 200120 mars 2003Weber Bernard H. F.Novel retina-specific human proteins C7orf9, C12orf7, MPP4 and F379
US20030064058 *9 sept. 20023 avr. 2003Nadir AskenasyMethods of utilizing bone marrow stem cells for inducing immunological tolerance
US20030064364 *11 avr. 20023 avr. 2003Lockhart David J.Nucleic acid analysis techniques
US20030073248 *24 sept. 200217 avr. 2003J.W. RothBovine pregnancy test
US20030078177 *31 oct. 200224 avr. 2003Estell David A.Proteases from gram positive organisms
US20030082596 *8 août 20021 mai 2003Michael MittmannMethods of genetic analysis of probes: test3
US20030086914 *12 juil. 20028 mai 2003Yissum Research Development Company Of The Hebrew University Of JerusalemMethod and device for inducing biological processes by micro-organs
US20030096344 *11 janv. 200222 mai 2003Cech Thomas R.Human telomerase catalytic subunit: diagnostic and therapeutic methods
US20030100093 *11 janv. 200229 mai 2003Cech Thomas R.Human telomerase catalytic subunit: diagnostic and therapeutic methods
US20030104355 *2 nov. 20015 juin 2003Caili WangAdapter-directed display systems
US20030104410 *15 mars 20025 juin 2003Affymetrix, Inc.Human microarray
US20030104491 *30 oct. 20025 juin 2003Cabantchik Ioav ZviMolecules and methods using same for measuring non-transferrin bound iron
US20030105770 *26 nov. 20015 juin 2003Macleod StewartExtending a directory schema independent of schema modification
US20030108927 *7 oct. 200212 juin 2003Kathryn LeishmanCompositions and methods for the prevention, treatment and detection of tuberculosis and other diseases
US20030113895 *23 déc. 200219 juin 2003Estell David A.Proteases from gram-positive organisms
US20030114410 *27 nov. 200219 juin 2003Technion Research And Development Foundation Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
US20030118593 *8 nov. 200226 juin 2003Dan Michael D.Antigen binding fragments, designated 4B5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US20030124676 *9 janv. 20033 juil. 2003Quax Wilhelmus J.Increasing production of proteins in gram-positive microorganisms
US20030152909 *17 déc. 200214 août 2003Mitrani Eduardo N.In vitro micro-organs, and uses related thereto
US20030157642 *4 déc. 200221 août 2003Caldwell Robert M.Increasing production of proteins in gram-positive microorganisms
US20030158070 *26 mars 200321 août 2003Estell David A.Proteases from gram-positive organisms
US20030158133 *19 juin 200221 août 2003Movsesian Matthew A.Isoform-selective inhibitors and activators of PDE3 cyclic nucleotide phosphodiesterases
US20030166248 *26 mars 20034 sept. 2003Estell David A.Proteases from gram-positive organisms
US20030175892 *26 mars 200318 sept. 2003Estell David A.Proteases from gram-positive organisms
US20030180757 *5 déc. 200225 sept. 2003Affymetrix, Inc.Nucleic acid labeling compounds
US20030180932 *26 mars 200325 sept. 2003Estell David A.Proteases from gram-positive organisms
US20030182669 *19 mars 200225 sept. 2003Rockman Howard A.Phosphoinositide 3-kinase mediated inhibition of GPCRs
US20030190752 *24 mars 20039 oct. 2003Tony RomeoEscherichia coli csrB gene, RNA encoded thereby, and methods of use thereof
US20030204069 *20 déc. 200230 oct. 2003Morin Gregg B.Segments of the human gene for telomerase reverse transcriptase
US20030211490 *10 janv. 200113 nov. 2003Hanan SteinPlants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby
US20030211556 *16 janv. 200313 nov. 2003Fatemi S. HosseinMarker for psychiatric conditions
US20030220475 *3 avr. 200127 nov. 2003Fields Howard A.Neutralizing immunogenic hev polypepetides
US20030222908 *3 juin 20024 déc. 2003Microsoft CorporationDynamic wizard interface system and method
US20030232979 *2 juin 200318 déc. 2003Mcgall GlennNucleic acid labeling compounds
US20040002595 *2 juin 20031 janv. 2004Affymetrix, Inc.Nucleic acid labeling compounds
US20040009164 *1 mai 200315 janv. 2004Jonathan ReevesPSP94 diagnostic reagents and assays
US20040013665 *21 mai 200322 janv. 2004Ortho Diagnostic Systems, Inc.Immunoreactive peptides from Epstein-Barr virus
US20040038237 *16 déc. 200226 févr. 2004Goldberg Steven L.Pichia pastoris formate dehydrogenase and uses therefor
US20040039184 *20 nov. 200226 févr. 2004Tanox, Inc.Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US20040052769 *29 nov. 200118 mars 2004Yair ReisnerMethods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease
US20040052928 *6 sept. 200218 mars 2004Ehud GazitPeptides and methods using same for diagnosing and treating amyloid-associated diseases
US20040082758 *21 août 200329 avr. 2004University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US20040091484 *29 août 200313 mai 2004Dan Michael D.Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US20040091946 *1 août 200313 mai 2004Oakley Robert H.Methods of screening compositions for G protein -coupled receptor desensitization inhibitory activity
US20040101892 *15 août 200327 mai 2004Affymetrix, Inc.Nucleic acid labeling compounds
US20040121442 *5 mai 200224 juin 2004Ilan ChetFungal chitinase, polynucleotide sequences encoding same, promoters of same, and uses thereof
US20040126868 *5 févr. 20041 juil. 2004Estell David A.Gram-positive microorganisms with an inactivated cysteine protease-3
US20040132109 *22 janv. 20028 juil. 2004Masato EnariMethod
US20040137505 *5 févr. 200415 juil. 2004Estell David A.Gram-positive microorganisms with an inactivated cysteine protease-2
US20040146949 *27 oct. 200329 juil. 2004Jun TanMethods and compounds for disruption of CD40R/CD40L signaling in the treatment of alzheimer's disease
US20040186280 *18 déc. 200323 sept. 2004Murdoch UniversityBmpB novel nucleotide and amino acid sequences and diagnostic and therapeutic uses thereof
US20040197334 *2 avr. 20037 oct. 2004Technion Research & Development Foundation Ltd.Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
US20040209246 *5 avr. 200421 oct. 2004Agouron Pharmaceuticals, Inc.Dual reporter/dye reduction methodology for evaluating antiviral and cytotoxicity of hepatitis C virus inhibitors
US20040209308 *24 févr. 200421 oct. 2004Duke UniversityMethods of assaying receptor activity and constructs useful in such methods
US20040210045 *11 mai 200421 oct. 2004Mcgall GlennNucleic acid labeling compounds
US20040214248 *3 avr. 200228 oct. 2004Roberts David DUse of semenogelin in the diagnosis, prognosis and treatment of cancer
US20040229245 *6 janv. 200418 nov. 2004Anton BittnerMethods and algorithms for performing quality control during gene expression profiling on DNA microarray technology
US20040242529 *24 juin 20042 déc. 2004Geron CorporationVector encoding inactivated telomerase for treating cancer
US20040247613 *24 juin 20049 déc. 2004Geron CorporationTreating cancer using a telomerase vaccine
US20040248093 *27 nov. 20029 déc. 2004Coombs James HowardMagneto-optical bio-discs and systems including related methods
US20040259113 *23 déc. 200323 déc. 2004Mayo Foundation For Medical Education And Research, Hybritech IncorporatedMethod for detection of metastatic prostate cancer
US20050009139 *3 août 200413 janv. 2005Caili WangCompositions and methods for generating chimeric heteromultimers
US20050009146 *25 août 200413 janv. 2005Estell David A.Proteases from gram-positive organisms
US20050013825 *24 juin 200420 janv. 2005Geron CorporationVaccine containing the catalytic subunit of telomerase for treating cancer
US20050014227 *24 août 200420 janv. 2005Estell David A.Proteases from gram positive organisms
US20050014244 *24 août 200420 janv. 2005Estell David A.Proteases from gram positive organisms
US20050019887 *24 août 200427 janv. 2005Estell David A.Proteases from gram positive organisms
US20050019888 *12 juin 200327 janv. 2005Estell David A.Proteases from gram positive organisms
US20050020499 *26 mai 200427 janv. 2005Bar Ilan UniversityMethods of attenuating cocaine seeking behavior employing glial cell-derived neurotrophic factor (GDNF) and pharmaceutical compositions and articles of manufacture suited for use in practice of the method
US20050022269 *18 juil. 200227 janv. 2005Joseph HirschbergPolypeptides having carotenoids isomerase catalytic activity, nucleic acids encoding same and uses thereof
US20050031618 *31 janv. 200210 févr. 2005Dror MevorachInduction of tolerance by apoptotic and/or necrotic cells
US20050032126 *2 mars 200410 févr. 2005Coombs James H.Methods and apparatus for use in detection and quantitation of various cell types and use of optical bio-disc for performing same
US20050054097 *29 janv. 200410 mars 2005Tony PeledEX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures
US20050054103 *4 mars 200410 mars 2005Tony PeledExpansion of renewable stem cell populations using modulators of PI 3-kinase
US20050059112 *25 août 200417 mars 2005Estell David A.Proteases from gram-positive organisms
US20050064435 *24 sept. 200324 mars 2005Xing SuProgrammable molecular barcodes
US20050064479 *12 août 200424 mars 2005Affymetrix, Inc.Compounds and methods for post incorporation labeling of nucleic acids
US20050069923 *12 juil. 200431 mars 2005Mullis Kary BanksDual bead assays using cleavable spacers and/or ligation to improve specificity and sensitivity including related methods and apparatus
US20050085432 *16 déc. 200221 avr. 2005Aviva LapidotMethods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections
US20050089939 *10 mai 200428 avr. 2005Jun TanAssay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
US20050089963 *24 août 200428 avr. 2005Estell David A.Proteases from gram positive organisms
US20050090644 *6 août 200328 avr. 2005Diaz-Torres Maria R.Production of secreted polypeptides
US20050095683 *16 déc. 20045 mai 2005Estell David A.Proteases from gram-positive organisms
US20050101001 *16 déc. 200412 mai 2005Estell David A.Proteases from gram-position organisms
US20050101504 *16 déc. 200412 mai 2005Estell David A.Proteases from gram positive organisms
US20050106623 *30 déc. 200419 mai 2005Oakley Robert H.Modified G-protein coupled receptors
US20050106668 *25 août 200419 mai 2005Estell David A.Proteases from gram-positive organisms
US20050113327 *29 sept. 200426 mai 2005Levava RoizMethods of and compositions for inhibiting the proliferation of mammalian cells
US20050136431 *29 juil. 200423 juin 2005Oakley Robert H.Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity
US20050142638 *16 déc. 200430 juin 2005Estell David A.Proteases from gram-positive organisms
US20050152912 *9 mars 200514 juil. 2005Technion Research & Development Foundation Ltd.Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20050158822 *20 janv. 200421 juil. 2005Insight Biopharmaceuticals Ltd.High level expression of recombinant human erythropoietin having a modified 5'-UTR
US20050164268 *18 janv. 200528 juil. 2005Affymetrix, Inc.Nucleic acid labeling compounds
US20050176137 *11 avr. 200511 août 2005Technion Research & Development Foundation Ltd.Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
US20050176143 *11 avr. 200511 août 2005Technion Research & DevelopmentMethod and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
US20050186646 *26 janv. 200525 août 2005Cruz Miguel A.Rapid assay to detect ADAMTS-13 activity
US20050191285 *3 mai 20051 sept. 2005University Of WashingtonCompounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US20050202098 *4 mai 200515 sept. 2005TolarenDisease therapy using dying or dead cells
US20050214816 *16 déc. 200429 sept. 2005Estell David AProteases from gram-positive organisms
US20050214827 *19 janv. 200529 sept. 2005Burstein Technologies, Inc.Assay device and method
US20050220774 *18 mars 20036 oct. 2005Tony PeledMethods of inducing differentiation in ex vivo expanded stem cells
US20050244925 *8 déc. 20043 nov. 2005Estell David AProteases from gram-positive organisms
US20050245417 *16 déc. 20043 nov. 2005Estell David AProteases from gram positive organisms
US20050249789 *12 juil. 200510 nov. 2005Estell David AAlpha/beta hydrolase-fold enzymes
US20050255101 *13 févr. 200217 nov. 2005Technion Research And Development Foundation Ltd.Antibody having a t-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US20050271643 *12 août 20048 déc. 2005Iryna SorokulovaBacterial strains, compositions including same and probiotic use thereof
US20050271655 *10 févr. 20058 déc. 2005Biogen Idec Ma Inc.Nogo receptor antagonists
US20050281916 *3 août 200522 déc. 2005Kirsten BojsenMethod of improving dough and bread quality
US20050287141 *15 août 200529 déc. 2005Technion Research & Development Foundation Ltd.Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US20050287563 *10 mai 200529 déc. 2005Affymetrix, Inc.Nucleic acid labeling compounds
US20050287604 *30 mai 200329 déc. 2005Bohmer Ralph MMaternal antibodies as fetal cell markers to identify and enrich fetal cells from maternal blood
US20060002135 *9 juin 20055 janv. 2006Eurodent S.P.A.Dental lamp particularly for medical and dental surgeries
US20060003358 *24 mai 20055 janv. 2006Sequenom, Inc.Polymorphic kinase anchor proteins and nucleic acids encoding the same
US20060008479 *1 août 200512 janv. 2006University Of WashingtonMethods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins
US20060019340 *17 mai 200526 janv. 2006David NaorCD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US20060026702 *30 juil. 20042 févr. 2006Duke UniversityPhosphoinositide 3-kinase mediated inhibition of GPCRs
US20060029984 *17 juin 20059 févr. 2006Jonathan ReevesPSP94 diagnostic reagents and assays
US20060035367 *21 juin 200216 févr. 2006Estell David AProteases from gram positive organisms
US20060035980 *5 avr. 200516 févr. 2006Scanlan Thomas SThyronamine derivatives and analogs and methods of use thereof
US20060039897 *20 mars 200323 févr. 2006Tamar LotanStinging cells expressing an exogenous polycleotide encoding a therpeutic, diagnostics or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derive therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
US20060040307 *17 août 200523 févr. 2006Geron CorporationHuman telomerase catalytic subunit
US20060051426 *5 déc. 20029 mars 2006Gershon GolombNanoparticles containing polymeric nucleic acid homologs pharmaceutical composition and articles of manufacture containing same and methods of use thereof
US20060057151 *2 août 200516 mars 2006Hampson David JBmpB novel nucleotide and amino acid sequences and diagnostic and therapeutic uses thereof
US20060073530 *15 août 20026 avr. 2006Olaf SchneewindMethods and compositions involving sortase B
US20060078951 *8 oct. 200413 avr. 2006Youn Byung SMonoclonal antibody selectively recognizing listeria monocytogenes, hybridoma producing the antibody, test kit comprising the antibody and detection method of listeria monocytogenes using the antibody
US20060079941 *11 oct. 200513 avr. 2006Eli OvsyshcherMethods and implantable devices for treating supraventricular arrhythmias
US20060083735 *25 mars 200420 avr. 2006Technion Research & Development Foundation Ltd.Antigen-presenting complex-binding compositions and uses thereof
US20060084091 *5 août 200520 avr. 2006Maxygen, Inc.Methods and compositions for polypeptide engineering
US20060099273 *5 nov. 200411 mai 2006Nanocyte Inc.Sterile preparations and compositions including stinging capsules and methods of producing and using same
US20060100422 *13 juil. 200511 mai 2006Goldberg Steven LPichia pastoris formate dehydrogenase and uses therefor
US20060105354 *18 nov. 200418 mai 2006Eppendorf Array Technologies S.A.Real-time quantification of multiple targets on a micro-array
US20060123516 *22 nov. 20058 juin 2006Gil RonenMethods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
US20060127366 *13 juil. 200315 juin 2006Mitrani Eduardo NMethod and device for inducing biological processes by micro-organs
US20060134538 *16 déc. 200422 juin 2006Radu Nora SAromatic chalcogen compounds and their use
US20060134680 *21 déc. 200522 juin 2006Alexander KotlyarHomogeneous populations of nucleic acids, methods of synthesyzing same and uses thereof
US20060140934 *23 sept. 200529 juin 2006Colin GeggModified Fc molecules
US20060147964 *22 déc. 20056 juil. 2006Affymetrix, Inc.Mycobacterial rpoB sequences
US20060148078 *30 nov. 20036 juil. 2006Sharon Gerecht-NirMethod of dynamically culturing embryonic stem cells
US20060159769 *15 mars 200620 juil. 2006Nanocyte Inc.Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
US20060166225 *24 mai 200527 juil. 2006Maxygen, Inc.Methods and compositions for polypeptide engineering
US20060188944 *9 mai 200224 août 2006Barak Lawrence SMethods of assaying receptor activity
US20060198817 *26 nov. 20027 sept. 2006Alverdy John CMaterials and methods for preventing and treating microbe-mediated epithelial disorders
US20060199216 *8 mai 20067 sept. 2006Intel CorporationProgrammable molecular barcodes
US20060204970 *4 févr. 200514 sept. 2006Affymetrix, Inc.Chip-based speciation and phenotypic characterization of microorganisms
US20060211064 *17 mars 200621 sept. 2006Hyesook KimDetection of hypertension using glucuronidated metabolic products
US20060233840 *29 mars 200619 oct. 2006Miltenyi Biotech GmbhAntigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
US20060234203 *19 avr. 200519 oct. 2006Nanocyte Inc.Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
US20060234947 *21 juin 200619 oct. 2006Tel Aviv University Future Technology Development L.PPeptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
US20060257429 *11 oct. 200416 nov. 2006Dreier Kimberly JVaccine for periodontal disease
US20060260002 *20 juin 200416 nov. 2006Gil RonenNucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
US20060263828 *26 janv. 200423 nov. 2006Sudha ShenoyModified trafficking patterns for arrestin and g-protein-coupled receptors via arrestin-ubiquitin chimera
US20060275267 *14 août 20067 déc. 2006Morin Gregg BNucleic acids encoding inactive variants of human telomerase
US20060281106 *25 avr. 200614 déc. 2006Andrews William HTelomerase promoter sequences for screening telomerase modulators
US20060281181 *19 déc. 200514 déc. 2006Caili WangAdaptor-directed helper systems
US20060292579 *5 juil. 200528 déc. 2006Affymetrix, Inc.Methods of enzymatic discrimination enhancement and surface bound double-stranded DNA
US20070026106 *7 juil. 20061 févr. 2007Kreij Arno DMethod
US20070032421 *12 juin 20068 févr. 2007Efrat LevyMethods and compositions relating to cystatin C
US20070037187 *17 mai 200615 févr. 2007Isabelle AlexandreIdentification and quantification of a plurality of biological (micro)organisms or their components
US20070054288 *8 mai 20068 mars 2007Intel CorporationProgrammable molecular barcodes
US20070059717 *15 sept. 200515 mars 2007Baylor Research InstituteSystemic lupus erythematosus diagnostic assay
US20070065429 *16 avr. 200422 mars 2007Biogen Idec Ma Inc.Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques
US20070071751 *14 juil. 200629 mars 2007Tanox, Inc.Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US20070077574 *14 juil. 20065 avr. 2007Tanox, Inc.family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US20070082371 *14 juil. 200612 avr. 2007Tanox, Inc.Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US20070087437 *21 févr. 200619 avr. 2007Jifan HuMethods for rejuvenating cells in vitro and in vivo
US20070099204 *24 mai 20063 mai 2007Isabelle AlexandreIdentification and quantification of a plurality of biological (micro)organisms or their components
US20070116597 *17 janv. 200724 mai 2007Mink Ronald WDevice for collection and assay of oral fluids
US20070122525 *7 juil. 200631 mai 2007Kreij Arno DMethod
US20070134658 *5 mars 200414 juin 2007Genetic Technologies Limited, A.C.N. 009 212 328Identification of fetal dna and fetal cell markers in maternal plasma or serum
US20070134814 *9 déc. 200514 juin 2007Kajander E OMethods and compositions for the detection of calcifying nano-particles, identification and quantification of associated proteins thereon, and correlation to disease
US20070135334 *23 janv. 200714 juin 2007Tel Aviv University Future Technology Development L.P.Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US20070141658 *27 oct. 200621 juin 2007The Regents Of The University Of CaliforniaFluorogenic probes for reactive oxygen species
US20070160546 *10 janv. 200612 juil. 2007Tamar LotanUse of stinging cells/capsules for the delivery of active agents to keratinous substances
US20070161007 *11 janv. 200612 juil. 2007Wisconsin Alumni Research FoundationSynthetic cofactor analogs of S-adenosylmethionine as ligatable probes of biological methylation and methods for their use
US20070178462 *14 févr. 20052 août 2007Uebele Victor NNucleic acid molecules encoding novel murine low-voltage activated calcium channel proteins, designated-alpha1h, encoded proteins and methods of use thereof
US20070184530 *5 févr. 20079 août 2007Fuad FaresLong-acting veterinary polypeptides and methods of producing and administering same
US20070190534 *26 janv. 200616 août 2007Genesis Genomics Inc.Mitochondrial sites and genes associated with prostate cancer
US20070190561 *26 mars 200716 août 2007Geron CorporationSegments of the Human Gene for Telomerase Reverse Transcriptase
US20070190610 *1 févr. 200716 août 2007Fuad FaresLong-acting EPO polypeptides and derivatives thereof and methods thereof
US20070190611 *1 févr. 200716 août 2007Fuad FaresLong-acting polypeptides and methods of producing same
US20070196369 *18 oct. 200623 août 2007Hoogenboom Henricus Renerus JMHC-peptide complex binding ligands
US20070202515 *12 oct. 200630 août 2007Pathologica, Llc.Promac signature application
US20070218511 *14 août 200620 sept. 2007Genzyme CorporationMethods for the diagnosis and treatment of lung cancer
US20070225242 *25 janv. 200727 sept. 2007The Board Of Trustees Of The Leland Stanford Junior UniversityMethod and composition for treating and preventing tumor metastasis in vivo
US20070232556 *31 mars 20064 oct. 2007Montine Thomas JMethods and compositions for the treatment of neurological diseases and disorders
US20070264274 *21 mai 200715 nov. 2007Yeda Research And Development Co. Ltd.Veto cells effective in preventing graft rejection and devoid of graft versus host potential
US20070281037 *5 nov. 20046 déc. 2007Nanocyte Inc.Sterile preparations and compositions including stinging capsules and methods of producing and using same
US20070281883 *5 juin 20066 déc. 2007Hanna RosenfeldDevelopment of follicle stimulating hormone agonists and antagonists in fish
US20070292930 *17 avr. 200720 déc. 2007Yissum Research Development Company Of The Hebrew University Of JerusalemMethod of producing recombinant Aspergillus niger beta-glucosidase and an aroma spreading plant
US20070298145 *18 avr. 200727 déc. 2007Andrei MiasnikovEnzymes
US20070299005 *8 déc. 200527 déc. 2007Tanox, Inc.Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US20080026394 *11 juil. 200731 janv. 2008Antara Biosciences Inc.Methods of detecting one or more cancer markers
US20080044416 *12 févr. 200721 févr. 2008Gang AnNovel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer
US20080064114 *7 sept. 200613 mars 2008Institut PasteurGenomic morse code
US20080075322 *13 sept. 200727 mars 2008Fluidigm CorporationMethods and systems for determining a baseline during image processing
US20080075380 *13 sept. 200727 mars 2008Fluidigm CorporationMethods and systems for image processing of microfluidic devices
US20080076904 *21 juin 200727 mars 2008University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US20080082678 *16 janv. 20063 avr. 2008Zlango Ltd.Communications Network System and Methods for Using Same
US20080085526 *7 sept. 200710 avr. 2008United Therapeutics CorporationClinical diagnosis of hepatic fibrosis using a novel panel of human serum protein biomarkers
US20080096225 *25 juil. 200724 avr. 2008The Regents Of The University Of CaliforniaAssays for detecting modulators of cytoskeletal function
US20080108085 *6 avr. 20078 mai 2008D-Gen LimitedMethod and Detection of the Presence of Prions Protein
US20080113393 *17 janv. 200815 mai 2008Fatemi S HMethods for Diagnosing Schizophrenia
US20080113394 *17 janv. 200815 mai 2008Fatemi S HMethods for Diagnosing Major Depression
US20080113395 *17 janv. 200815 mai 2008Fatemi S HMethods for Diagnosing Bi-Polar Disorder
US20080129736 *30 nov. 20075 juin 2008Fluidigm CorporationMethod and apparatus for biological sample analysis
US20080131419 *28 sept. 20055 juin 2008Yissum Research Development Company Of The Hebrew University Of JerusalemRecombinant Human T2 Rnase and Uses Thereof
US20080138346 *4 juin 200712 juin 2008Incyte CorporationAntibodies to a chemokine expressed in inflamed adenoid
US20080166757 *1 juin 200710 juil. 2008Sierd BronTwin-arginine translocation in Bacillus
US20080199895 *4 oct. 200721 août 2008Yeda Research And Development Co. Ltd.Highly purified and stabilized Na,K-ATPase isoforms and methods of producing same
US20080206188 *20 avr. 200528 août 2008Alverdy John CTherapeutic Delivery System Comprising a High Molecular Weight Peg-Like Compound
US20080214407 *11 oct. 20074 sept. 2008Eppendorf Array Technologies S.A.Method and system for quantification of a target compound obtained from a biological sample upon chips
US20080219995 *15 févr. 200811 sept. 2008Konkuk University Industrial Cooperation Corp.Il-32 monoclonal antibodies and uses thereof
US20080220438 *25 avr. 200811 sept. 2008Geron CorporationTelomerase Promoter Sequences for Screening Telomerase Modulators
US20080220498 *6 mars 200711 sept. 2008Cervin Marguerite AVariant Buttiauxella sp. phytases having altered properties
US20080248525 *1 juin 20079 oct. 2008Sierd BronTwin-Arginine translocation in bacillus
US20080261256 *19 oct. 200723 oct. 2008Duke UniversityMethods of assaying receptor activity and constructs useful in such methods
US20080274905 *28 mars 20086 nov. 2008The Trustees Of Columbia University In The City Of New YorkMicrofluidic cells with parallel arrays of individual dna molecules
US20080279871 *20 août 200713 nov. 2008Geron CorporationImmunogenic composition
US20080287667 *27 juin 200820 nov. 2008Affymetrix, Inc.Nucleic Acid Labeling Compounds
US20080299084 *21 mars 20084 déc. 2008Engeneic Therapy Pty. Ltd.Bacterially derived intact minicells that encompass plasma free functional nucleic acid for in vivo delivery to mammalian cells
US20080305512 *2 nov. 200711 déc. 2008Mattingly Phillip GAssay for cardiac troponin autoantibodies
US20080312179 *25 juil. 200818 déc. 2008Insight Biopharmaceuticals Ltd.High level expression of recombinant human erythropoietin having a modified 5'-UTR
US20090005410 *17 juin 20081 janv. 2009Chemocentryx, Inc.N-(2-(hetaryl)aryl) arylsulfonamides and n-(2-(hetaryl) hetaryl arylsulfonamides
US20090012272 *1 août 20088 janv. 2009Amgen Inc.Modified Fc molecules
US20090013087 *16 janv. 20078 janv. 2009Zlango Ltd.Communications Network System and Methods For Using Same
US20090022744 *1 août 200822 janv. 2009Amgen Inc.Modified Fc molecules
US20090023594 *29 nov. 200722 janv. 2009Exiqon A/SReagents for labelling nucleic acids and uses thereof
US20090035784 *1 août 20055 févr. 2009Mount Sinai School Of Medicine Of New York UniversityNpc1l1 and npc1l1 inhibitors and methods of use thereof
US20090036321 *3 juin 20045 févr. 2009Chiron CorporationMethods for predicting the course of a malignant disease
US20090042209 *31 août 200712 févr. 2009Nox Technologies, Inc.Neoplasia-Specific tNOX Isoforms and Methods
US20090053224 *1 août 200826 févr. 2009Arresto BiosciencesLox and loxl2 inhibitors and uses thereof
US20090068207 *11 avr. 200612 mars 2009Vascular Biogenics Ltd.Compositions Containing Beta 2-Glycoprotein I-Derived Peptides for the Prevention and/or Treatment of Vascular Disease
US20090068669 *12 sept. 200812 mars 2009Elias GeorgesSlc9a3r1 directed diagnostics for neoplastic disease
US20090081639 *30 mai 200826 mars 2009Phil HillAssay for sensitivity to chemotherapeutic agents
US20090089898 *15 août 20062 avr. 2009Hagai KarchiMethods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
US20090098249 *6 févr. 200816 avr. 2009Cervin Marguerite AVariant Buttiauxella sp. Phytases having altered properties
US20090104170 *31 oct. 200523 avr. 2009Richard William Wyatt ChildsCompositions and methods for treating hyperproliferative disorders
US20090104201 *1 août 200823 avr. 2009Victoria SmithMethods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
US20090121709 *5 janv. 200914 mai 2009Ramot At Tel Aviv University Ltd.Peptide nanostructures encapsulating A foreign material and method of manufacturing same
US20090123553 *2 janv. 200914 mai 2009Ramot At Tel Aviv University Ltd.Peptide nanostructures and methods of generating and using the same
US20090126042 *14 juin 200514 mai 2009Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US20090136916 *13 août 200828 mai 2009Trustees Of Tufts CollegeMethods and microarrays for detecting enteric viruses
US20090143243 *12 août 20084 juin 2009Gunning Kerry BMicroarray system with improved sequence specificity
US20090143321 *6 juil. 20064 juin 2009Avraham HochbergNucleic acid agents for downregulating h19 and methods of using same
US20090156471 *14 juil. 200518 juin 2009Ramot At Tel Aviv University Ltd.Use of anti-amyloid agents for treating and typing pathogen infections
US20090170072 *8 janv. 20092 juil. 2009Orasure Technologies, Inc.Device for collection and assay of oral fluids
US20090208533 *20 nov. 200720 août 2009University Of Georgia Research Foundation, Inc.Neisseria meningitidis serogroup a capsular polysaccharide acetyltransferase, methods and compositions
US20090209041 *9 avr. 200920 août 2009Tel Aviv University Future Technology Development L.P.Peptides and methods for inhibiting amyloid formation
US20090221015 *24 avr. 20073 sept. 2009Spinale Francis GDetecting Diastolic Heart Failure by Protease and Protease Inhibitor Plasma Profiling
US20090221681 *21 sept. 20063 sept. 2009Yissum Research Development Company Of The Hebrew University Of JerusalemNucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer
US20090226387 *22 déc. 200610 sept. 2009Partnership & Corp. Technology TransferSynthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of cellular relaxation
US20090233295 *29 janv. 200917 sept. 2009Elias GeorgesTrim59 directed diagnostics for neoplastic disease
US20090233946 *11 juil. 200817 sept. 2009Antoni KrasinskiFused heteroaryl pyridyl and phenyl benzenesuflonamides as ccr2 modulators for the treatment of inflammation
US20090233986 *22 juil. 200517 sept. 2009Mount Sinai School Of MedicineMethods and compositions for using sax2
US20090246800 *24 avr. 20091 oct. 2009Abbott LaboratoriesImmunoassay of analytes in samples containing endogenous anti-analyte antibodies
US20090253170 *9 févr. 20098 oct. 2009Evogene Ltd.Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
US20090269739 *20 août 200729 oct. 2009Geron CorporationKit for detection of telomerase reverse transcriptase nucleic acids
US20090269780 *22 avr. 200929 oct. 2009Luminex CorporationMethod for Creating a Standard for Multiple Analytes Found in a Starting Material of Biological Origin
US20090293146 *20 déc. 200726 nov. 2009Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US20090311695 *12 mars 200917 déc. 2009Talat NasimMethod
US20090324612 *24 juin 200931 déc. 2009Kaufman Daniel LModulating neuronal outgrowth via the major histocompatibility complex class i (mhc i) molecule
US20100004162 *18 déc. 20027 janv. 2010Nathaniel HeintzLynx, a novel family of receptor ligands in the central nervous system, corresponding nucleic acids and proteins and uses thereof
US20100015156 *6 mars 200821 janv. 2010Cedars-Sinai Medical CenterDiagnosis of inflammatory bowel disease in children
US20100015651 *11 juil. 200721 janv. 2010Musc Foundation For Research DevelopmentPredicting Heart Failure Following Myocardial Infarction by Protease and Protease Inhibitor Profiling
US20100022459 *2 juil. 200928 janv. 2010Tel Aviv University Future Technology Development L.PPeptides directed for diagnosis and treatment of amyloid-associated diseases
US20100041036 *5 sept. 200718 févr. 2010Institut PasteurGenomic morse code
US20100047230 *20 févr. 200625 févr. 2010Hellenic Pasteur InstituteAnti her2/neu antibody
US20100055033 *6 avr. 20074 mars 2010The Government Of The United States Of America As Represented By The SecretaryAntibody compositions and methods for treatment of neoplastic disease
US20100062443 *20 août 200911 mars 2010Genzyme CorporationMethods for the Diagnosis and Treatment of Lung Cancer
US20100062501 *25 juin 200911 mars 2010Paul WassellMethod
US20100062947 *10 janv. 200811 mars 2010Erasmus University Medical CenterCircular chromosome conformation capture (4c)
US20100068135 *8 août 200618 mars 2010Onconon, LlcAntibody compositions, methods for treating neoplastic disease and methods for regulating fertility
US20100080805 *17 nov. 20091 avr. 2010Technion Research & DevelopmentCompositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20100081177 *8 sept. 20091 avr. 2010TransAlgae LtdDecreasing RUBISCO content of algae and cyanobacteria cultivated in high carbon dioxide
US20100092386 *22 oct. 200915 avr. 2010David SegevSystem for delivering therapeutic agents into living cells and cells nuclei
US20100105071 *27 févr. 200829 avr. 2010Children's Medical Center CorporationMethods for predicting the onset of menarche
US20100105608 *22 déc. 200929 avr. 2010Tel Aviv University Future Technology Development L.P.Peptides and methods using same for diagnosis and treatment of amyloid-associated disease
US20100105759 *16 janv. 200829 avr. 2010Abraham HochbergH19 silencing nucleic acid agents for treating rheumatoid arthritis
US20100111869 *14 oct. 20096 mai 2010Nanocyte Inc.Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
US20100112626 *30 oct. 20096 mai 2010The United States Of America, As Represented By The Secretary, Dept. Of Health & Human ServicesUse of Semenogelin in the Diagnosis, Prognosis and Treatment of Cancer
US20100119515 *30 sept. 200913 mai 2010Gera NeufeldPharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
US20100129346 *22 août 200727 mai 2010G2 Inflammation Pty Ltd.Anti-C5aR Antibodies With Improved Properties
US20100184065 *11 janv. 201022 juil. 2010University Of South FloridaMethod of Predicting Non-Response to First Line Chemotherapy
US20100190662 *25 janv. 200829 juil. 2010Rebecca SutphenMethods and materials for detection, diagnosis and management of ovarian cancer
US20100196403 *27 janv. 20085 août 2010Jacob HochmanAntibody conjugates for circumventing multi-drug resistance
US20100196419 *2 mai 20085 août 2010Compans Richard WEnhancement of glycoprotein incorporation into virus-like particles
US20100215803 *16 févr. 201026 août 2010Niels Erik LarsenProcess
US20100221233 *8 mars 20102 sept. 2010University Of South FloridaCompositions and methods for enhancing neuroprotection via administration of stem cells and blood brain barrier permeabilizers
US20100221272 *27 juin 20082 sept. 2010University Of SaskatchewanImmunomodulatory compositions and methods for treating disease with modified host defense peptides
US20100222228 *11 oct. 20072 sept. 2010Janssen Pharmaceutica N.V.Compositions and methods for treating and diagnosing irritable bowel syndrome
US20100228007 *16 mars 20109 sept. 2010Technion Research & Development Foundation Ltd.Mhc-peptide complex binding ligands
US20100240065 *18 mars 200923 sept. 2010Boehringer Ingelheim International GmbhProlyl Hydroxylase Compositions and Methods of Use Thereof
US20100240101 *19 mars 200923 sept. 2010Massachusetts Institute Of TechnologyParallel Proximity Ligation Event Analysis
US20100255004 *11 avr. 20087 oct. 2010Dana Farber Cancer InstituteReceptor tyrosine kinase profiling
US20100267046 *18 janv. 200721 oct. 2010University Of Utah Research FoundationIsoform-selective inhibitor and activators of pde3 cyclic nucleotide phosphodiesterases
US20100291100 *26 mars 201018 nov. 2010Gojo Industries, Inc.Compositions And Methods For Screening And Using Compounds Antagonizing Spore-Surface Interactions
US20100291602 *13 mai 201018 nov. 2010University Of OxfordClinical diagnosis of hepatic fibrosis using a novel panel of low abundant human plasma protein biomarkers
US20100311079 *17 août 20109 déc. 2010Abbott LaboratoriesAssay for cardiac troponin autoantibodies
US20100331302 *8 juil. 201030 déc. 2010Chemocentryx, Inc.N-(2-(hetaryl)aryl) arylsulfonamides and n-(2-(hetaryl)hetaryl arylsulfonamides
US20110008314 *27 sept. 201013 janv. 2011Yissum Research Development Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US20110009861 *4 janv. 200813 janv. 2011Music Foundation For Research DevelopmentPredicting atrial fibrillation recurrence by protease and protease inhibitor profiling
US20110014317 *1 févr. 201020 janv. 2011Andrei MiasnikovLipolytic enzyme uses thereof in the food industry
US20110020357 *5 avr. 200927 janv. 2011Technion Research & Development Foundation Ltd.Anti human immunodeficiency antibodies and uses thereof
US20110027887 *18 oct. 20103 févr. 2011Technion Research & Development Foundation Ltd.Method of dynamically culturing embryonic stem cells
US20110033473 *5 avr. 200910 févr. 2011Yoram ReiterAnti influenza antibodies and uses thereof
US20110040248 *17 août 201017 févr. 2011Closed Loop Therapies BvMethods and implantable devices for treating supraventricular arrhythmias
US20110052501 *1 févr. 20093 mars 2011Liat DassaPolypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
US20110065649 *22 avr. 200717 mars 2011Centre National De La Recherche Scientifique (Cnrs)Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation
US20110070224 *30 nov. 201024 mars 2011Nanocyte Inc.Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
US20110081706 *28 sept. 20107 avr. 2011TransAlgae LtdMethod and system for efficient harvesting of microalgae and cyanobacteria
US20110082289 *28 sept. 20107 avr. 2011Affymetric, Inc.Nucleic Acid Labeling Compounds
US20110091454 *8 févr. 201021 avr. 2011Alex DiberMethods and systems for annotating biomolecular sequences
US20110091892 *22 nov. 201021 avr. 2011Genzyme CorporationMethods for the Diagnosis and Treatment of Lung Cancer
US20110111041 *29 déc. 201012 mai 2011EnGenelC Therapy Pty. Ltd.Bacterially derived intact minicells that encompass plasmid free functional nucleic acid for in vivo delivery to mammalian cells
US20110117560 *11 nov. 201019 mai 2011Musc Foundation For Research DevelopmentASSESSING LEFT VENTRICULAR REMODELING VIA TEMPORAL DETECTION AND MEASUREMENT OF microRNA IN BODY FLUIDS
US20110129818 *2 déc. 20092 juin 2011Abbott LaboratoriesASSAY FOR CARDIAC TROPONIN-T (cTnT)
US20110129854 *3 déc. 20092 juin 2011Abbott LaboratoriesAssay for diagnosis of cardiac myocyte damage
US20110130306 *8 juin 20092 juin 2011The Regents Of The University Of CaliforniaPro-fluorescent probes
US20110136103 *3 déc. 20099 juin 2011Abbott LaboratoriesAutoantibody enhanced immunoassays and kits
US20110136141 *3 déc. 20099 juin 2011Abbott LaboratoriesPeptide reagents and method for inhibiting autoantibody antigen binding
US20110136676 *25 oct. 20109 juin 2011Greene Eric CGeometric patterns and lipid bilayers for dna molecule organization and uses thereof
US20110147993 *10 avr. 200823 juin 2011Objet Geometries Ltd.System and method for three dimensional model printing
US20110150874 *20 déc. 201023 juin 2011Teva Pharmaceutical Industries Ltd.Fusion proteins, uses thereof and processes for producing same
US20110171346 *18 oct. 201014 juil. 2011Spaangner Christiansen LivProcess
US20110172113 *27 mars 200914 juil. 2011Mitomics Inc.Aberrant mitochondrial dna, associated fusion transcripts and hybridization probes therefor
US20110184747 *9 août 200728 juil. 2011Carmen BozicMethod for distribution of a drug
US20110189677 *3 févr. 20104 août 2011Massachusetts Institute Of TechnologyMethods For Preparing Sequencing Libraries
US20110190477 *19 févr. 20094 août 2011Peter WhitfeldHumanized Anti-C5aR Antibodies
US20110197315 *28 oct. 200911 août 2011Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield
US20110201559 *22 mai 200818 août 2011Centre National De La Recherche Scientifique (Cnrs)New Optically Pure Compounds for Improved Therapeutic Efficiency
US20110207664 *28 janv. 201125 août 2011Vegenics Pty LimitedMaterials and Methods Involving Hybrid Vascular Endothelial Growth Factor DNAs and Proteins
USRE31006 *2 mars 19783 août 1982Akzona IncorporatedProcess for the demonstration and determination of reaction components having specific binding affinity for each other
USRE32696 *22 déc. 197814 juin 1988Akzona IncorporatedEnzymatic immunological method for determination of antigens and antibodies
USRE4313520 sept. 200724 janv. 2012Danisco A/SMethod of improving dough and bread quality
DE2805961A1 *13 févr. 197819 oct. 1978Syva CoTheophyllin-antigene und -antikoerper und ihre verwendung zur bestimmung von theophyllin
DE102015220401A120 oct. 201519 mai 2016Gen-Probe IncorporatedErythrozyten-Lyselösung
DE212006000071U114 nov. 200624 juil. 2008Board of Regents, The University of Texas System, AustinQuantifizierung von Fusionsproteinen und ihrer Aktivität in Folge chromosomaler Translokation
EP0524502A29 juil. 199227 janv. 1993Bayer CorporationImmunoassay for free analyte
EP0699754A111 août 19956 mars 1996Myriad Genetics, Inc.Method for diagnosing a predisposition for breast and ovarian cancer
EP0703296A13 oct. 198827 mars 1996Chiron CorporationPolynucleotide determination by strand replacement of a capture probe
EP0705902A111 août 199510 avr. 1996Myriad Genetics, Inc.17q-Linked breast and ovarian cancer susceptibility gene
EP0705903A111 août 199510 avr. 1996Myriad Genetics, Inc.In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene
EP0785216A117 déc. 199623 juil. 1997Myriad Genetics, Inc.Chomosome 13-linked breast cancer susceptibility gene BRCA2
EP1333094A21 oct. 19976 août 2003Geron CorporationHuman telomerase catalytic subunit
EP1655381A12 nov. 200510 mai 2006Affymetrix, Inc. (A US Entity)Nucleic acid labeling methods
EP1683874A229 août 200126 juil. 2006YEDA RESEARCH AND DEVELOPMENT Co. LTD.Methods of isolating genes encoding proteins of specific function and of screening for pharmaceutically active agents
EP1696236A229 mars 199930 août 2006OraSure Technologies, Inc.Device for assay of antibodies in oral fluids
EP1728875A27 févr. 19976 déc. 2006Affymetrix, Inc.Chip-based speciation and phenotypic characterization of microorganisms
EP1762243A130 mars 200014 mars 2007Oxford Biomedica (UK) LtdFactor for regulation of neurite growth
EP1783139A21 oct. 19979 mai 2007Geron CorporationHuman telomerase catalytic subunit
EP1798286A231 juil. 199820 juin 2007Schering CorporationMammalian cell membrane proteins and related reagents
EP1798287A231 juil. 199820 juin 2007Schering CorporationMammalian cell membrane proteins and related reagents
EP1803816A212 déc. 19974 juil. 2007Schering CorporationMammalian cell surface antigens; related reagents
EP1810978A28 août 200125 juil. 2007St. Jude Children's Research HospitalGroup B streptococcus polypeptides nucleic acids and therapeutic composition and vaccines thereof
EP1897949A220 sept. 199912 mars 2008Schering CorporationHuman interleukin-B50. Therapeutic uses
EP1903107A125 sept. 200026 mars 2008Cybios LLCPluripotent embryonic-like stem cells, compositions, methods and uses thereof
EP1905832A28 sept. 20002 avr. 2008Schering CorporationMammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions
EP1908837A223 mai 20019 avr. 2008Schering CorporationHuman receptor proteins, related reagents and methods
EP1918377A110 mai 20017 mai 2008Schering CorporationMammalian cytokine receptor subunit proteins, related reagents and methods
EP1942114A29 mars 20009 juil. 2008Schering CorporationMammalian cytokines; related reagents and methods
EP1947183A114 août 199723 juil. 2008Schering CorporationMammalian cell surface antigens; related reagents
EP1950299A130 mai 200030 juil. 2008Schering CorporationMammalian receptor proteins; related reagents and methods
EP1964921A221 juin 20003 sept. 2008Oscient Pharmaceuticals CorporationThe high bone mass gene of 11q13.3
EP1975231A122 janv. 20031 oct. 2008Corixa CorporationCompositions and methods for the detection, diagnosis and therapy of hematological malignancies
EP1980573A28 juil. 199815 oct. 2008Schering CorporationIsolated dendritic cell membrane protein genes
EP1983001A223 sept. 199922 oct. 2008Schering CorporationAntibodies to mammalian Langerhans cell antigen and their uses
EP1988166A17 mai 19985 nov. 2008Schering CorporationHuman Toll-like receptor proteins, related reagents and methods
EP1990057A117 mai 200212 nov. 2008Merck & Co., Inc.Beta-secretase substrates and uses thereof
EP1995317A112 déc. 199726 nov. 2008Schering CorporationMammalian cell surface antigens; related reagents
EP1995318A112 déc. 199726 nov. 2008Schering CorporationMammalian cell surface antigens; related reagents
EP2020239A117 avr. 20014 févr. 2009Schering CorporationUse of IL-174 agonists for treating infectious diseases
EP2026070A19 sept. 200318 févr. 2009Arbor Vita CorporationMethods of diagnosing cervical cancer
EP2028187A17 sept. 200125 févr. 2009Board Of Regents, The University Of Texas SystemHuman and mouse targeting peptides identified by phage display
EP2031070A126 nov. 20034 mars 2009Applera CorporationMultiplex amplification of polynucleotides
EP2042869A26 déc. 20001 avr. 2009Board Of Trustees Of The University Of IllinoisHigh affinity TCR proteins and methods
EP2058275A17 janv. 200413 mai 2009Ramot at Tel-Aviv University Ltd.Peptide nanostructures encapsulating a foreign material and method of manufacturing same
EP2058333A222 juil. 199913 mai 2009Millennium Pharmaceuticals, Inc.Anti-CCR2 antibodies and methods of use therefor
EP2062918A227 nov. 200327 mai 2009Technion Research and Development Foundation, Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
EP2062919A227 nov. 200327 mai 2009Technion Research and Development Foundation, Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
EP2070944A111 oct. 200217 juin 2009Amgen Inc.Specific binding agents of human angiopoietin-2
EP2071021A212 déc. 200817 juin 2009University of South FloridaBone marrow-derived neuronal cells
EP2072045A211 févr. 200324 juin 2009Technion Research and Development Foundation, Ltd.Antibody having a t-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP2072059A111 oct. 200224 juin 2009Schering CorporationUse of bispecific antibodies to regulate immune responses
EP2077277A130 janv. 20038 juil. 2009Schering CorporationUse of mammalian cytokine; related reagents
EP2080766A16 juin 200222 juil. 2009Bristol-Myers Squibb CompanyB7-related nucleic acids and polypeptides useful for immunomodulation
EP2100959A224 juil. 199816 sept. 2009Schering CorporationMammalian cytokine: interleukin-B30 and related reagents
EP2107125A131 mars 20087 oct. 2009Eppendorf Array Technologies SA (EAT)Real-time PCR of targets on a micro-array
EP2116618A18 mai 200911 nov. 2009Agency for Science, Technology And ResearchDiagnosis and treatment of Kawasaki disease
EP2119771A223 déc. 200418 nov. 2009Danisco A/SProteins
EP2124055A1 *21 févr. 200825 nov. 2009Stella Chemifa CorporationKit for immunoassay of bsh, and method for measurement of bsh
EP2124055A4 *21 févr. 200827 juil. 2011Stella Chemifa CorpKit for immunoassay of bsh, and method for measurement of bsh
EP2128270A19 août 20042 déc. 2009Genenews Inc.Osteoarthritis biomarkers and uses thereof
EP2131198A220 sept. 20029 déc. 2009Board of Regents, The University of Texas SystemMeasuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
EP2135611A11 mars 200223 déc. 2009Hollis-Eden Pharmaceuticals Inc.Pregn-5-en-20-yne-3,7,17-triol derivatives for use in therapy
EP2135619A110 déc. 200323 déc. 2009Millennium Pharmaceuticals, Inc.Humanized anti-CCR2 antibodies and methods of use therefor
EP2138510A127 juil. 200030 déc. 2009Schering CorporationMethods of generating antibodies against cytokines
EP2157097A111 oct. 200224 févr. 2010Amgen, Inc.Specific binding agents of human angiopoietin-2
EP2172210A122 déc. 20067 avr. 2010Partnership&Corp. Technology TransferSynthetic peptides for use as inhibitors of neurotransmitter secretion
EP2172478A26 févr. 19987 avr. 2010THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICESActivity-dependent neurotrophic factor III (ADNF III)
EP2174668A214 nov. 200514 avr. 2010Vascular Biogenics Ltd.Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
EP2177503A121 févr. 200521 avr. 2010UCL Business PLCModulators of cannabinoid receptors
EP2182052A17 oct. 20035 mai 2010Technion Research and Development Foundation, Ltd.Human foreskin cells suitable for culturing stem cells
EP2186530A115 nov. 200119 mai 2010Vascular Biogenics Ltd.Promoters exhibiting endothelial cell specificity and methods of using same
EP2194147A126 nov. 20039 juin 2010Applied Biosystems, LLCMultiplex amplification of polynucleotides
EP2202240A117 août 200130 juin 2010Sterix LimitedCompound
EP2208782A24 févr. 200021 juil. 2010Pluristem Ltd.Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
EP2208797A21 mars 200521 juil. 2010Applied Biosystems, LLCMethods, compositions and kits for use in polynucleotide amplification
EP2210899A110 nov. 200528 juil. 2010Danisco A/Spntr transcription factor
EP2213740A11 oct. 19974 août 2010The Regents of the University of ColoradoHuman telomerase catalytic subunit
EP2216033A24 mars 200411 août 2010Yeda Research and Development Co. Ltd.Methods of treating disease by transplantation of allogeneic or xenogeneic organs or tissues
EP2224008A210 mai 20061 sept. 2010Murdoch UniversityGenes and proteins of brachyspira hyodysenteriae and use of same for diagnosis and therapy
EP2233574A124 juil. 199829 sept. 2010Schering CorporationMammalian cytokine: interleukin-B30 and related reagents
EP2236600A117 oct. 20056 oct. 2010Danisco A/SEnzymes
EP2236601A117 oct. 20056 oct. 2010Danisco A/SPhytases
EP2246444A114 sept. 20053 nov. 2010The Regents of the University of Colorado, A Body CorporateMethod for treatment with bucindolol based on genetic targeting
EP2256203A118 nov. 20041 déc. 2010Schering CorporationIL-23 and its receptor; related reagents and methods
EP2258726A113 juin 19968 déc. 2010The Regents of the University of CaliforniaHigh affinity human antibodies to c-erbB-2
EP2258834A121 mars 20018 déc. 2010The Scripps Research InstituteHuman aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis
EP2258849A130 mai 20008 déc. 2010Schering CorporationMammalian receptor proteins; related reagents and methods
EP2261256A215 nov. 200015 déc. 2010Schering CorporationMethods of inhibiting metastasis
EP2264156A117 oct. 200522 déc. 2010Danisco A/SPhytases
EP2266405A210 mars 200529 déc. 2010Danisco A/SFungal lipolytic enzymes
EP2266624A215 juil. 200329 déc. 2010Board of Regents, The University of Texas SystemDuramycin peptide binding to anionic phospholipids and aminophospholipids conjugates and their use in treating viral infections
EP2267107A218 juil. 200529 déc. 2010Danisco A/SLipolytic Enzyme. Uses Thereof In The Food Industry
EP2267108A118 juil. 200529 déc. 2010Danisco A/SEnzymatic oil-degumming method
EP2272869A211 oct. 200212 janv. 2011Amgen Inc.Angiopoietin-2 specific binding agents
EP2275445A211 mars 200519 janv. 2011Vasgene Therapeutics, Inc.Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
EP2275447A115 nov. 200019 janv. 2011Schering CorporationMethods of inhibiting metastasis
EP2275522A218 juil. 200519 janv. 2011Danisco A/SEnzymatic oil-degumming method
EP2275548A110 mai 200119 janv. 2011Schering CorporationMammalian cytokine receptor subunit proteins, related reagents and methods
EP2278015A115 janv. 200426 janv. 2011Danisco A/SMethod of producing a carbohydrate ester
EP2279726A225 mai 20062 févr. 2011Biorest Ltd.Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
EP2280285A115 sept. 20042 févr. 2011Oklahoma Medical Research FoundationMethod of using cytokine assays to diagnose, treat, and evaluate inflammatory and autoimmune diseases
EP2280286A115 sept. 20042 févr. 2011Oklahoma Medical Research FoundationMethod of using cytokine assays to diagnose, treat, and evaluate systemic lupus erythematosus
EP2281578A215 juil. 20039 févr. 2011Board of Regents, The University of Texas SystemSelected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in treating viral infections and cancer
EP2281841A230 nov. 20059 févr. 2011Schering CorporationBiomarkers for pre-selection of patients for anti-IGF1R therapy
EP2283831A230 nov. 200516 févr. 2011Schering CorporationBiomakers for pre-selection of patients for anti-IGF1R therapy
EP2287185A26 déc. 200023 févr. 2011Board Of Trustees Of The University Of IllinoisHigh affinity TCR proteins and methods
EP2287194A211 mars 200523 févr. 2011Vasgene Therapeutics, Inc.Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
EP2287317A215 janv. 200423 févr. 2011Danisco A/SMethod of producing a protein ester or a protein subunit ester
EP2287616A115 sept. 200423 févr. 2011Oklahoma Medical Research FoundationMethod of using cytokine assays to diagnose, treat, and evaluate systemic lupus erythematosus
EP2289567A215 déc. 20042 mars 2011Regentis Biomaterials Ltd.Matrix comprising naturally-occurring crosslinked protein backbone
EP2290085A215 janv. 20042 mars 2011Danisco A/SMethod for the in situ production of an emulsifier in a foodstuff
EP2292661A29 nov. 20049 mars 2011Schering CorporationInterleukin-10 antibodies
EP2292760A29 nov. 20019 mars 2011Schering CorporationMammalian cytokines, receptors, related reagents and methods
EP2295978A219 mars 199916 mars 2011The Curators Of The University Of MissouriEarly pregnancy diagnosis using PAGs(Pregnancy-associated Glycoproteins)
EP2295980A130 oct. 200316 mars 2011Yissum Research Development Company, of The Hebrew University of JerusalemMolecules and methods using same for measuring non-transferrin bound iron
EP2298315A128 août 200323 mars 2011Harbor BioSciences, Inc.Therapeutic treatment methods
EP2298316A128 août 200323 mars 2011Harbor BioSciences, Inc.Therapeutic treatment methods
EP2298789A17 sept. 200123 mars 2011Schering CorporationMammalian genes; related reagents and methods
EP2302072A118 nov. 200530 mars 2011Eppendorf Array Technologies S.A.Real time-PCR of targets on a micro-array
EP2302079A215 sept. 200630 mars 2011Baylor Research InstituteSystemic lupus erythematosus diagnostic assay
EP2305794A126 janv. 20036 avr. 2011Gamida Cell Ltd.Expansion of renewable stem cell populations
EP2308994A121 mars 200213 avr. 2011Yeda Research And Development Co., Ltd.Methods for determining a risk to develop cancer
EP2311869A130 janv. 200320 avr. 2011Schering CorporationUse of mammalian cytokine; related reagents
EP2311938A14 févr. 200020 avr. 2011Pluristem Ltd.Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
EP2314696A120 sept. 199927 avr. 2011Schering CorporationTherapeutic uses of human Interleukin-B50 antagonist.
EP2316441A116 févr. 20064 mai 2011Hadasit Medical Research Services And DevelopmentBisphosphonates for treating endometriosis
EP2316485A111 oct. 20024 mai 2011Schering CorporationUse of bispecific antibodies to regulate immune responses
EP2316845A111 oct. 20024 mai 2011Amgen Inc.Specific binding agents of human angiopoietin-2
EP2316950A119 mars 20014 mai 2011Technion Research and Development Foundation, Ltd.Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same
EP2319857A24 mars 200411 mai 2011Yeda Research And Development Co., Ltd.Pon polypeptides, polynucleotides encoding same and compositions and methods utilizing same
EP2319941A223 oct. 200611 mai 2011GeneNews Inc.Method and apparatus for correlating levels of biomarker products with disease
EP2322561A15 oct. 200418 mai 2011Yeda Research And Development Co., Ltd.Anti-NIK antibodies and uses thereof
EP2329814A111 févr. 20038 juin 2011Technion Research and Development Foundation, Ltd.Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer
EP2330132A14 avr. 20048 juin 2011Yeda Research and Development Co. Ltd.Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
EP2333049A125 sept. 200015 juin 2011ABT Holding CompanyPluripotent embryonic-like stem cells, compositions, methods and uses thereof
EP2335728A113 mai 200222 juin 2011Ludwig Institute for Cancer Research Ltd.Specific binding proteins and uses thereof
EP2336321A111 mai 200022 juin 2011Medical Research CouncilOx2 receptor homolog
EP2336330A214 juin 200522 juin 2011Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
EP2336775A26 déc. 200022 juin 2011Board Of Trustees Of The University Of IllinoisHigh affinity TCR proteins and methods
EP2338896A211 déc. 200329 juin 2011R.B.T. (Rakuto Bio Technologies) Ltd.Use of lignin peroxidase in skin and hair lightening
EP2338913A117 déc. 199629 juin 2011The University of Utah Research FoundationChromosome 13-linked breast cancer susceptibility gene
EP2339032A118 avr. 200629 juin 2011Mitomics Inc.Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers
EP2341143A111 mai 20006 juil. 2011Medical Research CouncilOX2 receptor homolog
EP2341144A110 janv. 20006 juil. 2011Schering CorporationInterleukin-17 related mammalian cytokines. Polynucleotides encoding them. Uses
EP2341346A217 oct. 20016 juil. 2011The Regents of the University of CaliforniaMethods of high-throughput screening for internalizing antibodies and metal-chelating liposomes
EP2343311A25 sept. 200513 juil. 2011Licentia OyPeptide inhibitors of HK2 and their use
EP2343373A114 juin 200513 juil. 2011Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
EP2354160A129 août 200610 août 2011Schering CorporationEngineered anti-IL-23-antibodies
EP2354164A15 oct. 200410 août 2011Yeda Research And Development Co., Ltd.Anti-NIK antibodies and uses thereof
EP2357478A230 nov. 200117 août 2011Crawford Healthcare Holdings LimitedDiagnosis of disease
EP2359832A225 juil. 200524 août 2011University of Maryland, BaltimoreTherapeutic agents targeting the NCCA-ATP channel and methods of use thereof
EP2359853A17 août 200124 août 2011Technion Research and Development Foundation, Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis
EP2359854A17 août 200124 août 2011Technion Research and Development Foundation, Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis
EP2364994A13 janv. 199514 sept. 2011Schering CorporationPurfied primate CTLA-8 antigens and related reagents
EP2365087A220 mai 200414 sept. 2011Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
EP2366775A122 mars 200721 sept. 2011Pluristem Ltd.Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
EP2371861A124 janv. 20035 oct. 2011G2 Therapies LimitedMonoclonal antibodies against extracellular loops of C5aR
EP2371955A126 sept. 20035 oct. 2011K.U. Leuven Research & DevelopmentIntegrase cofactor
EP2382977A116 sept. 20052 nov. 2011University of Maryland, BaltimoreTherapeutic agents targeting the ncca-atp channel and methods of use thereof
EP2383345A120 déc. 20072 nov. 2011Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
EP2385124A212 mai 20009 nov. 2011Arbor Vita CorporationPeptides or peptide analogues for modulating the binding of a PDZ protein and a PL protein
EP2386640A225 août 200516 nov. 2011EnGeneIC Molecular Delivery Pty LtdDelivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
EP2389943A117 avr. 200130 nov. 2011Schering CorporationUse of IL-174 antagonists for treating Th2-related diseases
EP2390312A129 nov. 200630 nov. 2011Gamida Cell Ltd.Methods of improving stem cell homing and engraftment
EP2395012A22 nov. 200614 déc. 2011Protiva Biotherapeutics Inc.Modified siRNA molecules and uses thereof
EP2395025A126 févr. 200814 déc. 2011Schering CorporationEngineered Anti-IL-23R Antibodies
EP2400030A118 mai 200528 déc. 2011The Board Of Trustees Of The University Of the Leland Stanford Junior UniversityDetection of protein translocation by beta-galactosidase reporter fragment complementation
EP2402444A117 août 19954 janv. 2012The Rockefeller UniversityModulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
EP2402752A229 oct. 20074 janv. 2012Janssen Pharmaceutica, N.V.A method for pharmacologically profiling compounds
EP2405007A125 janv. 200711 janv. 2012Danisco A/SProduction of a lipid acyltransferase from transformed bacillus cells
EP2407242A113 juil. 201018 janv. 2012Dublin City UniversityDirect clone analysis and selection technology
EP2407783A129 oct. 200718 janv. 2012Janssen Pharmaceutica, N.V.A method for pharmacologically profiling compounds
EP2423332A123 août 200729 févr. 2012Oncotherapy Science, Inc.Prognostic markers and therapeutic targets for lung cancer
EP2423333A123 août 200729 févr. 2012Oncotherapy Science, Inc.Prognostic markers and therapeutic targets for lung cancer
EP2425841A122 nov. 20017 mars 2012Vascular Biogenics Ltd.Methods Employing and Compositions Containing Defined Oxidized Phospholipids for Prevention and Treatment of Atherosclerosis
EP2425850A214 juin 20067 mars 2012The Regents of The University of CaliforniaBispecific single chain FV antibody molecules and methods of use thereof
EP2425860A111 août 20067 mars 2012Amgen Inc.Modified Fc molecules
EP2426144A121 févr. 20087 mars 2012Schering CorporationEngineered anti-IL-23p19 antibodies
EP2426145A121 févr. 20087 mars 2012Schering CorporationEngineered anti-IL-23p19 antibodies
EP2426199A219 oct. 20077 mars 2012Danisco US Inc.Polyol oxidases
EP2428522A117 mai 200514 mars 2012Agensys, Inc.Antibodies that bind to PSCA proteins for diagnosis of cancer
EP2441520A112 oct. 201018 avr. 2012Eppendorf AGReal-time amplification and micro-array based detection of nucleic acid targets in a flow chip assay
EP2441840A118 juil. 200618 avr. 2012Protalix Ltd.Mucosal or enteral administration of biologically active macromolecules
EP2444099A131 mars 200625 avr. 2012Agensys, Inc.Antibodies and related molecules that bind to 161P2F10B proteins
EP2450456A22 nov. 20079 mai 2012Yale UniversityAssessment of oocyte competence
EP2450702A228 janv. 20089 mai 2012University Of Louisville Research Foundation, Inc.Methods of detecting autoantibodies for diagnosing and characterizing disorders
EP2455404A222 août 200723 mai 2012G2 Inflammation Pty LtdAnti-C5AR antibodies with improved properties
EP2457999A27 déc. 200330 mai 2012Technion Research & Development Foundation Ltd.Culture medium for pluropotent stem cells
EP2460893A119 juin 20066 juin 2012Advanced Cell Diagnostics, Inc.Multiplex detection of nucleic acids
EP2463382A17 déc. 201113 juin 2012Enterologics, Inc.Method for identifying E. Coli M-17
EP2465920A225 févr. 201020 juin 2012Tel HaShomer Medical Research Infrastructure and Services Ltd.Isolated populations of renal stem cells and methods of isolating and using same
EP2465924A218 juin 200620 juin 2012Ramot at Tel-Aviv University Ltd.Isolated cells and populations comprising same for the treament of cns diseases
EP2469282A17 sept. 200727 juin 2012University of OxfordClinical diagnosis of hepatic fibrosis using a novel panel of human serum protein biomarkers
EP2469283A17 sept. 200727 juin 2012University of OxfordClinical diagnosis of hepatic fibrosis using human serum APOL1 as biomarker.
EP2471807A15 févr. 20074 juil. 2012Modigene IncLong-acting polypeptides and methods of producing and administering same
EP2478924A131 janv. 200825 juil. 2012Technion Research & Development FoundationAlbumin fibers and fabrics and methods of generating and using same
EP2484768A218 juil. 20068 août 2012Protalix Ltd.Mucosal or enteral administration of biologically active macromolecules
EP2487182A29 juil. 200615 août 2012FULCRUM SP Ltd.SP1 polypeptides, modified SP1 polypeptides and uses thereof
EP2500428A210 juil. 200819 sept. 2012Yeda Research and Development Co. Ltd.Nucleic acid construct systems capable of diagnosing or treating a cell state
EP2500439A119 juin 200619 sept. 2012Advanced Cell Diagnostics, Inc.Methods of detecting nucleic acids in individual cells and of identifying rare cells from large heterogeneous cell populations
EP2511708A12 oct. 200817 oct. 2012Affymetrix, Inc.Highly multiplexed particle-based assays
EP2514315A221 août 200624 oct. 2012Yeda Research and Development Co. Ltd.Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
EP2514763A118 févr. 200524 oct. 2012The Ludwig Institute for Cancer ResearchEgf receptor epitope peptides and uses thereof
EP2514766A227 mars 200824 oct. 2012Technion Research & Development Foundation Ltd.Antibodies, methods and kits for diagnosing and treating melanoma
EP2520669A26 févr. 20067 nov. 2012GeneNews Inc.Mild osteoathritis biomarkers and uses thereof
EP2526952A115 juil. 200428 nov. 2012Bar-Ilan UniversityMethods and pharmaceutical compositions for healing wounds
EP2526953A115 juil. 200428 nov. 2012Bar-Ilan UniversityMethods and pharmaceutical compositions for healing wounds
EP2526968A226 janv. 200728 nov. 2012Biogen Idec MA Inc.Nogo receptor antagonists
EP2527441A215 juil. 200828 nov. 2012Technion Research & Development FoundationCompositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis
EP2529754A13 mai 20085 déc. 2012Agency For Science, Technology And Research (A*star)Antibodies binding to an intracellular PRL-1 or PRL-3 polypeptide
EP2530087A226 mars 20095 déc. 2012Prionics AGSequences of brachyspira, immunogenic composition, methods for preparation and use thereof
EP2532674A15 févr. 200712 déc. 2012Modigene IncLong-acting polypeptides and methods of producing and administering same
EP2532675A15 févr. 200712 déc. 2012Modigene IncLong-acting polypeptides and methods of producing and administering same
EP2532746A226 mars 200812 déc. 2012EnGeneIC Molecular Delivery Pty Ltd.Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells
EP2540301A215 juil. 20042 janv. 2013Bar-Ilan UniversityMethods and pharmaceutical compositions for healing wounds
EP2540302A115 juil. 20042 janv. 2013Bar-Ilan UniversityMethods and pharmaceutical compositions for healing wounds
EP2546359A17 déc. 200616 janv. 2013Novartis AGEffects of inhibitors of FGFR3 on gene transcription
EP2548951A122 mars 200723 janv. 2013Pluristem Ltd.Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
EP2550982A126 juil. 201230 janv. 2013Technion Research & Development Foundation Ltd.Devices for surgical applications
EP2561889A231 juil. 200327 févr. 2013Yeda Research and Development Co. Ltd.Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
EP2574628A123 janv. 20093 avr. 2013Amgen Inc.Ferroportin antibodies and methods of use
EP2581445A17 août 200817 avr. 2013Yeda Research And Development Co. Ltd.Regulators of MMP-9 and uses thereof
EP2583981A217 mai 200524 avr. 2013Agensys, Inc.Antibodies and related molecules that bind to PSCA proteins
EP2591789A22 sept. 200815 mai 2013Pluristem Ltd.Adherent cells from adipose or placenta tissues and use thereof in therapy
EP2599790A126 nov. 20085 juin 2013Yissum Research Development Company of The Hebrew University of JerusalemCompositions comprising fibrous polypeptides and polysachharides
EP2620448A128 avr. 200931 juil. 2013Amgen Inc.Anti-hepcidin antibodies and methods of use
EP2620493A126 mai 200931 juil. 2013Ramot at Tel Aviv University Ltd.Mesenchymal stem cells for the treatment of CNS diseases
EP2626417A122 mars 200714 août 2013Pluristem Ltd.Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
EP2628752A113 déc. 200721 août 2013Merck Sharp & Dohme Corp.Engineered anti-TSLP antibody
EP2633854A13 déc. 20094 sept. 2013Yeda Research And Development Co. Ltd.miRNA-9 or miRNA-9* for use in treating MND
EP2636743A120 avr. 200711 sept. 2013Intervet International B.V.Pestivirus species
EP2641606A126 mai 200925 sept. 2013Pluristem Ltd.Methods of treating inflammatory colon diseases
EP2645106A24 avr. 20062 oct. 2013Biogen Idec MA Inc.Methods and products for evaluating an immune response to a therapeutic agent
EP2657342A110 août 200930 oct. 2013Genisphere Inc.DNA dendrimers protected against nuclease degradation are useful as vectors for the delivery of siRNA
EP2674440A25 déc. 200618 déc. 2013IBC Pharmaceuticals, Inc.Multivalent immunoglobulin-based bioactive assemblies
EP2679599A120 févr. 20091 janv. 2014Amgen Inc.Antibodies directed to Angiopoietin-1 and Angiopoietin-2 and use thereof
EP2700723A26 août 200826 févr. 2014Orion Genomics, LLCNovel single nucleotide polymorphisms and combinations of novel and known polymorphisms for determining the allele-specific expression of the IGF2 gene
EP2711434A119 juin 200626 mars 2014Advanced Cell Diagnostics, Inc.Multiplex detection of nucleic acids
EP2712620A16 févr. 20092 avr. 2014Cornell UniversityMethods for Preventing or Treating Insulin Resistance
EP2716654A124 oct. 20069 avr. 2014Evogene Ltd.Isolated polypeptides, polynucleotides encoding same, transgenic plants expressing same and methods of using same
EP2719394A129 juin 200416 avr. 2014Tel Aviv University Future Technology Development L.P.Peptides antibodies directed thereagainst for diagnosing and treating amyloid-associated diseases
EP2770057A115 avr. 200927 août 2014Protiva Biotherapeutics Inc.Silencing of CSN5 gene expression using interfering RNA
EP2774987A114 août 200710 sept. 2014Affymetrix, Inc.Nucleic acid quantitation from tissue slides
EP2781223A12 oct. 200824 sept. 2014Rappaport Family Institute for Research in the Medical SciencesCompositions comprising semaphorins for the treatment of angiogenesis related diseases
EP2789626A223 sept. 200915 oct. 2014Tel Hashomer Medical Research Infrastructure and Services Ltd.Peptides and compositions for prevention of cell adhesion and methods of using same
EP2799876A213 mai 20105 nov. 2014The Chancellors, Masters and Scholars of the University of OxfordClinical diagnosis of hepatic fibrosis using a novel panel of low abundant human plasma protein biomarkers
EP2803675A223 janv. 200919 nov. 2014Amgen, IncFerroportin antibodies and methods of use
EP2806023A229 nov. 201026 nov. 2014Pluristem Ltd.Adherent cells from placenta and use of same in disease treatment
EP2808344A11 juin 20113 déc. 2014Monash UniversityAntibodies directed to the receptor tyrosine kinase c-Met
EP2808402A229 déc. 20093 déc. 2014Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Methods of predicting responsiveness to interferon treatment
EP2816059A128 avr. 200924 déc. 2014Amgen, IncAnti-hepcidin antibodies and methods of use
EP2816117A228 sept. 200524 déc. 2014Collplant Ltd.Collagen producing plants and methods of generating and using same
EP2826791A219 févr. 200921 janv. 2015G2 Inflammation Pty LtdHumanized anti-C5aR antibodies
EP2839839A128 févr. 200825 févr. 2015Yeda Research And Development Company LimitedNuclear targeting sequences
EP2851091A111 avr. 200825 mars 2015Dana-Farber Cancer Institute, Inc.Methods for treating cancer resistant to ERBB therapeutics
EP2853536A15 févr. 20071 avr. 2015OPKO Biologics Ltd.Long-acting erythropoietin polypeptides and uses thereof
EP2853541A15 févr. 20071 avr. 2015OPKO Biologics Ltd.Long-acting polypeptides and uses thereof
EP2862929A19 déc. 201022 avr. 2015Quark Pharmaceuticals, Inc.Compositions and methods for treating diseases, disorders or injury of the CNS
EP2865755A226 mars 200829 avr. 2015EnGeneIC Molecular Delivery Pty LtdBacterially derived, intact minicells encompassing regulatory RNA
EP2881468A120 avr. 200710 juin 2015Intervet International B.V.Pestivirus species
EP2889041A126 juil. 20061 juil. 2015Rutgers, The State University of New JerseyKit of reagents for tuberculosis assay
EP2902036A16 févr. 20095 août 2015Cornell UniversityMethods for preventing or treating insulin resistance
EP2907873A116 juil. 201019 août 2015Bioatla LLCSimulataneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
EP2910638A224 juil. 200826 août 2015Evogene Ltd.Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance and/or biomass and/or yield in plants expressing same
EP2913344A117 févr. 20102 sept. 2015Ludwig Institute for Cancer Research LtdSpecific binding proteins and uses thereof
EP2923709A128 mars 201430 sept. 2015Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Multi-component-multistage malaria vaccine
EP2933265A25 juin 200621 oct. 2015Amicus Therapeutics, Inc.Pharmacological chaperones for treating obesity
EP2936976A121 avr. 200928 oct. 2015Danziger Innovations Ltd.Plant viral expression vectors and use of same for generating genotypic variations in plant genomes
EP2942627A15 mai 201511 nov. 2015MicroBPlex, Inc.Media elaborated with newly synthesized antibodies (mensa) from recently proliferated antibody secreting cells (asc) and uses thereof
EP2944649A19 janv. 200918 nov. 2015Research Development FoundationVaccines and diagnostics for the ehrlichioses
EP2952588A16 août 20089 déc. 2015Orion Genomics, LLCSingle nucleotide polymorphism in igf2 for determining the allele-specific expression of the igf2 gene
EP2955234A111 févr. 201016 déc. 2015Orion Genomics, LLCCombinations of polymorphisms for determining allele-specific expression of igf2
EP2977445A229 nov. 201027 janv. 2016Pluristem Ltd.Adherent cells from placenta and use of same in disease treatment
EP2990421A129 avr. 20102 mars 2016Tel HaShomer Medical Research Infrastructure and Services Ltd.Anti ceacam1 antibodies and methods of using same
EP2992895A18 sept. 20149 mars 2016Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Three-component-multistage malaria vaccine
EP2995194A115 août 200616 mars 2016Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
EP3000889A21 mars 201030 mars 2016Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
EP3000899A126 nov. 200330 mars 2016Applied Biosystems, LLCMultiplex amplification of polynucleotides
EP3006039A12 mars 200513 avr. 2016Acceleron Pharma Inc.Alk7 polypeptides for use in promoting fat loss
EP3018139A23 août 200711 mai 2016Boehringer Ingelheim Vetmedica GmbHGenes and proteins of brachyspira hyodysenteriae and uses thereof
EP3020410A116 avr. 200918 mai 2016Collplant Ltd.Methods of generating and using procollagen
EP3023438A131 août 201025 mai 2016Merck Sharp & Dohme Corp.Anti-gitr antibodies
EP3026057A29 mars 20101 juin 2016Ramot at Tel Aviv University Ltd.Compositions for prevention and treatment of neurodegenerative diseases
EP3032259A11 mai 200815 juin 2016Tel Hashomer Medical Research Infrastructure and Services Ltd.Methods for detecting trophoblast cells in maternal blood based on cytokeratin-7
EP3034087A16 déc. 201222 juin 2016Yeda Research and Development Co. Ltd.Mammalian fetal pulmonary cells and therapeutic use of same
EP3034625A121 oct. 201122 juin 2016Advanced Cell Diagnostics, Inc.An ultra sensitive method for in situ detection of nucleic acids
EP3037435A117 nov. 201029 juin 2016MUSC Foundation For Research DevelopmentHuman monoclonal antibodies to human nucleolin
EP3042957A116 juil. 201013 juil. 2016Bioatla LLCSimultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
EP3056569A222 déc. 201017 août 2016Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency
EP3059247A17 déc. 200924 août 2016Abraxis BioScience, LLCSparc binding peptides and uses thereof
EP3072972A218 août 200928 sept. 2016Evogene Ltd.Isolated polypeptides and polynucleotides useful for increasing nitrogen use efficiency, abiotic stress tolerance, yield and biomass in plants
EP3075396A110 oct. 20115 oct. 2016Yeda Research and Development Co. Ltd.Methods and compositions for the treatment of insulin-associated medical conditions
EP3075854A115 juil. 20085 oct. 2016Technion Research & Development Foundation Ltd.Compositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis
EP3081937A118 juil. 201219 oct. 2016President and Fellows of Harvard CollegeEngineered microbe-targeting molecules and uses thereof
EP3088528A128 sept. 20052 nov. 2016Collplant Ltd.Collagen producing plants and methods of generating and using same
EP3091026A19 mai 20169 nov. 2016Centrillion Technology Holdings CorporationDisulfide-linked reversible terminators
EP3091071A122 mars 20079 nov. 2016Pluristem Ltd.Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
EP3103451A111 janv. 200814 déc. 2016University of Maryland, BaltimoreTargetting ncca-atp channel for organ protection following ischemic episode
EP3103463A12 sept. 200814 déc. 2016Pluristem Ltd.Adherent cells from adipose or placenta tissues and use thereof in therapy
EP3103467A16 févr. 200914 déc. 2016Cornell UniversityMethods for preventing or treating insulin resistance
EP3115451A11 sept. 200911 janv. 2017Pluristem Ltd.Adherent cells from placenta tissue and use thereof in therapy
EP3130346A11 juil. 201015 févr. 2017OPKO Biologics Ltd.Long-acting factor vii coagulation factors
EP3133172A15 sept. 200722 févr. 2017Institut PasteurGenomic morse code
EP3136103A12 oct. 20081 mars 2017Affymetrix, Inc.Highly multiplexed assays
EP3147365A120 avr. 200729 mars 2017Intervet International B.V.Pestivirus species
EP3159405A15 janv. 201126 avr. 2017Vascular Biogenics Ltd.Methods for use of a specific anti-angiogenic adenoviral agent
EP3176183A11 déc. 20167 juin 2017Yeda Research and Development Co. LtdCompositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki)
EP3184109A129 déc. 201028 juin 2017Gamida-Cell Ltd.Methods for enhancing natural killer cell proliferation and activity
EP3184637A18 sept. 200028 juin 2017Merck Sharp & Dohme Corp.Mammalian interleukin-12 p40 and interleukin b30 complexes, antibodies, uses in pharmaceutical compositions
EP3190125A129 août 200612 juil. 2017Merck Sharp & Dohme Corp.Engineered anti-il-23 antibodies
EP3202779A25 févr. 20079 août 2017OPKO Biologics Ltd.Long-acting hgh polypeptides and uses thereof
EP3205724A126 mars 200816 août 2017EnGeneIC Molecular Delivery Pty Ltd.Bacterially derived, intact minicells encompassing regulatory rna
EP3208338A12 août 201223 août 2017Yeda Research and Development Co., Ltd.Micro-rna mir-15 and compositions comprising same for the treatment of corticotropin-releasing hormone- associated medical conditions
EP3216805A127 janv. 201113 sept. 2017Yeda Research and Development Co. LtdAntibodies that inhibit metalloproteins
EP3216878A117 janv. 201213 sept. 2017Life Technologies CorporationWorkflow for detection of ligands using nucleic acids
EP3238534A28 juin 20101 nov. 2017Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and/or abiotic stress tolerance
WO1980002747A1 *19 mai 198011 déc. 1980Rapidex LtdUltrasensitive enzymatic radioimmunoassay method
WO1982004323A1 *28 mai 19829 déc. 1982O Neill SeanImmunoprecipitation assay
WO1985000605A1 *20 juil. 198414 févr. 1985American Hospital Supply CorporationProcess for selective nitrile reduction
WO1998014593A21 oct. 19979 avr. 1998Geron CorporationHuman telomerase catalytic subunit
WO1999045124A23 mars 199910 sept. 1999Genencor International, Inc.Modified forms of pullulanase
WO2000015824A115 mars 199923 mars 2000Karolinska Innovations AbTransfer method for specific cellular localisation of nucleic acids
WO2000073451A130 mai 20007 déc. 2000Schering CorporationMammalian receptor proteins; related reagents and methods
WO2001062271A120 févr. 200130 août 2001The Board Of Trustees Of The University Of ArkansasCompositions and methods for the early diagnosis of ovarian cancer
WO2001075078A121 mars 200111 oct. 2001The Scripps Research InstituteHUMAN AMINOACYL-tRNA SYNTHETASE POLYPEPTIDES USEFUL FOR THE REGULATION OF ANGIOGENESIS
WO2002020569A27 sept. 200114 mars 2002Schering CorporationMammalian genes; related reagents and methods
WO2002044736A230 nov. 20016 juin 2002Molecular Skincare LimitedDiagnosis and treatment of epidermal or skin diseases
WO2003030835A211 oct. 200217 avr. 2003Schering CorporationUse of bispecific antibodies to regulate immune responses
WO2003043524A220 nov. 200230 mai 2003The Curators Of The University Of MissouriCompositions and methods for accurate early pregnancy diagnosis
WO2003072799A221 févr. 20034 sept. 2003The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human ServicesBrother of the regulator of imprinted sites (boris)
WO2003101386A229 mai 200311 déc. 2003Memorial Sloan-Kettering Cancer CenterKinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis
WO2004037251A123 oct. 20036 mai 2004Sterix LimitedInhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2
WO2004060135A231 déc. 200322 juil. 2004Rappaport Family Institute For Research In The Medical SciencesMethods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients
WO2004060909A217 nov. 200322 juil. 2004Genencor International, Inc.Increasing production of proteins in gram-positive microorganisms
WO2004096157A25 mars 200411 nov. 2004New England Medical Center Hospitals, Inc.Treatment of igai deposition diseases
WO2005016282A213 août 200424 févr. 2005Exelixis, Inc.Prkcs as modifiers of the beta catenin pathway and methods of use
WO2005019409A215 juil. 20033 mars 2005Board Of Regents, The University Of Texas SystemCombinatorial protein library screening by periplasmic expression
WO2005033142A25 oct. 200414 avr. 2005Yeda Research And Development Co. Ltd.Anti-nik antibodies and uses thereof
WO2005033145A15 oct. 200414 avr. 2005Yeda Research And Development Co. Ltd.Antibodies to nik, their preparation and use
WO2005051423A230 nov. 20049 juin 2005Yeda Research And Development Co. LtdMethods and agents for immune modulation and methods for identifying immune modulators
WO2005118864A217 mai 200515 déc. 2005Agensys, Inc.Antibodies and related molecules that bind to psca proteins
WO2006024694A25 sept. 20059 mars 2006Licentia OyPeptide inhibitors of hk2 and their use
WO2006034048A216 sept. 200530 mars 2006University Of Maryland, BaltimoreTherapeutic agents targeting the ncca-atp channel and methods of use thereof
WO2006043178A217 oct. 200527 avr. 2006Danisco A/SEnzymes
WO2006090388A223 févr. 200631 août 2006The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), Volcani CenterFruit cell culture extract for treating inflammation
WO2006107962A24 avr. 200612 oct. 2006Biogen Idec Ma IncMethods and products for evaluating an immune response to a therapeutic protein
WO2006134602A218 juin 200621 déc. 2006Ramot At Tel Aviv University Ltd.Isolated cells and populations comprising same for the treatment of cns diseases
WO2007001986A219 juin 20064 janv. 2007Yuling LuoMethods of detecting nucleic acids in individual cells and of identifying rare cells from large heterogeneous cell populations
WO2007020638A215 août 200622 févr. 2007Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
WO2007023491A221 août 20061 mars 2007Yeda Research And Development Co. Ltd.Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
WO2007027714A229 août 20068 mars 2007Schering CorporationEngineered anti-il-23 antibodies
WO2007031996A111 sept. 200622 mars 2007Rappaport Family Institute For Research In The Medical SciencesCompositions and methods for diagnosing and treating an inflammation
WO2007034487A121 sept. 200629 mars 2007Yissum Research Development Company Of The Hebrew University Of JerusalemNucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer
WO2007056352A26 nov. 200618 mai 2007The Scripps Research InstituteCompositions and methods for controlling tissue factor signaling specificity
WO2007088051A226 janv. 20079 août 2007Bayer Schering Pharma AktiengesellschaftModulation of mdl-1 activity for treatment of inflammatory disease
WO2007091254A16 févr. 200716 août 2007Rappaport Family Institute For Research In The Medical SciencesMethods and kit for diagnosing t1dm
WO2007094985A25 févr. 200723 août 2007Modigene IncLong-acting polypeptides and methods of producing and administering same
WO2007110869A228 mars 20074 oct. 2007Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods and kits for determining predisposition to warfarin resistance
WO2008005429A22 juil. 200710 janv. 2008Charles David AdairComposition for modulating the expression of cell adhesion molecules
WO2008010228A222 juil. 200724 janv. 2008Yeda Research And Development Co. Ltd.Photosyntheticorganisms and compositions and methods of generating same
WO2008010934A210 juil. 200724 janv. 2008Chemocentryx, Inc.Triazolyl phenyl benzenesulfonamides
WO2008026198A215 août 20076 mars 2008Yeda Research And Development Co. Ltd.Methods of generating glial and neuronal cells and use of same for the treatment of medical conditions of the cns
WO2008041183A22 oct. 200710 avr. 2008Technion Research & Development Foundation Ltd.Microtubes and methods of producing same
WO2008043566A211 oct. 200717 avr. 2008Janssen Pharmaceutica N.V.Compositions and methods for treating and diagnosing irritable bowel syndrome
WO2008051761A217 oct. 20072 mai 2008Abbott LaboratoriesAssay for cardiac troponin autoantibodies
WO2008067547A230 nov. 20075 juin 2008Research Development FoundationImproved immunoglobulin libraries
WO2008076321A113 déc. 200726 juin 2008Schering CorporationEngineered anti-tslp antibody
WO2008092164A228 janv. 200831 juil. 2008University Of Louisville Research Foundation, Inc.Methods of detecting autoantibodies for diagnosing and characterizing disorders
WO2008093341A231 janv. 20087 août 2008Technion Research & Development Foundation Ltd.Electrospun scaffolds and methods of generating and using same
WO2008093342A231 janv. 20087 août 2008Technion Research & Development Foundation Ltd.Albumin fibers and fabrics and methods of generating and using same
WO2008110006A112 mars 200818 sept. 2008Miraculins Inc.Biomarkers of prostate cancer and uses thereof
WO2008120202A227 mars 20089 oct. 2008Technion Research & Development Foundation Ltd.Antibodies, methods and kits for diagnosing and treating melanoma
WO2008120216A12 avr. 20089 oct. 2008Ramot At Tel Aviv University Ltd.Methods of detecting cancer cells and use of same for diagnosing and monitoring treatment of the disease
WO2008124670A27 avr. 200816 oct. 2008Becton, Dickinson And CompanyCompositions and methods for the identification of a carbapenemase gene
WO2008132753A21 mai 20086 nov. 2008Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods and kits for detecting fetal cells in the maternal blood
WO2008137475A230 avr. 200813 nov. 2008Research Development FoundationImmunoglobulin fc libraries
WO2009010968A215 juil. 200822 janv. 2009Yitzchak HillmanDisease treatment via antimicrobial peptides or their inhibitors
WO2009021054A26 août 200812 févr. 2009Orion Genomics LlcNovel single nucleotide polymorphisms and combinations of novel and known polymorphisms for determining the allele-specific expression of the igf2 gene
WO2009032477A28 août 200812 mars 2009The Board Of Regents Of The University Of Texas SystemVegfr-1/nrp-1 targeting peptides
WO2009034574A211 sept. 200819 mars 2009Yeda Research And Development Co. Ltd.Methods of treating tumors in immune-privileged sites
WO2009038847A118 juin 200826 mars 2009Chemocentryx, Inc.N-(2-(hetaryl)aryl)arylsulfonamides and n-(2-(hetaryl)hetaryl)arylsulfonamides
WO2009082817A123 déc. 20089 juil. 2009Protiva Biotherapeutics, Inc.Silencing of polo-like kinase expression using interfering rna
WO2009083958A223 déc. 20089 juil. 2009Evogene Ltd.Isolated polypeptides, polynucleotides useful for modifying water user efficiency, fertilizer use efficiency, biotic/abiotic stress tolerance, yield and biomass in plants
WO2009094551A123 janv. 200930 juil. 2009Amgen Inc.Ferroportin antibodies and methods of use
WO2009104174A212 févr. 200927 août 2009Technion Research & Development Foundation Ltd .A method of attaching a cell-of-interest to a microtube
WO2009105833A127 févr. 20093 sept. 2009Murdoch UniversityNovel sequences of brachyspira, immunogenic compositions, methods for preparation and use thereof
WO2009117773A126 mars 20091 oct. 2009Murdoch UniversityNovel sequences of brachyspira, immunogenic compositions, methods for preparation and use thereof
WO2009127060A115 avr. 200922 oct. 2009Protiva Biotherapeutics, Inc.Novel lipid formulations for nucleic acid delivery
WO2009129319A215 avr. 200922 oct. 2009Protiva Biotherapeutics, Inc.Silencing of csn5 gene expression using interfering rna
WO2009132124A222 avr. 200929 oct. 2009The Trustees Of Columbia University In The City Of New YorkGeometric patterns and lipid bilayers for dna molecule organization and uses thereof
WO2009139822A128 avr. 200919 nov. 2009Amgen Inc.Anti-hepcidin antibodies and methods of use
WO2010016806A17 août 200911 févr. 2010Agency For Science, Technology And Research (A*Star)Vhz for diagnosis and treatment of cancers
WO2010017544A210 août 200911 févr. 2010Genisphere, Inc.Long-acting dna dendrimers and methods thereof
WO2010029545A210 sept. 200918 mars 2010Ben Gurion University Of The Negev Research And Development AuthorityCompositions and methods for treating s. pneumoniae infection
WO2010031006A114 sept. 200918 mars 2010Cryopraxis Criobiologia Ltda.Ischemic tissue cell therapy
WO2010035261A224 sept. 20091 avr. 2010Ben Gurion University Of The Negev Research And Development AuthorityAmyloid beta-peptides and methods of use thereof
WO2010040277A19 oct. 200915 avr. 2010The University Of Hong KongCadherin-17 as diagnostic marker and therapeutic target for liver cancer
WO2010049897A228 oct. 20096 mai 2010Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficieny
WO2010054328A29 nov. 200914 mai 2010Research Development FoundationCompositions and methods for the inhibition of cripto/grp78 complex formation and signaling
WO2010055525A117 nov. 200920 mai 2010Technion Research & Development Foundation Ltd.Method for predicting a patient's responsiveness to anti-folate therapy
WO2010058396A117 nov. 200927 mai 2010Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.A cd44vra antibody and diagnostic and therapeutic methods using same
WO2010061383A124 nov. 20093 juin 2010Biodalia Microbiological Technologies Ltd.A method of in-situ enrichment of foods with fructan
WO2010064231A129 nov. 200910 juin 2010Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods of analyzing a-i rna editing and nucleic acid constructs capable of same
WO2010064247A13 déc. 200910 juin 2010Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods and kits for determining predisposition to cancer
WO2010065437A130 nov. 200910 juin 2010Research Development FoundationModulation of olfml-3 mediated angiogenesis
WO2010066252A19 déc. 200917 juin 2010Dako Denmark A/SMethod for evaluating pre-treatment
WO2010068757A110 déc. 200917 juin 2010The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesCompositions and methods useful for detecting and treating diseases associated with 16p chromosomal disruptions
WO2010071610A121 déc. 200924 juin 2010Agency For Science, Technology And Research (A*Star)Severe chikungunya biomarkers
WO2010076642A128 déc. 20098 juil. 2010Tel Hashomer Medical Research, Infrastructure And Services LtdPeptides and compositions for prevention of cell adhesion and methods of using same
WO2010076756A228 déc. 20098 juil. 2010Evogene Ltd.Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance, biomass and/or yield in plants expressing same
WO2010076788A229 déc. 20098 juil. 2010Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection
WO2010076794A130 déc. 20098 juil. 2010Technion Research & Development Foundation Ltd.Method of denitrifying brine and systems capable of same
WO2010086856A231 janv. 20105 août 2010Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of generating tissue using devitalized, acellular scaffold matrices derived from micro-organs
WO2010086867A22 févr. 20105 août 2010Ramot At Tel Aviv University Ltd.Peptides, pharmaceutical compositions comprising same and uses thereof
WO2010089707A14 févr. 201012 août 2010Yeda Research And Development Co. Ltd.Methods and kits for determining sensitivity or resistance of prostate cancer to radiation therapy
WO2010093450A211 févr. 201019 août 2010Ludwing Institute For Cancer Research Ltd.Pten phosphorylation-driven resistance to cancer treatment and altered patient prognosis
WO2010093820A211 févr. 201019 août 2010Orion Genomics LlcCombinations of polymorphisms for determining allele-specific expression of igf2
WO2010096434A217 févr. 201026 août 2010Ludwig Institute For Cancer ResearchSpecific binding proteins and uses thereof
WO2010096658A119 févr. 201026 août 2010The Cleveland Clinic FoundationCorin as a marker for heart failure
WO2010097793A225 févr. 20102 sept. 2010Tel Hashomer Medical Research Infrastructure And Services Ltd.Isolated populations of renal stem cells and methods of isolating and using same
WO2010097794A125 févr. 20102 sept. 2010Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods of reprogramming renal cells
WO2010100595A21 mars 201010 sept. 2010Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
WO2010103517A110 mars 201016 sept. 2010Rappaport Family Institute For Research In The Medical SciencesSoluble compositions for the treatment of cxcr3-ligand associated diseases
WO2010113096A128 mars 20107 oct. 2010Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods of predicting clinical course and treating multiple sclerosis
WO2010113146A128 févr. 20107 oct. 2010The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical CenterA method of regulating proliferation and differentiation of keratinocyes
WO2010115261A129 mars 201014 oct. 2010Genesis Genomics Inc.Aberrant mitochondrial dna, associated fusion transcripts and translation products and hybridization probes therefor
WO2010116375A18 avr. 201014 oct. 2010Yeda Research And Development Co. Ltd.Isolated peptides for regulating apoptosis
WO2010126670A226 mars 20104 nov. 2010Gojo Industries, Inc.Compositions and methods for screening and using compounds antagonizing spore-surface interactions
WO2010134035A119 mai 201025 nov. 2010Danisco A/SUse
WO2010137013A125 mai 20102 déc. 2010Ramot At Tel Aviv University Ltd.Crystallized photosystem i units from the pea plant and their use in solid state devices
WO2010137017A226 mai 20102 déc. 2010Yeda Research And Development Co. Ltd.Proteasome inhibitors and uses thereof
WO2010137020A127 mai 20102 déc. 2010Yeda Research And Development Co. Ltd.Methods of treating inflammation
WO2010137021A227 mai 20102 déc. 2010Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of generating connective tissue
WO2010141421A11 juin 20109 déc. 2010The Board Of Regents Of The University Of Texas SystemIdentification of small molecules recognized by antibodies in subjects with neurodegenerative diseases
WO2010150213A123 juin 201029 déc. 2010Danisco A/SProtein
WO2010150259A124 juin 201029 déc. 2010Fund For Medical Research Development Of Infrastructure And Health Services -Rambam Medical CenterMethods and kits for isolating placental derived microparticles and use of same for diagnosis of fetal disorders
WO2011000107A130 juin 20106 janv. 2011Protiva Biotherapeutics, Inc.Novel lipid formulations for delivery of therapeutic agents to solid tumors
WO2011002834A230 juin 20106 janv. 2011American Type Culture CollectionCompositions and methods for diagnosis and treatment of type 1 diabetes
WO2011004361A21 juil. 201013 janv. 2011Prolor Biotech Inc.Long-acting coagulation factors and methods of producing same
WO2011004379A18 juil. 201013 janv. 2011Tel Hashomer Medical Research Infrastructure And Services Ltd.Compositions and methods for treating cancer
WO2011010309A121 juil. 201027 janv. 2011Tel Hashomer Medical Research Infrastructure And Services Ltd.A method of diagnosing cancer
WO2011011447A120 juil. 201027 janv. 2011Protiva Biotherapeutics, Inc.Compositions and methods for silencing ebola virus gene expression
WO2011013130A229 juil. 20103 févr. 2011Ramot At Tel-Aviv University Ltd.Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
WO2011019423A214 mai 201017 févr. 2011Schering CorporationModulation of pilr receptors to treat microbial infections
WO2011021171A122 août 201024 févr. 2011Beeologics, LlcPreventing and curing beneficial insect diseases via plant transcribed molecules
WO2011021194A217 août 201024 févr. 2011Technion Research & Development Foundation Ltd.Pericyte progenitor cells and methods of generating and using same
WO2011024172A226 août 20103 mars 2011Technion Research & Development Foundation Ltd.Liposomal compositions and uses of same
WO2011030329A131 août 201017 mars 2011Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of treating tumors
WO2011030332A25 sept. 201017 mars 2011Yeda Research And Development Co. Ltd.Methods for hematopoietic precursor mobilization
WO2011030336A16 sept. 201017 mars 2011Ramot At Tel-Aviv University Ltd.Methods of diagnosing amyotrophic lateral sclerosis (als)
WO2011033506A215 sept. 201024 mars 2011Yeda Research And Development Co. Ltd.Isolated pon1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
WO2011033511A116 sept. 201024 mars 2011Ramot At Tel-Aviv University Ltd.Peptides for the treatment of oxidative stress related disorders
WO2011034950A115 sept. 201024 mars 2011Vaxart, Inc.Immunization strategy to prevent h1n1 infection
WO2011038160A223 sept. 201031 mars 2011Protiva Biotherapeutics, Inc.Compositions and methods for silencing genes expressed in cancer
WO2011038403A128 sept. 201031 mars 2011Yuling LuoMethods of detecting nucleic acid sequences with high specificity
WO2011040972A11 oct. 20107 avr. 2011Ludwig Institute For Cancer Research Ltd.Anti-fibroblast activation protein antibodies and methods and uses thereof
WO2011040973A21 oct. 20107 avr. 2011Ludwig Institute For Cancer Research Ltd.Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof
WO2011041319A228 sept. 20107 avr. 2011Ludwig Institute For Cancer ResearchSpecific binding proteins and uses thereof
WO2011044186A16 oct. 201014 avr. 2011The Board Of Trustees Of The University Of IllinoisHuman single-chain t cell receptors
WO2011044553A111 oct. 201014 avr. 2011Biogen Idec Ma Inc.Anti-vla-4 related assays
WO2011045796A114 oct. 201021 avr. 2011Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Compositions for controlling varroa mites in bees
WO2011046570A116 oct. 200921 avr. 2011The University Of Medicine And Dentistry Of New JerseyMethod for treating chronic nerve tissue injury using a cell therapy strategy
WO2011048600A121 oct. 201028 avr. 2011Danziger Innovations Ltd.Generating genotypic variations in plant genomes by gamete infection
WO2011055366A18 nov. 201012 mai 2011Medical Research & Development Fund For Health Services Bnai Zion Medical Center, The State Of IsraelMo-1 conditional knock-out non-human animal and uses thereof
WO2011056688A227 oct. 201012 mai 2011Caris Life Sciences, Inc.Molecular profiling for personalized medicine
WO2011058555A111 nov. 201019 mai 2011Yeda Research And Development Co. Ltd.A method of editing dna in a cell and constructs capable of same
WO2011058557A111 nov. 201019 mai 2011Ramot At Tel-Aviv University Ltd.Compositions comprising pedf and uses of same in the treatment and prevention of ovary-related syndromes
WO2011061657A18 nov. 201026 mai 2011Danisco A/SMethod
WO2011061736A117 nov. 201026 mai 2011Protalix Ltd.Alkaline alpha galactosidase for the treatment of fabry disease
WO2011064669A229 nov. 20103 juin 2011Pluristem Ltd.Adherent cells from placenta and use of same in disease treatment
WO2011064773A124 nov. 20103 juin 2011Collplant Ltd.Method of generating collagen fibers
WO2011067745A26 déc. 20109 juin 2011Rosetta Green Ltd.Compositions and methods for enhancing plants resistance to abiotic stress
WO2011068676A117 nov. 20109 juin 2011Abbott LaboratoriesPeptide reagents and method for inhibiting autoantibody antigen binding
WO2011068680A117 nov. 20109 juin 2011Abbott LaboratoriesAssay for diagnosis of cardiac myocyte damage
WO2011068681A117 nov. 20109 juin 2011Abbott LaboratoriesASSAY FOR CARDIAC TROPONIN-T (cTnT)
WO2011072091A19 déc. 201016 juin 2011Quark Pharmaceuticals, Inc.Methods and compositions for treating diseases, disorders or injury of the cns
WO2011076881A122 déc. 201030 juin 2011Arabian Gulf UniversityMutant ldl receptor gene
WO2011080674A222 déc. 20107 juil. 2011Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency
WO2011080740A129 déc. 20107 juil. 2011Gamida-Cell Ltd.Methods for enhancing natural killer cell proliferation and activity
WO2011084357A110 déc. 201014 juil. 2011Schering CorporationModulation of pilr to treat immune disorders
WO2011084882A25 janv. 201114 juil. 2011Contrafect CorporationMethods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria
WO2011086509A112 janv. 201121 juil. 2011Vascular Biogenics Ltd.Methods of producing adenovirus vectors and viral preparations generated thereby
WO2011092700A127 janv. 20114 août 2011Yeda Research And Development Co. Ltd.Antibodies that inhibit metalloproteins
WO2011094669A131 janv. 20114 août 2011Advanced Cell Diagnostics, Inc.Methods of in situ detection of nucleic acids
WO2011096926A14 févr. 201011 août 2011Massachusetts Institute Of TechnologyMethods for preparing sequencing libraries
WO2011097627A18 févr. 201111 août 2011Agensys, Inc.Antibody drug conjugates (adc) that bind to 161p2f10b proteins
WO2011099006A210 févr. 201118 août 2011Yeda Research And Development Co. Ltd.Enzymatic systems for carbon fixation and methods of generating same
WO2011104708A223 févr. 20111 sept. 2011Ben Gurion University Of The Negev Research And Development AuthorityMethods for inhibiting necrosis
WO2011107939A11 mars 20119 sept. 2011Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of predicting efficacy of an anti-vegfa treatment for solid tumors
WO2011107994A13 mars 20119 sept. 2011Yeda Research And Development Co. Ltd.Methods of measuring protein stability
WO2011111034A125 janv. 201115 sept. 2011Yeda Research And Development Co. Ltd.Recombinant protein production in heterologous systems
WO2011111050A210 mars 201115 sept. 2011Jacob EdreiMethods of generating hydrogen
WO2011114251A11 mars 201122 sept. 2011Danisco A/SFoodstuff
WO2011125015A24 avr. 201113 oct. 2011Bar-Ilan UniversityProtease-activatable pore-forming polypeptides
WO2011128897A112 avr. 201120 oct. 2011Technion Research & Development Foundation Ltd.Populations of pancreatic progenitor cells and methods of isolating and using same
WO2011132182A122 mars 201127 oct. 2011Yeda Research And Development Co. Ltd.MOLECULES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES
WO2011135527A227 avr. 20113 nov. 2011Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
WO2011138776A24 mai 201110 nov. 2011Hervana Ltd.Biologic female contraceptives
WO2011138778A24 mai 201110 nov. 2011Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of identifying inhibitors of polypeptides-of-interest
WO2011138785A25 mai 201110 nov. 2011Rappaport Family Institute For Research In The Medical SciencesUse of ccl1 in therapy
WO2011140234A14 mai 201110 nov. 2011Abbott LaboratoriesMethods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor
WO2011141914A112 mai 201117 nov. 2011Tel Hashomer Medical Research Infrastructure And Services Ltd.Isolated populations of adult renal cells and methods of isolating and using same
WO2011146479A117 mai 201124 nov. 2011The Texas A&M University SystemMethod and composition for the diagnosis and monitoring of inflammatory diseases
WO2011151833A12 juin 20118 déc. 2011Ramot At Tel-Aviv University Ltd.Methods of treating diabetes and compositions capable of same
WO2011154940A16 juin 201115 déc. 2011Osnat Ashur-FabianMethods and kits for diagnosing conditions related to hypoxia
WO2011158242A216 juin 201122 déc. 2011Futuragene Israel Ltd.Pest -resistant plants containing a combination of a spider toxin and a chitinase
WO2011158243A216 juin 201122 déc. 2011Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of diagnosing and treating cancer
WO2012004759A27 juil. 201112 janv. 2012Danisco A/SMethod
WO2012006056A228 juin 201112 janv. 2012Oregon Health & Science UniversityCcr6 as a biomarker of alzheimer's disease
WO2012007537A113 juil. 201119 janv. 2012Dublin City UniversityDirect clone analysis and selection technology
WO2012007919A214 juil. 201119 janv. 2012Technion Research & Development Foundation Ltd.Nucleic acid construct for increasing abiotic stress tolerance in plants
WO2012007950A214 juil. 201119 janv. 2012Technion Research & Development Foundation Ltd.Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides
WO2012007951A114 juil. 201119 janv. 2012Technion Research & Development Foundation Ltd.Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides
WO2012009627A215 juil. 201119 janv. 2012Vanderbilt UniversityLow resource processor using surface tension valves for extracting, concentrating and detecting molecular species
WO2012011113A221 juil. 201126 janv. 2012Shai YarkoniRegulatory immune cells with enhanced targeted cell death effect
WO2012014205A127 juil. 20112 févr. 2012Technion Research & Development Foundation Ltd.Isolated mesenchymal progenitor cells and extracellular matrix produced thereby
WO2012014207A227 juil. 20112 févr. 2012Technion Research & Development Foundation Ltd.Method for generating induced pluripotent stem cells from keratinocytes derived from plucked hair follicles
WO2012014208A227 juil. 20112 févr. 2012Yeda Research And Development Co. Ltd.Methods and systems for assessing clonality of cell cultures
WO2012017439A24 août 20119 févr. 2012Ramot At Tel-Aviv University Ltd.Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases
WO2012018476A18 juil. 20119 févr. 2012Abbott LaboratoriesAntibodies relating to pivka-ii and uses thereof
WO2012025914A17 juil. 20111 mars 2012Ramot At Tel-Aviv University Ltd.Induced pluripotent stem cells derived from human pancreatic beta cells
WO2012025925A124 août 20111 mars 2012Rappaport Family Institute For Research In The Medical SciencesMethods of improving transplantation using sdf-1alpha
WO2012032510A16 sept. 201115 mars 2012Yeda Research And Development Co. Ltd.Primers for amplifying dna and methods of selecting same
WO2012032519A27 sept. 201115 mars 2012Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of diagnosing parkinson's disease
WO2012032520A17 sept. 201115 mars 2012Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Readthrough acetylcholinesterase (ache-r) for treating or preventing parkinson's disease
WO2012032521A27 sept. 201115 mars 2012Technion Research & Development Foundation Ltd.Novel methods and culture media for culturing pluripotent stem cells
WO2012032525A28 sept. 201115 mars 2012Yeda Research And Development Co. Ltd.An immunosuppressive drug combination for a stable and long term engraftment
WO2012032526A28 sept. 201115 mars 2012Yeda Research And Development Co. Ltd.Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment
WO2012035539A115 sept. 201122 mars 2012Ramot At Tel-Aviv University Ltd.Methods of expanding and redifferentiating islet beta cells
WO2012038956A120 sept. 201129 mars 2012Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of treating neurodegenerative diseases
WO2012040168A220 sept. 201129 mars 2012Advanced Cell Diagnostics, Inc.Biomarkers for differentiating melanoma from benign nevus in the skin
WO2012047724A129 sept. 201112 avr. 2012Agensys, Inc.Antibody drug conjugates (adc) that bind to 191p4d12 proteins
WO2012049066A26 oct. 201119 avr. 2012Eppendorf AgReal-time amplification and micro-array based detection of nucleic acid targets in a flow chip assay
WO2012052872A210 oct. 201126 avr. 2012Yeda Research And Development Co. Ltd.Methods and compositions for the treatment of insulin-associated medical conditions
WO2012052878A112 oct. 201126 avr. 2012Vascular Biogenics Ltd.Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells
WO2012054795A121 oct. 201126 avr. 2012Advanced Cell Diagnostics, Inc.An ultra sensitive method for in situ detection of nucleic acids
WO2012056452A227 oct. 20113 mai 2012Nanocyte (Israel) Ltd.Pharmaceutical compositions and delivery devices comprising stinging cells or capsules
WO2012056455A127 oct. 20113 mai 2012Yeda Research And Development Co. Ltd.Methods of generating antibodies to metalloenzymes
WO2012059922A23 nov. 201110 mai 2012Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Transgenic plants with improved saccharification yields and methods of generating same
WO2012059925A23 nov. 201110 mai 2012Ben-Gurion University Of The Negev Research And Development AuthorityAcyl-coa: diacylglycerol acyltransferase 1-like gene (ptdgat1) and uses thereof
WO2012066495A217 nov. 201124 mai 2012Ben Gurion University Of The Negev Research And Development AuthorityT-cell therapy to neurodegenerative diseases
WO2012081029A115 déc. 201121 juin 2012Kadimastem Ltd.Insulin producing cells derived from pluripotent stem cells
WO2012090205A228 déc. 20115 juil. 2012Kamedis Ltd.Plant extracts for the treatment and prevention of infections
WO2012098537A17 sept. 201126 juil. 2012Protalix Ltd.Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
WO2012099896A217 janv. 201226 juil. 2012Life Technologies CorporationWorkflow for detection of ligands using nucleic acids
WO2012103414A227 janv. 20122 août 2012Advanced Cell Diagnostics, Inc.Rnascope® hpv assay for determining hpv status in head and neck cancers and cervical lesions
WO2012104851A131 janv. 20129 août 2012Yeda Research And Development Co. Ltd.Methods of diagnosing disease using overlap extension pcr
WO2012109133A16 févr. 201216 août 2012Research Development FoundationEngineered immunoglobulin fc polypeptides
WO2012114339A123 févr. 201230 août 2012Rappaport Family Institute For Research In The Medical SciencesHigh affinity molecules capable of binding a type a plexin receptor and uses of same
WO2012117373A11 mars 20127 sept. 2012Ramot At Tel-Aviv University Ltd.Genetically modified muscle cells which express neurotrophic factors
WO2012117406A21 mars 20127 sept. 2012Futuragene Israel Ltd.Bacterial resistant transgenic plants
WO2012120377A28 mars 201213 sept. 2012King Abdullah University Of Science And TechnologyMolecular biomarker set for early detection of ovarian cancer
WO2012120500A25 mars 201213 sept. 2012Merck Serono S.A.Low fucose cell lines and uses thereof
WO2012120518A18 mars 201213 sept. 2012Ramot At Tel-Aviv University Ltd.Compositions and methods for diagnosing and treating phenylketonuria (pku)
WO2012123938A126 févr. 201220 sept. 2012Tel Hashomer Medical Research Infrastructure And Services Ltd.Quinolone analogs for treating autoimmune diseases
WO2012123949A115 mars 201220 sept. 2012Ramot At Tel-Aviv University Ltd.Bi- and monospecific, asymmetric antibodies and methods of generating the same
WO2012125582A112 mars 201220 sept. 2012Board Of Regents Of The University Of NebraskaBiomarker for coronary artery disease
WO2012127320A122 mars 201227 sept. 2012Pluristem Ltd.Methods for treating radiation or chemical injury
WO2012127475A122 mars 201227 sept. 2012Neurim Pharmaceuticals (1991) Ltd.Neuroprotective peptides
WO2012129378A122 mars 201227 sept. 2012Keutgen Xavier MDistinguishing benign and malignant indeterminate thyroid lesions
WO2012131594A128 mars 20124 oct. 2012Novartis AgMarkers associated with cyclin-dependent kinase inhibitors
WO2012131680A228 mars 20124 oct. 2012Yeda Research And Development Co. Ltd.Compositions and methods for treating inflammation
WO2012135360A128 mars 20124 oct. 2012Ludwig Institute For Cancer Research Ltd.Binding proteins specific for egfr expressed on tumor and uses thereof
WO2012137147A14 avr. 201211 oct. 2012Danisco Us, Inc.Compositions
WO2012137202A13 avr. 201211 oct. 2012Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Composition comprising an iron indicator attached to a microparticle and uses of same for quantifying non-transferrin bound iron (ntbi) and cellular labile iron (lci)
WO2012137207A14 avr. 201211 oct. 2012Ramot At Tel-Aviv University Ltd.Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same
WO2012138941A15 avr. 201211 oct. 2012Longevity Biotech, Inc.Compositions comprising glucagon analogs and methods of making and using the same
WO2012140519A215 avr. 201218 oct. 2012Pluristem Ltd.Methods and systems for harvesting cells
WO2012150600A23 mai 20128 nov. 2012Ramot At Tel-Aviv University Ltd.Regulation of amyloid beta molecular composition for the treatment of alzheimer's disease
WO2012150959A19 nov. 20118 nov. 2012Abbott LaboratoriesMethods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor
WO2012153333A19 mai 201215 nov. 2012Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Regeneration and repair of mesenchymal tissue using amelogenin
WO2012153336A210 mai 201215 nov. 2012Rakuto Bio Technologies Ltd.Methods and device for lightening skin complexion
WO2012156976A116 mai 201222 nov. 2012Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of producing artemisinin in non-host plants and vectors for use in same
WO2012160526A223 mai 201229 nov. 2012Ofir MenasheFormulations of microorganism comprising particles and uses of same
WO2012164380A231 mai 20126 déc. 2012Hutchison Biofilm Medical Solutions LimitedDispersion and detachment of cell aggregates
WO2012164565A131 mai 20126 déc. 2012Yeda Research And Development Co. Ltd.Compositions and methods for downregulating prokaryotic genes
WO2012172555A114 juin 201220 déc. 2012Yeda Research And Development Co. Ltd.Combination therapy to prevent dcis formation and progression to breast cancer
WO2012176203A119 juin 201227 déc. 2012Kaiima Bio Agritech Ltd.Common wheat, plants or parts thereof having partially or fully multiplied genome, hybrids and products thereof and methods of generating and using same
WO2013010170A116 juil. 201217 janv. 2013Lovell Mark AProcess for detection of alzheimer's disease from a serum sample
WO2013011507A117 juil. 201224 janv. 2013Kaiima Bio Agritech Ltd.Maize plants having a partially or fully multiplied genome and uses thereof
WO2013012924A218 juil. 201224 janv. 2013President And Fellows Of Harvard CollegeEngineered microbe-targeting molecules and uses thereof
WO2013018060A22 août 20127 févr. 2013Yeda Research And Development Co. Ltd.Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
WO2013021389A29 août 201214 févr. 2013Yeda Research And Development Co.Ltd.Downregulation of mir-7 for promotion of beta cell differentiation and insulin production
WO2013022599A125 juil. 201214 févr. 2013Research Development FoundationImproved methods and compositions for modulation of olfml3 mediated angiogenesis
WO2013024481A113 août 201221 févr. 2013Kaiima Bio Agritech Ltd.Durum wheat plants having a partially or fully multiplied genome and uses thereof
WO2013035071A16 sept. 201214 mars 2013Yeda Research And Development Co. Ltd.Novel risk biomarkers for lung cancer
WO2013035099A16 sept. 201214 mars 2013Yeda Research And Development Co. Ltd.Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
WO2013052643A14 oct. 201211 avr. 2013The Rockefeller UniversityDimeric bacteriophage lysins
WO2013054331A110 oct. 201218 avr. 2013Tel Hashomer Medical Research Infrastructure And Services Ltd.Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
WO2013056377A119 oct. 201225 avr. 2013Augurex Life Sciences CorporationAntigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis
WO2013061328A225 oct. 20122 mai 2013Yeda Research And Development Co. Ltd.Method of treating cancer
WO2013064163A11 nov. 201110 mai 2013Academisch Medisch CentrumMethylation markers for colorectal cancer
WO2013067076A21 nov. 201210 mai 2013Quark Pharmaceuticals, Inc.Methods and compositions for neuroprotection
WO2013070821A18 nov. 201216 mai 2013Quark Pharmaceuticals, Inc.Methods and compositions for treating diseases, disorders or injury of the nervous system
WO2013076729A122 nov. 201230 mai 2013Danziger Dan Flower FarmOtomeria plants
WO2013076730A127 nov. 201230 mai 2013Yeda Research And Development Co. Ltd.Methods of regulating angiogenesis and compositions capable of same
WO2013084190A16 déc. 201213 juin 2013Yeda Research And Development Co. Ltd.Mammalian fetal pulmonary cells and therapeutic use of same
WO2013093921A120 déc. 201227 juin 2013Collplant Ltd.Collagen coated synthetic polymer fibers
WO2013098813A131 déc. 20124 juil. 2013Qbi Enterprises Ltd.Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
WO2013098820A126 déc. 20124 juil. 2013Kaiima Bio Agritech Ltd.Cultivated sorghum plant having a partially or fully multiplied genome and uses of same
WO2013101758A121 déc. 20124 juil. 2013Baylor Research InstituteBiomarkers for kawasaki disease
WO2013114363A230 janv. 20138 août 2013Yeda Research And Development Co.Ltd.Antimicrobial agents
WO2013114371A131 janv. 20138 août 2013Protalix Ltd.Dry powder formulations of dnase i
WO2013114373A131 janv. 20138 août 2013Protalix Ltd.Inhalable liquid formulations of dnase i
WO2013114374A131 janv. 20138 août 2013Protalix Ltd.Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy
WO2013121405A119 févr. 201322 août 2013Protalix Ltd.Oral unit dosage forms and uses of same for the treatment of gaucher disease
WO2013121416A15 févr. 201322 août 2013Prolor Biotech Inc.Long-acting coagulation factors and methods of producing same
WO2013121426A113 févr. 201322 août 2013Gamida-Cell Ltd.Culturing of mesenchymal stem cells
WO2013121427A113 févr. 201322 août 2013Gamida-Cell Ltd.Mesenchymal stem cells conditioned medium and methods of generating and using the same
WO2013124816A221 févr. 201329 août 2013Brainstem Biotec Ltd.Generation of neural stem cells and motor neurons
WO2013124817A221 févr. 201329 août 2013Brainstem Biotec Ltd.MicroRNAS FOR THE GENERATION OF ASTROCYTES
WO2013126803A122 févr. 201329 août 2013Protiva Biotherapeutics Inc.Trialkyl cationic lipids and methods of use thereof
WO2013128454A128 févr. 20136 sept. 2013The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), Volcani CenterMale sterile garlic plants, hybrid offspring of same and methods of generating and using same
WO2013130811A128 févr. 20136 sept. 2013Chemocentryx, Inc.Pyrazol-1-yl benzene sulfonamides as ccr9 antagonists
WO2013132495A17 mars 201312 sept. 2013Yeda Research And Development Co. Ltd.Compositions for inhibition of quiescin sulfhydryl oxidase (qsox1) and uses of same
WO2013136335A114 mars 201319 sept. 2013Yeda Research And Development Co. Ltd.Isolated pon1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
WO2013140389A110 mars 201326 sept. 2013Ramot At Tel-Aviv University Ltd.Plif multimeric peptides and uses thereof
WO2013149219A230 mars 20133 oct. 2013Sorrento Therapeutics Inc.Fully human antibodies that bind to vegfr2
WO2013152295A15 avr. 201310 oct. 2013Advanced Cell Diagnostics, Inc.Detection of immunoglobulin light chain restrication by rna in situ hybridization
WO2013153553A211 avr. 201317 oct. 2013Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Compositions for controlling varroa mites in bees
WO2013160895A124 avr. 201331 oct. 2013Biokine Therapeutics Ltd.Peptides and use thereof in the treatment of large cell lung cancer
WO2013163035A119 avr. 201331 oct. 2013Uhl Ii, LlcDevices and methods for detecting analyte in bodily fluid
WO2013168164A19 mai 201314 nov. 2013Yeda Research And Development Co. Ltd.Variants of tace pro-domain as tnf-a inhibitor and their medical use
WO2013170168A110 mai 201314 nov. 2013Bioatla LlcMulti-specific monoclonal antibodies
WO2013183048A13 juin 201312 déc. 2013Ben-Gurion University Of The Negev Research And Development AuthorityFunctionalized titanium binding peptides and implants coated with same
WO2013183052A14 juin 201312 déc. 2013Prolor Biotech Inc.Pegylated oxm variants
WO2013192616A124 juin 201327 déc. 2013Htg Molecular Diagnostics, Inc.Molecular malignancy in melanocytic lesions
WO2014006621A13 juil. 20139 janv. 2014Nanospun Technologies Ltd.Methods and devices for adsorption and biodegradation of petroleum
WO2014011398A126 juin 201316 janv. 2014Novartis AgBiomarkers associated with cdk inhibitors
WO2014011881A211 juil. 201316 janv. 2014Imstem Biotechnology, Inc.Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
WO2014014788A212 juil. 201323 janv. 2014President And Fellows Of Harvard CollegeModification of surfaces for simulataneous repellency and targeted binding of desired moieties
WO2014018375A118 juil. 201330 janv. 2014Xenon Pharmaceuticals Inc.Cyp8b1 and uses thereof in therapeutic and diagnostic methods
WO2014020502A225 juil. 20136 févr. 2014Novartis AgMarkers associated with human double minute 2 inhibitors
WO2014020599A129 juil. 20136 févr. 2014Yeda Research And Development Co. Ltd.Use of the reductive glycine pathway for generating formatotrophic and autotrophic microorganisms
WO2014020608A131 juil. 20136 févr. 2014Yeda Research And Development Co. Ltd.Methods of diagnosing and treating motor neuron diseases
WO2014024183A14 août 201313 févr. 2014Brainstorm Cell Therapeutics Ltd.Methods of generating mesenchymal stem cells which secrete neurotrophic factors
WO2014033723A13 sept. 20136 mars 2014A.B. Seeds Ltd.Method of improving abiotic stress tolerance of plants and plants generated thereby
WO2014041544A112 sept. 201320 mars 2014Ramot At Tel-Aviv University Ltd.Immunoparticles and methods of generating and using same
WO2014057490A19 oct. 201317 avr. 2014Ramot At Tel-Aviv University Ltd.Methods and kits for predicting prognosis of cancer using soluble mortalin in blood
WO2014062635A115 oct. 201324 avr. 2014Novartis AgMarkers for acute lymphoblastic leukemia
WO2014063097A118 oct. 201324 avr. 2014Danisco Us Inc.Stabilization of biomimetic membranes
WO2014064682A117 oct. 20131 mai 2014Yeda Research And Development Co. Ltd.Combinations of epidermal growth factor receptor targeting antibodies for treating cancer
WO2014066590A124 oct. 20131 mai 2014Research Development FoundationJam-c antibodies and methods for treatment of cancer
WO2014068553A127 oct. 20138 mai 2014Yeda Research And Development Co. Ltd.Aptamers, multimeric aptamers and uses thereof
WO2014083567A228 nov. 20135 juin 2014Yeda Research And Development Co. Ltd.Methods of preventing tumor metastasis, treating and prognosing cancer and identifying agents which are putative metastasis inhibitors
WO2014106837A230 déc. 201310 juil. 2014A. B. Seeds Ltd.ISOLATED dsRNA MOLECULES AND METHODS OF USING SAME FOR SILENCING TARGET MOLECULES OF INTEREST
WO2014106838A230 déc. 201310 juil. 2014A.B. Seeds Ltd.Methods of introducing dsrna to plant seeds for modulating gene expression
WO2014108850A29 janv. 201417 juil. 2014Yeda Research And Development Co. Ltd.High throughput transcriptome analysis
WO2014108854A19 janv. 201417 juil. 2014Fusimab Ltd.Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies
WO2014121077A231 janv. 20147 août 2014The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesMETHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs)
WO2014136113A16 mars 201412 sept. 2014Protalix Ltd.Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same
WO2014136114A16 mars 201412 sept. 2014Protalix Ltd.TNF alpha INHIBITOR POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, CELLS EXPRESSING SAME AND METHODS OF PRODUCING SAME
WO2014136117A16 mars 201412 sept. 2014Protalix Ltd.USE OF PLANT CELLS EXPRESSING A TNFalpha POLYPEPTIDE INHIBITOR IN THERAPY
WO2014141038A210 mars 201418 sept. 2014Irm LlcMarkers associated with wnt inhibitors
WO2014144170A114 mars 201418 sept. 2014The Cleveland Clinic FoundationIn-vitro method for monoclonal antibody production using non-human act1 -deficient mice
WO2014147622A119 mars 201425 sept. 2014Collplant Ltd.Compositions comprising collagen and prp for tissue regeneration
WO2014153056A214 mars 201425 sept. 2014Parkash GillCancer treatment using antibodies that bing cell surface grp78
WO2014155376A119 mars 20142 oct. 2014Biokine Therapeutics Ltd.Methods of treating myeloid leukemia
WO2014159239A210 mars 20142 oct. 2014Novartis AgAntibodies against notch 3
WO2014159242A110 mars 20142 oct. 2014Novartis AgNotch 3 mutants and uses thereof
WO2014174470A123 avr. 201430 oct. 2014Yeda Research And Development Co. Ltd.Isolated naive pluripotent stem cells and methods of generating same
WO2014174511A113 avr. 201430 oct. 2014Yeda Research And Development Co. Ltd.Agents for downregulation of the activity and/or amount of bcl-xl and/or bcl-w
WO2014174520A124 avr. 201430 oct. 2014Yeda Research And Development Co. Ltd.Use of inhibitory peptides for the treatment of inflammatory diseases
WO2014176047A111 avr. 201430 oct. 2014Novartis AgMarkers for ezh2 inhibitors
WO2014188423A121 mai 201427 nov. 2014Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Treatment of mast cell related pathologies
WO2014191995A227 mai 20144 déc. 2014Rakuto Bio Technologies Ltd.Enzymatic system-containing cosmetic compositions
WO2014204814A113 juin 201424 déc. 2014Dnatrix, Inc.Treatment of brain cancer with oncolytic adenovirus
WO2014207744A124 juin 201431 déc. 2014Ramot At Tel-Aviv University Ltd.Omentum based scaffold and delivery system
WO2015015489A128 juil. 20145 févr. 2015Biolinerx Ltd.Antibody for treating diabetes and autoimmune diseases
WO2015017552A130 juil. 20145 févr. 2015Agensys, Inc.Antibody drug conjugates (adc) that bind to cd37 proteins
WO2015033337A12 sept. 201412 mars 2015Technion Research & Development Foundation Limited.A flap for de-novo tissue regeneration
WO2015033343A13 sept. 201412 mars 2015Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Compositions and methods for expressing recombinant polypeptides
WO2015033344A14 sept. 201412 mars 2015Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods and kits for inhibiting pathogenicity of group a streptococcus (gas) or group g streptococcus (ggs)
WO2015037009A116 sept. 201419 mars 2015Plexicure Ltd.Isolated proteins capable of binding plexin-a4 and methods of producing and using same
WO2015059690A114 oct. 201430 avr. 2015Yeda Research And Development Co. Ltd.Polynucleotides encoding brex system polypeptides and methods of using s ame
WO2015063768A130 oct. 20147 mai 2015Biokine Therapeutics Ltd.Methods of treating acute myeloid leukemia with a flt3 mutation
WO2015079413A227 nov. 20144 juin 2015Yeda Research And Development Co. Ltd.Synaptojanin-2 inhibitors and uses thereof
WO2015094527A114 nov. 201425 juin 2015Danisco Us Inc.Use of hydrophobins to increase gas transferin aerobic fermentation processes
WO2015114633A129 janv. 20156 août 2015Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd.Actin binding peptides and compositions comprising same for inhibiting angiogenes is and treating medical conditions associated with same
WO2015114638A23 févr. 20156 août 2015Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of eliminating stem cells
WO2015116753A129 janv. 20156 août 2015Dana-Farber Cancer Institute, Inc.Antibodies against the muc1-c/extracellular domain (muc1-c/ecd)
WO2015118537A25 févr. 201513 août 2015Yeda Research And Development Co. Ltd.Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
WO2015118538A15 févr. 201513 août 2015Yeda Research And Development Co. Ltd.Anti cd84 antibodies, compositions comprising same and uses thereof
WO2015118547A19 févr. 201513 août 2015Protalix Ltd.Method of maintaining disease stability in a subject having gaucher's disease
WO2015120273A16 févr. 201513 août 2015The General Hospital CorporationDifferential diagnosis of hepatic neoplasms
WO2015121859A111 févr. 201520 août 2015Brainstorm Cell Therapeutics Ltd.Method of qualifying cells
WO2015123565A113 févr. 201520 août 2015The General Hospital CorporationMethods for diagnosing igg4-related disease
WO2015131099A127 févr. 20153 sept. 2015The General Hospital CorporationDiagnosis of multiple myeloma and lymphoma
WO2015132784A13 mars 201511 sept. 2015Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method and device for detection of pseudomonas aeruginosa
WO2015144874A127 mars 20151 oct. 2015Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Multi-component-multistage malaria vaccines
WO2015159292A214 avr. 201522 oct. 2015Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.A method and kit for determining the tissue or cell origin of dna
WO2015159293A214 avr. 201522 oct. 2015Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.A method and kit for determining the tissue or cell origin of dna
WO2015159295A116 avr. 201522 oct. 2015Yeda Research And Development Co. Ltd.Methods and kits for analyzing dna binding moieties attached to dna
WO2015166492A228 avr. 20155 nov. 2015Yeda Research And Development Co. Ltd.Microbiome response to agents
WO2015170320A24 mai 201512 nov. 2015Forrest Innovations Ltd.Compositions and methods of using same for controlling pathogenically infected mosquitoes
WO2015170322A24 mai 201512 nov. 2015Forrest Innovations Ltd.Compositions and methods of using same for increasing resistance of infected mosquitoes
WO2015170323A24 mai 201512 nov. 2015Forrest Innovations Ltd.Compositions and methods of using same for reducing resistance to mosquito larvicides
WO2015170324A24 mai 201512 nov. 2015Forrest Innovations Ltd.Compositions for mosquito control and uses of same
WO2015170325A24 mai 201512 nov. 2015Forrest Innovations Ltd.Compositions and methods for reducing pathogen-induced citrus greening
WO2015177800A221 mai 201526 nov. 2015Yeda Research And Development Co. Ltd.Recombinant microorganisms capable of carbon fixation
WO2015179435A119 mai 201526 nov. 2015Bayer Healthcare LlcOptimized humanized monoclonal antibodies against activated protein c and uses thereof
WO2015186129A12 juin 201510 déc. 2015Technion Research & Development Foundation Limited.Compositions and methods of selectively inhibiting irp1 and treating inflammation
WO2015198320A124 juin 201530 déc. 2015Insight Biopharmaceuticals Ltd.Methods of purifying antibodies
WO2015198334A225 juin 201530 déc. 2015Tel Hashomer Medical Research Infrastructure And Services Ltd.Identification of cancer stem cells and use of same for diagnosis and treatment
WO2016005985A29 juil. 201514 janv. 2016Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method for reprogramming cells
WO2016009436A115 juil. 201521 janv. 2016Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Isolated polypeptides of cd44 and uses thereof
WO2016016894A130 juil. 20154 févr. 2016Yeda Research And Development Co. Ltd.Media for culturing pluripotent stem cells
WO2016030899A127 août 20153 mars 2016Yeda Research And Development Co. Ltd.Methods of treating amyotrophic lateral scleroses
WO2016038550A19 sept. 201517 mars 2016Novartis AgInhibition of prmt5 to treat mtap-deficiency-related diseases
WO2016038609A18 sept. 201517 mars 2016Yeda Research And Development Co. Ltd.Anti-her3 antibodies and uses of same
WO2016038610A18 sept. 201517 mars 2016Yeda Research And Development Co. Ltd.Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
WO2016042561A221 sept. 201524 mars 2016Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Downregulating mir-132 for the treatment of lipid related disorders
WO2016061111A113 oct. 201521 avr. 2016Life Technologies CorporationMethods, kits & compositions for determining gene copy numbers
WO2016062855A123 oct. 201528 avr. 2016Dupont Nutrition Biosciences ApsProline tolerant tripeptidyl peptidases and uses thereof
WO2016062857A123 oct. 201528 avr. 2016Dupont Nutrition Biosciences ApsUse of proline tolerant tripeptidyl peptidases in feed additive compositions
WO2016065238A123 oct. 201528 avr. 2016Danisco Us Inc.Method for producing alcohol by use of a tripeptidyl peptidase
WO2016079731A217 nov. 201526 mai 2016Yeda Research And Development Co. Ltd.Method of analyzing microbiome
WO2016079736A217 nov. 201526 mai 2016Yeda Research And Development Co. Ltd.Methods of treating diseases related to mitochondrial function
WO2016079739A219 nov. 201526 mai 2016Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Compositions and methods for producing polypeptides with a modified glycosylation pattern in plant cells
WO2016089883A11 déc. 20159 juin 2016Novartis AgCompositions and methods for diagnosis and treatment of prostate cancer
WO2016092555A210 déc. 201516 juin 2016Yeda Research And Development Co. Ltd.Isolated phosphotriesterase polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
WO2016103269A123 déc. 201530 juin 2016Ramot At Tel-Aviv University Ltd.Populations of neural progenitor cells and methods of producing and using same
WO2016108239A130 déc. 20157 juil. 2016Cell Cure Neurosciences Ltd.Rpe cell populations and methods of generating same
WO2016108240A130 déc. 20157 juil. 2016Cell Cure Neurosciences Ltd.Assessing retinal pigment epithelial cell populations
WO2016108244A14 janv. 20167 juil. 2016Protalix Ltd.Modified dnase and uses thereof
WO2016116935A121 janv. 201628 juil. 2016Yeda Research And Development Co. Ltd.Use of rasa2 as a prognostic and therapeutic marker for melanoma
WO2016130516A19 févr. 201618 août 2016Research Development FoundationEngineered immunoglobulin fc polypeptides displaying improved complement activation
WO2016135732A125 févr. 20161 sept. 2016Yeda Research And Development Co. Ltd.Method of promoting hair growth
WO2016142948A110 mars 201615 sept. 2016Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Decoy oligonucleotides for the treatment of diseases
WO2016147194A117 mars 201622 sept. 2016Yeda Research And Development Co. Ltd.Anti amphiregulin antibodies, compositions comprising same and uses thereof
WO2016157190A131 mars 20166 oct. 2016Yeda Research And Development Co. Ltd.Glutamate oxaloacetate transaminase 1 (got1), preparations and methods of generating same and uses thereof
WO2016162870A17 avr. 201613 oct. 2016Ilana NathanCompositions for treating and/or preventing cell or tissue necrosis specifically targeting cathepsin c and/or cela1 and/or cela3a and/or structurally related enzymes thereto
WO2016174652A130 avr. 20153 nov. 2016Technion Research & Development Foundation LimitedChimeric antigen receptors and methods of their use
WO2016174674A126 avr. 20163 nov. 2016The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical CenterEgr1 targeting molecules for the treatment of inflammatory and hyperproliferative conditions
WO2016181393A110 mai 201617 nov. 2016Yeda Research And Development Co. Ltd.Citrin inhibitors for the treatment of cancer
WO2016185457A119 oct. 201524 nov. 2016Yeda Research And Development Co. Ltd.Methods of promoting lymphangiogenesis
WO2016185469A117 mai 201624 nov. 2016Yeda Research And Development Co. Ltd.Bacterial populations for promoting health
WO2016185481A219 mai 201624 nov. 2016Yeda Research And Development Co. Ltd.Method of targeting senescent cells
WO2016199140A18 juin 201615 déc. 2016Adicet Bio Inc.T cell receptor like antibodies having fine specificity
WO2016199141A28 juin 201615 déc. 2016Adicet Bio Inc.Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
WO2016203476A116 juin 201622 déc. 2016Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods and compositions for diagnosing and treating urothelial cancer
WO2016203477A116 juin 201622 déc. 2016Yeda Research And Development Co. Ltd.Conditioning protocols and use of same for tissue regeneration
WO2016210395A127 juin 201629 déc. 2016Dupont Nutrition Biosciences ApsAminopeptidases for protein hydrlyzates
WO2017009842A214 juil. 201619 janv. 2017Biokine Therapeutics Ltd.Compositions and methods for treating cancer
WO2017009852A114 juil. 201619 janv. 2017Yeda Research And Development Co. Ltd.Use of anti third party central memory t cells
WO2017009853A114 juil. 201619 janv. 2017Yeda Research And Development Co. Ltd.Genetically modified anti-third party central memory t cells and use of same in immunotherapy
WO2017013661A121 juil. 201626 janv. 2017Phytopharma International Ltd.Bee-ingestible compositions, methods of using same for producing honey and honey produced thereby
WO2017017686A128 juil. 20162 févr. 2017Hadasit Medical Research Services And Development Ltd.Large scale production of retinal pigment epithelial cells
WO2017021961A12 août 20169 févr. 2017Yeda Research And Development Co. Ltd.Methods of screening for riboswitches and attenuators
WO2017021963A12 août 20169 févr. 2017Biokine Therapeutics Ltd.Cxcr4 binding agents for treatment of diseases
WO2017021972A14 août 20169 févr. 2017Cell Cure Neurosciences Ltd.Preparation of photoreceptors for the treatment of retinal diseases
WO2017021973A14 août 20169 févr. 2017Cell Cure Neurosciences Ltd.Preparation of retinal pigment epithelium cells
WO2017025967A111 août 201616 févr. 2017Forrest Innovations Ltd.Formulations and compositions for delivery of nucleic acids to plant cells
WO2017033152A125 août 20162 mars 2017Prothena Biosciences LimitedMethods for detecting phosphorylated alpha-synuclein
WO2017033188A124 août 20162 mars 2017Yeda Research And Development Co. Ltd.Algal oil and biofuel and methods of producing same
WO2017040380A229 août 20169 mars 2017Research Development FoundationEngineered antibody fc variants
WO2017042814A18 sept. 201616 mars 2017Yeda Research And Development Co. Ltd.Use of perforin positive immature dendritic cells in disease treatment
WO2017059108A129 sept. 20166 avr. 2017Htg Molecular Diagnostics, Inc.Methods for subtyping diffuse b-cell lymphoma (dlbcl)
WO2017062953A110 oct. 201613 avr. 2017Intrexon CorporationImproved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
WO2017072757A125 oct. 20164 mai 2017Yeda Research And Development Co. Ltd.Antibodies targeting quiescin sulfhydryl oxidase (qsox1) and uses of same
WO2017072763A126 oct. 20164 mai 2017Cell Cure Neurosciences Ltd.Preparation of retinal pigment epithelium cells
WO2017072772A127 oct. 20164 mai 2017Yeda Research And Development Co. Ltd.A method of inducing cardiomyocytes proliferation and treating heart diseases
WO2017072773A127 oct. 20164 mai 2017Ilana NathanCompositions comprising cannabidiol and second therapeutic agents for the treatment of cancer
WO2017077539A13 nov. 201611 mai 2017Ariel-University Research And Development Company Ltd.Compositions for regeneration and repair of neural tissue
WO2017109679A119 déc. 201629 juin 2017Novartis AgCompositions and methods for decreasing tau expression
WO2017118985A15 janv. 201713 juil. 2017Yeda Research And Development Co. Ltd.Compositions and methods for treating malignant, autoimmune and inflammatory diseases
WO2017130205A131 janv. 20173 août 2017Hadasit Medical Research Services And Development Ltd.Autosomal-identical pluripotent stem cell populations having non-identical sex chromosomal composition and uses thereof
WO2017134671A13 févr. 201710 août 2017Yeda Research And Development Co. Ltd.Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant p53
WO2017138007A114 févr. 201717 août 2017Yeda Research And Development Co. Ltd. At The Weizmann Institute Of ScienceMicrobiome-based diagnosis, prediction and treatment of relapsing obesity
WO2017138008A214 févr. 201717 août 2017Yeda Research And Development Co. Ltd.Methods of modulating protein exocytosis and uses of same in therapy
WO2017141253A116 févr. 201724 août 2017Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Non-protein phenylalanine analogues for inhibiting cyanobacteria and plant growth
WO2017147060A121 févr. 201731 août 2017Dupont Nutrition Biosciences ApsMethod for producing a protein hydrolysate employing an aspergillus fumigatus tripeptidyl peptidase
WO2017147186A122 févr. 201731 août 2017Ursure, Inc.System and method for detecting therapeutic agents to monitor adherence to a treatment regimen
WO2017153982A16 mars 201714 sept. 2017Yeda Research And Development Co. Ltd.Method for modulating myelination
WO2017158610A117 mars 201721 sept. 2017Yeda Research And Development Co. Ltd.Methods of isolating barrel-like proteases and identifying peptides processed thereby
WO2017172518A124 mars 20175 oct. 2017Stcube, Inc.Dual function antibodies specific to glycosylated pd-l1 and methods of use thereof
WO2017189746A126 avr. 20172 nov. 2017Gen-Probe IncorporatedBlood cell lysis reagent
Classifications
Classification aux États-Unis435/7.93, 436/547, 435/25, 436/815, 435/964, 436/808, 435/975, 436/518, 436/817, 436/530, 435/188
Classification internationaleG01N33/543
Classification coopérativeY10S435/964, G01N33/543, Y10S436/808, Y10S435/975, Y10S436/815, Y10S436/817
Classification européenneG01N33/543
Événements juridiques
DateCodeÉvénementDescription
12 juil. 1983CCCertificate of correction